GENEMEDICS APP
GENEMEDICS NUTRITION
Dehydroepiandrosterone (DHEA), also known as androstenolone, is one of the most abundant circulating steroids in humans. Once secreted into the blood stream, the body converts DHEA into several other hormones such as testosterone and estrogen. Because of this vital function, DHEA is sometimes referred to as the “mother of all hormones” or “parent hormone”. DHEA is produced in the adrenal glands (small glands located on top of each kidney), the gonads (sex glands), and the brain.
Aside from being a precursor to other important hormones, DHEA plays the following important functions:
Touted as the “super hormone”, DHEA plays several important functions in women:
In men, this powerful hormone works in numerous ways:
The levels of DHEA tend to gradually deteriorate with age. In addition, certain factors such as lifestyle, diet, emotional health, and stress levels can affect DHEA levels. It is a known fact that the level of this hormone start to decline after the age of 30, causing a wide array of negative health implications. Typical symptoms of DHEA deficiency (adrenal insufficiency) include:
If you are experiencing one or more of these symptoms, consult immediately with a qualified hormone replacement therapy doctor to assess your DHEA levels and come up with an appropriate medical management that is tailored to your needs.
DHEA replacement therapy has gained worldwide attention over recent years. An overwhelming body of clinical research supports the significant beneficial effects of DHEA administration in patients with complete DHEA deficiency. Whether taken orally in the form of tablets or capsules, or given in the form of injections or applied directly to the skin, studies show that this “super hormone” can benefit almost every organ system in the body and can help combat a wide array of fatal diseases.
Inflammation is the root cause of most diseases and is strongly linked with almost all age-related health problems. DHEA’s potent anti-inflammatory properties can help ward off various inflammatory disorders associated with advancing age and improve overall quality of life. Several research studies confirm the anti-inflammatory effects of DHEA:
DHEA possesses potent anti-aging properties that help protect against loss of bone mineral density and strength, thereby reducing the risk of fractures and osteoporosis. Apart from aging, bone loss occur at higher rates in people with hormonal imbalances, poor eating habits, unhealthy lifestyle, and those with medical conditions that affect bone quality. As the “mother of all hormones”, evidence suggests that DHEA replacement therapy improves bone production and quality by boosting the production of other hormones necessary for bone production:
DHEA appears to play a major role in cardiovascular function and deficiency in this vital hormone may compromise heart health. In fact several high quality studies found a strong link between DHEA deficiency and higher incidence of heart diseases in both men and women. [193-207] This suggests that replacing DHEA to youthful levels can help boost heart health and prevent various fatal heart diseases. A number of clinical trials support the beneficial effects of DHEA replacement therapy on the cardiovascular system:
As a nootropic agent or cognitive-enhancer, DHEA is among the most important neurosteroids. Neurosteroids are steroids synthesized within the brain that help maintain the functions of nerve cells. There is strong scientific evidence that DHEA supplementation can help boost brain function in the elderly as well as those with cognitive impairments related to various brain problems:
For women who want to increase their chances of getting pregnant, DHEA supplementation can help. In fact, DHEA supplements are actually prescribed by doctors in women with diminished ovarian reserve (DOR), a condition in which the ovaries lose their reproductive potential. Several clinical trials assessing the beneficial effects of DHEA replacement therapy on pregnancy rate have shown positive outcomes for many women:
While proper diet and regular exercise are important factors involved in maintaining a healthy weight, hormones like DHEA play an important role too. This “super hormone” boosts the body’s natural ability to utilize energy reserves and burn fat, two metabolic processes that gradually decline with advancing age. Studies show that DHEA replacement therapy promotes weight loss, thus reducing one’s risk of developing obesity-related diseases:
Acquiring more DHEA can help combat diabetes and other diseases linked with high blood sugar levels. Results of human studies assessing the anti-diabetic effects of DHEA suggest that it can protect against insulin resistance induced by aging and unhealthy lifestyle:
Troublesome and frustrating, sleeping problems associated with aging can negatively impact one’s quality of life. Hormonal imbalance during this stage is thought to affect sleep quality, resulting in lack of sleep and extreme fatigue. Specifically, the age-related decline in various hormones such as testosterone, estrogen, and DHEA contributes to insomnia. Because DHEA is a precursor to several other important hormones in the body, researchers believe that restoring DHEA to youthful levels can help improve sleep quality. A number of clinical trials support the beneficial effects of DHEA on sleep:
Regular exercises along with proper diet are known to increase muscle mass and strength. However, not all older individuals may benefit from these strategies due to reduced activity levels and slower metabolism. Interestingly, there is increasing evidence that DHEA supplementation can aid in improving muscle mass and strength especially in the older population. Studies show that DHEA replacement therapy is beneficial in both older men and women:
Menopausal women often experience debilitating symptoms that ruin their quality of life, including hot flushes, sleeping difficulties, fatigue, sexual dysfunction, headaches, body pains, and mood swings. Researchers believe that menopause and low DHEA levels go hand in hand, and by restoring DHEA to youthful levels through hormone replacement therapy, menopausal women can significantly experience relief from these unpleasant symptoms. A number of high quality studies conducted in menopausal women support the benefits of DHEA:
DHEA doesn’t only treat sexual dysfunction in women, but also in men with ED. As a building block for testosterone, the key male sex hormone, DHEA may be able to ramp up sexual power in men with ED. Strong scientific evidence supports the beneficial effects of DHEA on this condition:
DHEA does not only have anti-aging capability but it also has potent anti-cancer properties. There is strong scientific evidence that this hormone is capable of destroying various cancer cell types, thereby preventing its spread in different body parts (metastasis). Results from numerous studies show that DHEA fights cancer through various mechanisms:
The age-related decline in DHEA levels is believed to contribute to various medical conditions, including impairment of immune function. This predisposes older individuals to a wide array of fatal diseases like autoimmune disorders and inflammatory conditions. Research suggests that DHEA supplementation may help improve symptoms and even prevent immune system-related disorders by boosting immune function via several different mechanisms:
Low mood and depression are among the most common psychological symptoms associated with old age. There is increasing evidence that age-related DHEA deficiency is strongly linked with depression, [340-341] suggesting that DHEA replacement therapy can be beneficial in improving depressive symptoms as well as quality of life. Results from various human studies assessing the beneficial effects of DHEA on mood show that this hormone can help maintain a positive outlook, energy and motivation:
Cholesterol is required for DHEA production. In fact, the process by which DHEA is produced starts when cholesterol enters the “powerhouse” of cells known as mitochondria. [362] Researchers believe that this process may help lower cholesterol and increase DHEA levels in the body, thereby boosting overall health. Results from several studies support the beneficial effects of DHEA supplementation on cholesterol levels:
DHEA can reduce wrinkles and other skin imperfections associated with aging. Studies show that this hormone exerts its anti-aging effect through various mechanisms:
Stroke is one of the most deadly diseases worldwide. Interestingly, aside from diet and lifestyle, studies show that low DHEA levels are strongly associated with increased risk of stroke and related death. [376] Fortunately, increasing DHEA levels through replacement therapy can significantly prevent stroke, according to studies:
Khorram O, Vu L, Yen SS. Activation of immune function by dehydroepiandrosterone (DHEA) in age-advanced men. The journals of gerontology. Series A, Biological sciences and medical sciences. 1997; 52(1):M1-7.
Activation of immune function by dehydroepiandrosterone (DHEA) in age-advanced men
The study “Activation of immune function by dehydroepiandrosterone (DHEA) in age-advanced men,” published in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences in 1997, investigates the effects of DHEA on immune function in older men. This research explores how the hormone DHEA, known to decrease with age, might influence the immune system’s functionality in the aging male population.
For a detailed understanding: https://academic.oup.com/biomedgerontology/article-abstract/52A/1/M1/550201
Buford TW, Willoughby DS. Impact of DHEA(S) and cortisol on immune function in aging: a brief review. Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme. 2008; 33(3):429-33.
Impact of DHEA(S) and cortisol on immune function in aging: a brief review
The review “Impact of DHEA(S) and cortisol on immune function in aging: a brief review” by Buford TW and Willoughby DS, published in Applied Physiology, Nutrition, and Metabolism in 2008, discusses the effects of the hormones DHEA(S) and cortisol on immune function in the context of aging. It examines how these hormones, which tend to change with age, influence the immune system. This brief review contributes to understanding the complex interplay between hormonal changes and immune function in the aging process.
For more details: https://www.nrcresearchpress.com/doi/10.1139/H08-019#.Y2m7_3ZBy3A
Catania RA, Angele MK, Ayala A, Cioffi WG, Bland KI, Chaudry IH. Dehydroepiandrosterone restores immune function following trauma-haemorrhage by a direct effect on T lymphocytes. Cytokine. 1999; 11(6):443-50.
Dehydroepiandrosterone restores immune function following trauma-haemorrhage by a direct effect on T lymphocytes
The study “Dehydroepiandrosterone restores immune function following trauma-haemorrhage by a direct effect on T lymphocytes” by Catania RA, Angele MK, Ayala A, and others, published in the journal Cytokine in 1999, examines the effect of dehydroepiandrosterone (DHEA) on immune function, particularly focusing on T lymphocytes, after trauma and hemorrhage. The research suggests that DHEA has a direct positive impact on restoring immune function under these conditions. This study contributes to understanding the potential therapeutic role of DHEA in trauma-induced immune dysfunction.
For more details: https://www.sciencedirect.com/science/article/pii/S1043466698904586
Loria RM, Padgett DA. Control of the immune response by DHEA and its metabolites. Rinsho byori. The Japanese journal of clinical pathology. 1998; 46(6):505-17.
Control of the immune response by DHEA and its metabolites
The study “Control of the immune response by DHEA and its metabolites,” by Loria RM and Padgett DA, published in Rinsho Byori (The Japanese Journal of Clinical Pathology) in 1998, explores the regulatory role of dehydroepiandrosterone (DHEA) and its metabolites on the immune response. This research likely investigates how DHEA, a steroid hormone, influences various aspects of the immune system, contributing to the understanding of its potential in immunomodulation.
For more details: https://europepmc.org/article/med/9691759
Chen CC, Parker CR. Adrenal androgens and the immune system. Seminars in reproductive medicine. 2004; 22(4):369-77.
Adrenal androgens and the immune system. Seminars in reproductive medicine
The article “Adrenal androgens and the immune system” by Chen CC and Parker CR, published in Seminars in Reproductive Medicine in 2004, discusses the role of adrenal androgens in the functioning of the immune system. This study likely focuses on how hormones produced by the adrenal glands, such as DHEA and androstenedione, interact with and influence immune responses. The research provides insights into the complex interactions between endocrine and immune systems, shedding light on the potential impact of adrenal androgens on immune-related health and disease processes.
For more details: https://www.thieme-connect.com/products/ejournals/html/10.1055/s-2004-861553
Ledochowski M, Murr C, Jäger M, Fuchs D. Dehydroepiandrosterone, ageing and immune activation. Experimental gerontology. 2001; 36(10):1739-47.
Dehydroepiandrosterone, ageing and immune activation
The study “Dehydroepiandrosterone, ageing and immune activation,” by Ledochowski M, Murr C, Jäger M, Fuchs D, published in Experimental Gerontology in 2001, investigates the relationship between the hormone dehydroepiandrosterone (DHEA), aging, and immune system activation. This research likely examines how DHEA levels, which decline with age, affect the immune system’s activity and responsiveness, particularly in the context of aging-related immune changes.
For more details: https://www.sciencedirect.com/science/article/pii/S053155650100122X
Heffner KL. Neuroendocrine effects of stress on immunity in the elderly: implications for inflammatory disease. Immunology and allergy clinics of North America. 2011; 31(1):95-108.
Neuroendocrine effects of stress on immunity in the elderly: implications for inflammatory disease
The article “Neuroendocrine effects of stress on immunity in the elderly: implications for inflammatory disease” by Heffner KL, published in Immunology and Allergy Clinics of North America in 2011, examines the impact of stress on the neuroendocrine system and its subsequent effects on the immune system in older adults. It discusses how this interaction may influence the development and progression of inflammatory diseases in the elderly. This study is crucial for understanding the complex relationship between stress, hormonal changes, and immune function in aging populations.
For more details, you can access the article: https://www.immunology.theclinics.com/article/S0889-8561(10)00087-7/fulltext
Butcher SK, Lord JM. Stress responses and innate immunity: aging as a contributory factor. Aging cell. 2004; 3(4):151-60.
Stress responses and innate immunity: aging as a contributory factor.
The study “Stress responses and innate immunity: aging as a contributory factor,” by Butcher SK and Lord JM, published in Aging Cell in 2004, explores the relationship between stress responses and the innate immune system, particularly considering aging as a key factor. This research likely investigates how aging influences the body’s stress responses and its impact on innate immunity, contributing to the understanding of the aging immune system and its responsiveness to stress.
For details: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1474-9728.2004.00103.x
Loria RM, Padgett DA, Huynh PN. Regulation of the immune response by dehydroepiandrosterone and its metabolites. The Journal of endocrinology. 1996; 150 Suppl:S209-20.
Regulation of the immune response by dehydroepiandrosterone and its metabolites
The study “Regulation of the immune response by dehydroepiandrosterone and its metabolites,” by Loria RM, Padgett DA, Huynh PN, published in The Journal of Endocrinology in 1996, focuses on how dehydroepiandrosterone (DHEA) and its metabolites regulate the immune response. This research likely delves into the mechanisms by which DHEA, a steroid hormone, influences immune system activity, providing insights into its potential role in immunoregulation and the implications for health and disease management.
For more information visit at https://joe.bioscientifica.com/view/journals/joe/150/3_Suppl/joe_150_Suppl_026.xml
Oberbeck R, Dahlweid M, Koch R, et al. Dehydroepiandrosterone decreases mortality rate and improves cellular immune function during polymicrobial sepsis. Critical care medicine. 2001; 29(2):380-4.
Dehydroepiandrosterone decreases mortality rate and improves cellular immune function during polymicrobial sepsis
The study “Dehydroepiandrosterone decreases mortality rate and improves cellular immune function during polymicrobial sepsis” by Oberbeck R, Dahlweid M, Koch R, et al., published in Critical Care Medicine in 2001, investigates the effects of dehydroepiandrosterone (DHEA) on mortality and immune function during severe polymicrobial sepsis. The research likely demonstrates that DHEA can reduce mortality and enhance immune response in such critical conditions, offering potential therapeutic implications.
For more detailed information, you can access here https://journals.lww.com/ccmjournal/Abstract/2001/02000/Dehydroepiandrosterone_decreases_mortality_rate.28.aspx
Morfin R, Lafaye P, Cotillon AC, Nato F, Chmielewski V, Pompon D. 7 alpha-hydroxy-dehydroepiandrosterone and immune response. Annals of the New York Academy of Sciences. 2000; 917:971-82.
7 alpha-hydroxy-dehydroepiandrosterone and immune response
The study “7 alpha-hydroxy-dehydroepiandrosterone and immune response,” published in the Annals of the New York Academy of Sciences in 2000, by Morfin R, Lafaye P, Cotillon AC, Nato F, Chmielewski V, Pompon D, explores the effects of 7 alpha-hydroxy-dehydroepiandrosterone, a metabolite of dehydroepiandrosterone (DHEA), on the immune response. This research likely investigates the specific role and potential benefits of this DHEA metabolite in modulating immune function, contributing to the broader understanding of the interactions between hormones and the immune system.
For more detailed information: https://nyaspubs.onlinelibrary.wiley.com/doi/abs/10.1111/j.1749-6632.2000.tb05464.x
Brazão V, Santello FH, Caetano LC, Del Vecchio Filipin M, Toldo MP, do Prado JC. Immunomodulatory effects of zinc and DHEA on the Th-1 immune response in rats infected with Trypanosoma cruzi. Immunobiology. 2010; 215(5):427-34.
Immunomodulatory effects of zinc and DHEA on the Th-1 immune response in rats infected with Trypanosoma cruzi
The study “Immunomodulatory effects of zinc and DHEA on the Th-1 immune response in rats infected with Trypanosoma cruzi,” by Brazão V, Santello FH, Caetano LC, et al., published in Immunobiology in 2010, investigates how zinc and dehydroepiandrosterone (DHEA) affect the Th-1 immune response in rats infected with Trypanosoma cruzi. This research focuses on understanding the potential immunomodulatory roles of these substances in the context of infection with this parasite.
For more detailed information, you can access the study https://www.sciencedirect.com/science/article/abs/pii/S0171298509001518?via%3Dihub
Araneo B, Daynes R. Dehydroepiandrosterone functions as more than an antiglucocorticoid in preserving immunocompetence after thermal injury. Endocrinology. 1995; 136(2):393-401.
Dehydroepiandrosterone functions as more than an antiglucocorticoid in preserving immunocompetence after thermal injury
The study “Dehydroepiandrosterone functions as more than an antiglucocorticoid in preserving immunocompetence after thermal injury” by Araneo B, Daynes R, published in Endocrinology in 1995, examines the role of dehydroepiandrosterone (DHEA) beyond its antiglucocorticoid properties in maintaining immune function after thermal injury. This research likely explores the multifaceted effects of DHEA on the immune system, particularly in the context of injury-induced stress and immunosuppression.
For more details: https://academic.oup.com/endo/article-abstract/136/2/393/3036311
Sawalha AH, Kovats S. Dehydroepiandrosterone in systemic lupus erythematosus. Current rheumatology reports. 2008;10(4):286-291.
Dehydroepiandrosterone in systemic lupus erythematosus
The article “Dehydroepiandrosterone in systemic lupus erythematosus” by Sawalha AH and Kovats S, published in Current Rheumatology Reports in 2008, discusses the role and therapeutic potential of dehydroepiandrosterone (DHEA) in treating systemic lupus erythematosus (SLE), an autoimmune disease. This review likely covers how DHEA, a steroid hormone, impacts SLE and its possible benefits in managing this condition.
For a detailed overview, you can access the article: https://link.springer.com/article/10.1007%2Fs11926-008-0046-z
Alexaki VI, Fodelianaki G, Neuwirth A, et al. DHEA inhibits acute microglia-mediated inflammation through activation of the TrkA-Akt1/2-CREB-Jmjd3 pathway. Molecular psychiatry. 2017.
DHEA inhibits acute microglia-mediated inflammation through activation of the TrkA-Akt1/2-CREB-Jmjd3 pathway
The study “DHEA inhibits acute microglia-mediated inflammation through activation of the TrkA-Akt1/2-CREB-Jmjd3 pathway” by Alexaki VI, Fodelianaki G, Neuwirth A, et al., published in Molecular Psychiatry in 2017, explores the anti-inflammatory effects of dehydroepiandrosterone (DHEA) on microglia, the central nervous system’s primary immune cells. This study likely examines how DHEA influences inflammatory pathways in the brain, particularly focusing on the TrkA-Akt1/2-CREB-Jmjd3 pathway, providing insights into the potential use of DHEA in treating neuroinflammatory conditions.
For more information: https://www.nature.com/articles/mp2017167
Genazzani AD, Stomati M, Strucchi C, Puccetti S, Luisi S, Genazzani AR. Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone-releasing hormone-induced growth hormone and insulin-like growth factor-1 secretion in early and late postmenopausal women. Fertility and sterility. 2001; 76(2):241-8.
Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone-releasing hormone-induced growth hormone and insulin-like growth factor-1 secretion in early and late postmenopausal women
The study “Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone-releasing hormone-induced growth hormone and insulin-like growth factor-1 secretion in early and late postmenopausal women” by Genazzani AD, Stomati M, Strucchi C, et al., published in Fertility and Sterility in 2001, investigates the effects of oral DHEA supplementation on growth hormone (GH) and insulin-like growth factor-1 (IGF-1) secretion in postmenopausal women. The study focuses on how DHEA influences these hormone levels both spontaneously and when induced by growth hormone-releasing hormone, providing important insights into hormone regulation in postmenopausal women.
For more details: https://www.sciencedirect.com/science/article/abs/pii/S0015028201017455?via%3Dihub
Miller WL. Androgen biosynthesis from cholesterol to DHEA. Molecular and cellular endocrinology. 2002; 198(1-2):7-14.
Androgen biosynthesis from cholesterol to DHEA
The article “Androgen biosynthesis from cholesterol to DHEA” by Miller WL, published in Molecular and Cellular Endocrinology in 2002, likely provides a detailed overview of the biochemical pathways involved in the synthesis of androgens, specifically detailing the process from cholesterol to dehydroepiandrosterone (DHEA). This review would be essential for understanding the complex steps and enzymes involved in the conversion of cholesterol into various androgens, including DHEA, within the endocrine system.
For more detailed information: https://www.sciencedirect.com/science/article/pii/S0303720702003635
Kritchevsky D, Tepper SA, Klurfeld DM, Schwartz AG. Influence of dehydroepiandrosterone (DHEA) on cholesterol metabolism in rats. Pharmacological research communications. 1983; 15(9):797-803.
Influence of dehydroepiandrosterone (DHEA) on cholesterol metabolism in rats
The study “Influence of dehydroepiandrosterone (DHEA) on cholesterol metabolism in rats” by Kritchevsky D, Tepper SA, Klurfeld DM, Schwartz AG, published in Pharmacological Research Communications in 1983, investigates how DHEA affects cholesterol metabolism in rats. This research is significant for understanding the potential impact of DHEA, a steroid hormone, on cholesterol levels and lipid metabolism, which are critical factors in cardiovascular health and disease.
For more details: https://www.sciencedirect.com/science/article/pii/S0031698983800873
Miller WL. Early steps in androgen biosynthesis: from cholesterol to DHEA. Bailliere’s clinical endocrinology and metabolism. 1998; 12(1):67-81.
Early steps in androgen biosynthesis: from cholesterol to DHEA
The article “Early steps in androgen biosynthesis: from cholesterol to DHEA” by Miller WL, published in Bailliere’s Clinical Endocrinology and Metabolism in 1998, delves into the initial stages of androgen biosynthesis. This study likely details the biochemical processes and enzymatic pathways involved in converting cholesterol into dehydroepiandrosterone (DHEA), a key androgen in the body. Understanding these early steps is crucial for comprehending how androgens are produced and regulated, and their impact on various physiological processes.
For more information: https://www.sciencedirect.com/science/article/pii/S0303720702003635
Miller WL. Disorders of androgen synthesis–from cholesterol to dehydroepiandrosterone. Medical principles and practice : international journal of the Kuwait University, Health Science Centre. 2005; 14 Suppl 1:58-68
Disorders of androgen synthesis–from cholesterol to dehydroepiandrosterone
The article “Disorders of androgen synthesis–from cholesterol to dehydroepiandrosterone” by Miller WL, published in Medical Principles and Practice in 2005, focuses on various disorders associated with androgen synthesis. This comprehensive review likely discusses the biochemical pathways from cholesterol to dehydroepiandrosterone (DHEA) and examines how disruptions in these processes can lead to different medical conditions. Understanding these disorders is crucial for clinical diagnosis and the development of effective treatments for conditions related to androgen imbalance.
For more information: https://karger.com/mpp/article-pdf/14/Suppl.%201/58/3120088/000086185.pdf
Jedrzejuk D, Medras M, Milewicz A, Demissie M. Dehydroepiandrosterone replacement in healthy men with age-related decline of DHEA-S: effects on fat distribution, insulin sensitivity and lipid metabolism. The aging male : the official journal of the International Society for the Study of the Aging Male. 2003; 6(3):151-6.
Dehydroepiandrosterone replacement in healthy men with age-related decline of DHEA-S: effects on fat distribution, insulin sensitivity and lipid metabolism
The study “Dehydroepiandrosterone replacement in healthy men with age-related decline of DHEA-S: effects on fat distribution, insulin sensitivity and lipid metabolism” by Jedrzejuk D, Medras M, Milewicz A, Demissie M, published in The Aging Male in 2003, examines the effects of DHEA supplementation in men experiencing age-related declines in DHEA-S levels. The research focuses on how DHEA replacement influences body fat distribution, insulin sensitivity, and lipid metabolism, providing insights into the potential benefits of DHEA in managing age-related metabolic and hormonal changes.
For more information: https://www.tandfonline.com/doi/abs/10.1080/tam.6.3.151.156
Boxer RS, Kleppinger A, Brindisi J, Feinn R, Burleson JA, Kenny AM. Effects of dehydroepiandrosterone (DHEA) on cardiovascular risk factors in older women with frailty characteristics. Age and Ageing. 2010;39(4):451-458. doi:10.1093/ageing/afq043.
Effects of dehydroepiandrosterone (DHEA) on cardiovascular risk factors in older women with frailty characteristics
The study “Effects of dehydroepiandrosterone (DHEA) on cardiovascular risk factors in older women with frailty characteristics” by Boxer RS, Kleppinger A, Brindisi J, et al., published in Age and Ageing in 2010, investigates the impact of DHEA supplementation on cardiovascular risk factors in older women exhibiting characteristics of frailty. This research likely assesses how DHEA influences factors like cholesterol levels, blood pressure, and body composition, which are crucial in cardiovascular health.
For more details, you can access the study using this link: https://academic.oup.com/ageing/article/39/4/451/41921
Hayashi T, Esaki T, Muto E, et al. Dehydroepiandrosterone retards atherosclerosis formation through its conversion to estrogen: the possible role of nitric oxide. Arteriosclerosis, thrombosis, and vascular biology. 2000; 20(3):782-92.
Dehydroepiandrosterone retards atherosclerosis formation through its conversion to estrogen: the possible role of nitric oxide
The study “Dehydroepiandrosterone retards atherosclerosis formation through its conversion to estrogen: the possible role of nitric oxide” by Hayashi T, Esaki T, Muto E, et al., published in Arteriosclerosis, Thrombosis, and Vascular Biology in 2000, explores how dehydroepiandrosterone (DHEA) may slow down the development of atherosclerosis by converting to estrogen and potentially influencing nitric oxide production. This study provides significant insights into the mechanisms by which DHEA could impact cardiovascular health, particularly in the context of atherosclerosis prevention.
For more details, you can access the study using this link: https://www.ahajournals.org/doi/abs/10.1161/01.atv.20.3.782
Samaras N, Samaras D, Frangos E, Forster A, Philippe J. A Review of Age-Related Dehydroepiandrosterone Decline and Its Association with Well-Known Geriatric Syndromes: Is Treatment Beneficial? Rejuvenation Research. 2013;16(4):285-294. doi:10.1089/rej.2013.1425.
A Review of Age-Related Dehydroepiandrosterone Decline and Its Association with Well-Known Geriatric Syndromes: Is Treatment Beneficial?
The review “A Review of Age-Related Dehydroepiandrosterone Decline and Its Association with Well-Known Geriatric Syndromes: Is Treatment Beneficial?” by Samaras N, Samaras D, Frangos E, et al., published in Rejuvenation Research in 2013, discusses the decline of dehydroepiandrosterone (DHEA) with age and its potential links to various geriatric syndromes. The review also examines whether DHEA supplementation could be beneficial in treating these age-related conditions. This comprehensive analysis provides a deeper understanding of DHEA’s role in aging and the implications of its supplementation in senior health.
For more details: https://www.liebertpub.com/doi/abs/10.1089/rej.2013.1425
Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocrine reviews. 2003; 24(2):183-217.
Androgens and coronary artery disease
The review article “Androgens and Coronary Artery Disease” by Wu FC and von Eckardstein A, published in Endocrine Reviews in 2003, provides an in-depth analysis of the relationship between androgens, such as testosterone, and coronary artery disease. It explores how these sex hormones might influence the development and progression of cardiovascular diseases, particularly focusing on the complex interplay between androgens and various risk factors for coronary artery disease. This comprehensive review offers valuable insights into the endocrine aspects of cardiovascular health and disease.
For more detailed information: https://academic.oup.com/edrv/article-abstract/24/2/183/2424255
Jiménez MC, Sun Q, Schürks M, et al. Low dehydroepiandrosterone sulphate is associated with increased risk of ischemic stroke among women: DHEAS and Risk of Ischemic Stroke in Women. Stroke; a journal of cerebral circulation. 2013;44(7):10.1161/STROKEAHA.111.000485. doi:10.1161/STROKEAHA.111.000485.
Low dehydroepiandrosterone sulphate is associated with increased risk of ischemic stroke among women: DHEAS and Risk of Ischemic Stroke in Women
The study “Low dehydroepiandrosterone sulphate is associated with increased risk of ischemic stroke among women: DHEAS and Risk of Ischemic Stroke in Women” by Jiménez MC, Sun Q, Schürks M, et al., published in Stroke in 2013, examines the association between low levels of dehydroepiandrosterone sulphate (DHEAS) and the risk of ischemic stroke in women. This research provides important insights into how hormonal factors, specifically the levels of DHEAS, might influence the risk of stroke in women, contributing to the broader understanding of stroke pathophysiology and risk factors.
For more information: https://www.ahajournals.org/doi/abs/10.1161/strokeaha.111.000485
Mannic T, Viguie J, Rossier MF. In vivo and in vitro evidences of dehydroepiandrosterone protective role on the cardiovascular system. International journal of endocrinology and metabolism. 2015; 13(2):e24660.
In vivo and in vitro evidences of dehydroepiandrosterone protective role on the cardiovascular system
The article “In vivo and in vitro evidences of dehydroepiandrosterone protective role on the cardiovascular system” by Mannic T, Viguie J, Rossier MF, published in the International Journal of Endocrinology and Metabolism in 2015, discusses the protective effects of dehydroepiandrosterone (DHEA) on the cardiovascular system. This study likely presents both in vivo (within living organisms) and in vitro (in laboratory settings) evidence to support the role of DHEA in cardiovascular health, highlighting its potential benefits and mechanisms of action in protecting the heart and blood vessels.
For more information: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389253/
Available at https://academic.oup.com/aje/article/157/1/25/66203.
Corona G, Rastrelli G, Giagulli VA, et al. Dehydroepiandrosterone supplementation in elderly men: a meta-analysis study of placebo-controlled trials. The Journal of clinical endocrinology and metabolism. 2013; 98(9):3615-26.
Dehydroepiandrosterone supplementation in elderly men: a meta-analysis study of placebo-controlled trials
The study “Dehydroepiandrosterone supplementation in elderly men: a meta-analysis study of placebo-controlled trials” by Corona G, Rastrelli G, Giagulli VA, et al., published in The Journal of Clinical Endocrinology and Metabolism in 2013, is a meta-analysis of trials assessing the effects of DHEA supplementation in older men. This comprehensive analysis likely evaluates the impact of DHEA on various health parameters, providing valuable insights into its potential benefits and risks in the elderly male population.
For more information: https://academic.oup.com/jcem/article-abstract/98/9/3615/2833096
Golden SH, Maguire A, Ding J, et al. Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort. American journal of epidemiology. 2002; 155(5):437-45.
The study “Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort” by Golden SH, Maguire A, Ding J, et al., published in the American Journal of Epidemiology in 2002, investigates the relationship between natural postmenopausal hormone levels and carotid atherosclerosis. This research likely focuses on how endogenous hormone levels in postmenopausal women influence the development or severity of carotid artery disease, providing insights into cardiovascular health in this population.
For more information: https://academic.oup.com/aje/article-abstract/155/5/437/171506
Pluchino N, Drakopoulos P, Bianchi-Demicheli F, Wenger JM, Petignat P, Genazzani AR. Neurobiology of DHEA and effects on sexuality, mood and cognition. The Journal of steroid biochemistry and molecular biology. 2015; 145:273-80.
Neurobiology of DHEA and effects on sexuality, mood, and cognition
The article “Neurobiology of DHEA and effects on sexuality, mood, and cognition” by Pluchino N, Drakopoulos P, Bianchi-Demicheli F, et al., published in The Journal of Steroid Biochemistry and Molecular Biology in 2015, explores the role of dehydroepiandrosterone (DHEA) in the brain and its effects on sexual function, mood, and cognitive processes. This study provides a comprehensive look at the neurological and psychological impacts of DHEA, a hormone known for its wide-ranging effects on the body and mind.
For more details: https://www.sciencedirect.com/science/article/pii/S0960076014000983
Sripada, R. K., Marx, C. E., King, A. P., Rajaram, N., Garfinkel, S. N., Abelson, J. L., & Liberzon, I. (2013). DHEA Enhances Emotion Regulation Neurocircuits and Modulates Memory for Emotional Stimuli. Neuropsychopharmacology, 38(9), 1798–1807. http://doi.org/10.1038/npp.2013.79
The study “DHEA Enhances Emotion Regulation Neurocircuits and Modulates Memory for Emotional Stimuli” by Sripada R. K., Marx C. E., King A. P., et al., published in Neuropsychopharmacology in 2013, investigates how dehydroepiandrosterone (DHEA) influences emotion regulation and memory processing for emotional stimuli. The research likely examines the neural mechanisms through which DHEA affects these cognitive and emotional processes, contributing to the understanding of DHEA’s role in the brain’s response to emotional stimuli.
For more details, the study can be accessed at http://doi.org/10.1038/npp.2013.79
Rabkin JG, Ferrando SJ, Wagner GJ, Rabkin R. DHEA treatment for HIV+ patients: effects on mood, androgenic and anabolic parameters. Psychoneuroendocrinology. 2000; 25(1):53-68.
DHEA treatment for HIV+ patients: effects on mood, androgenic and anabolic parameters
The study “DHEA treatment for HIV+ patients: effects on mood, androgenic and anabolic parameters” by Rabkin JG, Ferrando SJ, Wagner GJ, Rabkin R, published in Psychoneuroendocrinology in 2000, explores the effects of dehydroepiandrosterone (DHEA) supplementation on mood, as well as androgenic and anabolic parameters in HIV-positive patients. This research is significant in understanding how DHEA might benefit individuals with HIV, particularly in terms of psychological well-being and hormonal balance.
For more details, visit https://www.sciencedirect.com/science/article/pii/S0306453099000360
Young EA. DHEA: mood, memory, and aging. Biological psychiatry. 1999; 45(12):1531-2.
DHEA: mood, memory, and aging
The article “DHEA: mood, memory, and aging” by Young EA, published in Biological Psychiatry in 1999, likely discusses the role of dehydroepiandrosterone (DHEA) in relation to mood, memory, and the aging process. The paper may explore how DHEA levels, which decline with age, impact cognitive functions and emotional well-being, shedding light on the potential therapeutic uses of DHEA in aging-related cognitive and mood disorders.
For more details, visit https://pubmed.ncbi.nlm.nih.gov/10376112/
Hunt PJ, Gurnell EM, Huppert FA, et al. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison’s disease in a randomized, double-blind trial. The Journal of clinical endocrinology and metabolism. 2000; 85(12):4650-6.
Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison’s disease in a randomized, double-blind trial
The study “Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison’s disease in a randomized, double-blind trial” by Hunt PJ, Gurnell EM, Huppert FA, et al., published in The Journal of Clinical Endocrinology and Metabolism in 2000, examines the effects of DHEA replacement therapy on mood and fatigue in patients with Addison’s disease. This randomized, double-blind trial likely highlights the potential benefits of DHEA supplementation in improving psychological well-being and reducing fatigue in individuals with this condition.
For more detailed information: https://academic.oup.com/jcem/article-abstract/85/12/4650/2854033
Peixoto C, Devicari Cheda JN, Nardi AE, Veras AB, Cardoso A. The effects of dehydroepiandrosterone (DHEA) in the treatment of depression and depressive symptoms in other psychiatric and medical illnesses: a systematic review. Current drug targets. 2014; 15(9):901-14.
The effects of dehydroepiandrosterone (DHEA) in the treatment of depression and depressive symptoms in other psychiatric and medical illnesses
The systematic review “The effects of dehydroepiandrosterone (DHEA) in the treatment of depression and depressive symptoms in other psychiatric and medical illnesses” by Peixoto C, Devicari Cheda JN, Nardi AE, et al., published in Current Drug Targets in 2014, examines the role of DHEA in treating depression and depressive symptoms associated with various psychiatric and medical conditions. This review provides a comprehensive analysis of the effectiveness and potential applications of DHEA as a treatment option in these contexts.
For more detailed information: https://www.ingentaconnect.com/content/ben/cdt/2014/00000015/00000009/art00008
Wolkowitz OM, Reus VI, Roberts E, et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biological psychiatry. 1997; 41(3):311-8.
Dehydroepiandrosterone (DHEA) treatment of depression
The study “Dehydroepiandrosterone (DHEA) treatment of depression” by Wolkowitz OM, Reus VI, Roberts E, et al., published in Biological Psychiatry in 1997, investigates the use of DHEA as a treatment for depression. This research explores the antidepressant effects of DHEA, a hormone supplement, and its potential as an alternative or adjunct therapy for depressive disorders, providing insights into the hormone’s role in mood regulation.
For more detailed information: https://www.sciencedirect.com/science/article/pii/S0006322396000431
Sripada RK, Marx CE, King AP, et al. DHEA Enhances Emotion Regulation Neurocircuits and Modulates Memory for Emotional Stimuli. Neuropsychopharmacology. 2013;38(9):1798-1807. doi:10.1038/npp.2013.79.
DHEA Enhances Emotion Regulation Neurocircuits and Modulates Memory for Emotional Stimuli
The study “DHEA Enhances Emotion Regulation Neurocircuits and Modulates Memory for Emotional Stimuli” by Sripada RK, Marx CE, King AP, et al., published in Neuropsychopharmacology in 2013, examines how dehydroepiandrosterone (DHEA) impacts emotion regulation and memory processing for emotional stimuli. The research likely explores the neurobiological mechanisms through which DHEA influences these cognitive and emotional processes, providing valuable insights into the hormone’s role in brain function related to emotions and memory.
For more detailed information: https://www.nature.com/articles/npp201379
Wolkowitz OM, Reus VI, Roberts E, et al. Antidepressant and cognition-enhancing effects of DHEA in major depression. Annals of the New York Academy of Sciences. 1995; 774:337-9.
Antidepressant and cognition-enhancing effects of DHEA in major depression
The study “Antidepressant and cognition-enhancing effects of DHEA in major depression” by Wolkowitz OM, Reus VI, Roberts E, et al., published in the Annals of the New York Academy of Sciences in 1995, investigates the potential benefits of dehydroepiandrosterone (DHEA) in treating major depression. This study focuses on the antidepressant and cognitive enhancement properties of DHEA, contributing to the understanding of its therapeutic potential in depressive disorders, especially in terms of cognitive functions.
For more details: https://nyaspubs.onlinelibrary.wiley.com/doi/abs/10.1111/j.1749-6632.1995.tb17403.x-i1
Peixoto C, Devicari Cheda JN, Nardi AE, Barciela Veras A, Cardoso A. The effects of dehydroepiandrosterone (DHEA) in the treatment of depression and depressive symptoms in other psychiatric and medical illness: a systematic review. Current Drug Targets 2014; 15(9): 901.
The effects of dehydroepiandrosterone (DHEA) in the treatment of depression and depressive symptoms in other psychiatric and medical illnesses
The systematic review “The effects of dehydroepiandrosterone (DHEA) in the treatment of depression and depressive symptoms in other psychiatric and medical illnesses” by Peixoto C, Devicari Cheda JN, Nardi AE, et al., published in Current Drug Targets in 2014, assesses the role of DHEA in treating depression and depressive symptoms related to various psychiatric and medical conditions. This comprehensive review analyzes the effectiveness of DHEA as a therapeutic agent in these contexts, providing a detailed overview of its potential benefits and applications in mental health and associated medical conditions.
For more details: https://www.ingentaconnect.com/content/ben/cdt/2014/00000015/00000009/art00008
Markopoulou K, Papadopoulos A, Juruena MF, Poon L, Pariante CM, Cleare AJ. The ratio of cortisol/DHEA in treatment resistant depression. Psychoneuroendocrinology. 2009; 34(1):19-26.
The ratio of cortisol/DHEA in treatment resistant depression
The study “The ratio of cortisol/DHEA in treatment resistant depression” by Markopoulou K, Papadopoulos A, Juruena MF, et al., published in Psychoneuroendocrinology in 2009, investigates the relationship between cortisol and DHEA levels in individuals with treatment-resistant depression. This research likely explores how the balance between these two hormones affects the severity and treatment outcomes of depression, contributing to the understanding of the biological underpinnings of treatment-resistant depressive states.
For more details: https://www.sciencedirect.com/science/article/pii/S0306453008002114
Załuska M, Janota B. [Dehydroepiandrosteron (DHEA) in the mechanisms of stress and depression]. Psychiatria polska. ; 43(3):263-74.
Dehydroepiandrosterone (DHEA) in the mechanisms of stress and depression
The article “[Dehydroepiandrosterone (DHEA) in the mechanisms of stress and depression]” by Załuska M, Janota B, published in Psychiatria Polska, examines the role of dehydroepiandrosterone (DHEA) in the context of stress and depression. This study likely delves into the biological mechanisms through which DHEA influences stress response and depressive symptoms, shedding light on its potential therapeutic implications in psychiatric disorders related to stress and depression.
Glick R, Jimenez X. P02.62. DHEA augmentation strategy for treatment of fatigue and depression: a case presentation. BMC Complementary and Alternative Medicine. 2012;12(Suppl 1):P118. doi:10.1186/1472-6882-12-S1-P118.
P02.62. DHEA augmentation strategy for treatment of fatigue and depression: a case presentation
The article “P02.62. DHEA augmentation strategy for treatment of fatigue and depression: a case presentation” by Glick R and Jimenez X, published in BMC Complementary and Alternative Medicine in 2012, discusses a case study involving the use of dehydroepiandrosterone (DHEA) as an augmentation strategy for treating fatigue and depression. This study likely explores the clinical outcomes and effectiveness of DHEA supplementation in this context, offering insights into alternative treatment approaches for these conditions.
For more details: https://doi.org/10.1186/1472-6882-12-S1-P118
Angold A. Adolescent depression, cortisol and DHEA. Psychological medicine. 2003; 33(4):573-81.
Adolescent depression, cortisol and DHEA
The study “Adolescent depression, cortisol and DHEA” by Angold A, published in Psychological Medicine in 2003, investigates the relationship between adolescent depression and the levels of cortisol and dehydroepiandrosterone (DHEA). This research likely focuses on the hormonal changes during adolescence and how these changes correlate with the incidence and severity of depression in this age group, providing valuable insights into the biological aspects of adolescent mental health.
For more details: https://www.cambridge.org/core/journals/psychological-medicine/article/adolescent-depression-cortisol-and-dhea/0E29CDC4F46573D94FCF78867C686922
Maninger N, Wolkowitz OM, Reus VI, Epel ES, Mellon SH. Neurobiological and Neuropsychiatric Effects of Dehydroepiandrosterone (DHEA) and DHEA Sulfate (DHEAS). Frontiers in neuroendocrinology. 2009;30(1):65-91. doi:10.1016/j.yfrne.2008.11.002.
Neurobiological and Neuropsychiatric Effects of Dehydroepiandrosterone (DHEA) and DHEA Sulfate (DHEAS)
The article “Neurobiological and Neuropsychiatric Effects of Dehydroepiandrosterone (DHEA) and DHEA Sulfate (DHEAS)” by Maninger N, Wolkowitz OM, Reus VI, et al., published in Frontiers in Neuroendocrinology in 2009, offers a comprehensive review of the effects of DHEA and DHEAS on the brain and their potential neuropsychiatric implications. It likely discusses how these hormones influence neurobiology and their potential roles in various neuropsychiatric disorders.
For more information: https://doi.org/10.1016/j.yfrne.2008.11.002
Wolkowitz OM, Reus VI, Keebler A, et al. Double-blind treatment of major depression with dehydroepiandrosterone. The American journal of psychiatry. 1999; 156(4):646-9.
Double-blind treatment of major depression with dehydroepiandrosterone
The study “Double-blind treatment of major depression with dehydroepiandrosterone” by Wolkowitz OM, Reus VI, Keebler A, et al., published in The American Journal of Psychiatry in 1999, investigates the efficacy of dehydroepiandrosterone (DHEA) in treating major depression. This double-blind study likely assesses the therapeutic potential and safety of DHEA as a treatment option for depression, contributing to the understanding of alternative treatments in psychiatric care.
For more information: https://ajp.psychiatryonline.org/doi/abs/10.1176/ajp.156.4.646
Gallagher P, Young A. Cortisol/DHEA ratios in depression. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2002; 26(3):410.
Cortisol/DHEA ratios in depression
The article “Cortisol/DHEA ratios in depression” by Gallagher P and Young A, published in Neuropsychopharmacology in 2002, examines the relationship between the cortisol/DHEA ratio and depression. This study likely explores how imbalances in these hormones might correlate with the severity or presence of depressive symptoms, offering insights into the hormonal aspects of depression.
For more detailed information, the article can be accessed here: https://www.nature.com/articles/1395863
Hsiao CC. Difference in pre- and post-treatment plasma DHEA levels were significantly and positively correlated with difference in pre- and post-treatment Hamilton depression scores following successful therapy for major depression. Psychoneuroendocrinology. 2006; 31(7):839-46.
Difference in pre- and post-treatment plasma DHEA levels were significantly and positively correlated with difference in pre- and post-treatment Hamilton depression scores following successful therapy for major depression
In the study by Hsiao CC, changes in plasma DHEA levels before and after treatment were found to be positively correlated with changes in Hamilton depression scores in individuals with major depression who responded successfully to therapy. This suggests that alterations in DHEA levels may play a role in the improvement of depressive symptoms following treatment. The study provides insights into the potential link between DHEA and depression outcomes.
For more information: https://pubmed.ncbi.nlm.nih.gov/16731052/
Kritz-Silverstein D, von Mühlen D, Laughlin GA, Bettencourt R. Effects of Dehydroepiandrosterone Supplementation on Cognitive Function and Quality of Life: The DHEA and Well-Ness (DAWN) Trial. Journal of the American Geriatrics Society. 2008;56(7):1292-1298. doi:10.1111/j.1532-5415.2008.01768.x.
Effects of Dehydroepiandrosterone Supplementation on Cognitive Function and Quality of Life
The DHEA and Well-Ness (DAWN) Trial investigated the effects of dehydroepiandrosterone (DHEA) supplementation on cognitive function and quality of life. The study found that DHEA supplementation did not significantly improve cognitive function or quality of life in older adults. These results suggest that DHEA may not have substantial benefits for cognitive function or well-being in this population.
For more details: https://pubmed.ncbi.nlm.nih.gov/18522625/
Maayan R, Morad O, Dorfman P, Overstreet DH, Weizman A, Yadid G. The involvement of dehydroepiandrosterone (DHEA) and its sulfate ester (DHEAS) in blocking the therapeutic effect of electroconvulsive shocks in an animal model of depression. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2005; 15(3):253-62.
The involvement of dehydroepiandrosterone (DHEA) and its sulfate ester (DHEAS) in blocking the therapeutic effect of electroconvulsive shocks in an animal model of depression
The study investigated the role of dehydroepiandrosterone (DHEA) and its sulfate ester (DHEAS) in blocking the therapeutic effect of electroconvulsive shocks (ECS) in a depression model. The results suggest that DHEA and DHEAS may interfere with the antidepressant effects of ECS, potentially reducing their efficacy in treating depression in this animal model.
For more information: https://pubmed.ncbi.nlm.nih.gov/15784338/
Souza-Teodoro LH, de Oliveira C, Walters K, Carvalho LA. Higher serum dehydroepiandrosterone sulfate protects against the onset of depression in the elderly: Findings from the English Longitudinal Study of Aging (ELSA). Psychoneuroendocrinology. 2016;64:40-46. doi:10.1016/j.psyneuen.2015.11.005.
Higher serum dehydroepiandrosterone sulfate protects against the onset of depression in the elderly
This study found that higher serum levels of dehydroepiandrosterone sulfate (DHEAS) are associated with a reduced risk of developing depression in the elderly. The research, conducted using data from the English Longitudinal Study of Aging (ELSA), suggests that DHEAS may have a protective effect against depression onset in older individuals.
For more information: https://pubmed.ncbi.nlm.nih.gov/26630034/
Kurita H, Maeshima H, Kida S, et al. Serum dehydroepiandrosterone (DHEA) and DHEA-sulfate (S) levels in medicated patients with major depressive disorder compared with controls. Journal of affective disorders. 2013; 146(2):205-12.
Serum dehydroepiandrosterone (DHEA) and DHEA-sulfate (S) levels in medicated patients with major depressive disorder compared with controls
This study compared serum dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEA-S) levels in medicated patients with major depressive disorder (MDD) to those in controls. It found that patients with MDD had significantly lower levels of DHEA and DHEA-S compared to the control group. This suggests a potential relationship between low DHEA and MDD, though further research is needed to understand the implications and mechanisms involved.
For more details: https://pubmed.ncbi.nlm.nih.gov/23062318/
DHEA: over-the-counter antidote for depression. Non-prescription hormonal supplement can help relieve minor and major depression in middle age. Health news (Waltham, Mass.). 2005; 11(6):12-3.
Non-prescription hormonal supplement can help relieve minor and major depression in middle age
This article discusses the potential use of over-the-counter dehydroepiandrosterone (DHEA) as an antidote for depression, both minor and major, especially in middle-aged individuals. It highlights the role of DHEA as a hormonal supplement that may help alleviate depression symptoms. However, it’s important to note that while there is some research supporting its potential benefits, more studies are needed to fully understand its effectiveness and safety in treating depression.
For more information: https://dsc.duq.edu/etd/770/
Davis SR, Shah SM, McKenzie DP, Kulkarni J, Davison SL, Bell RJ. Dehydroepiandrosterone sulfate levels are associated with more favorable cognitive function in women. The Journal of clinical endocrinology and metabolism. 2008; 93(3):801-8.
Dehydroepiandrosterone sulfate levels are associated with more favorable cognitive function in women
This study investigated the association between dehydroepiandrosterone sulfate (DHEA-S) levels and cognitive function in women. The research found that higher DHEA-S levels were linked to more favorable cognitive function in women. This suggests that DHEA-S may play a positive role in cognitive health in women.
For more details: https://academic.oup.com/jcem/article/93/3/801/2598143
Huppert FA, Van Niekerk JK. Dehydroepiandrosterone (DHEA) supplementation for cognitive function. The Cochrane database of systematic reviews. 2001.
Dehydroepiandrosterone (DHEA) supplementation for cognitive function
The Cochrane database of systematic reviews published a review on dehydroepiandrosterone (DHEA) supplementation for cognitive function in 2001. This review examined the available evidence on the use of DHEA for cognitive enhancement. However, it is important to note that I cannot provide a detailed summary of the review’s findings due to its length and complexity. For a comprehensive understanding of the review’s results, I recommend accessing the full review through appropriate medical databases or sources.
For more details visit at https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000304/abstract
Grimley Evans J, Malouf R, Huppert F, van Niekerk JK. Dehydroepiandrosterone (DHEA) supplementation for cognitive function in healthy elderly people. The Cochrane database of systematic reviews. 2006.
Dehydroepiandrosterone (DHEA) supplementation for cognitive function in healthy elderly people
The Cochrane database of systematic reviews published a review in 2006 on dehydroepiandrosterone (DHEA) supplementation for cognitive function in healthy elderly people. The review aimed to assess the effects of DHEA on cognitive function in older individuals. However, the specific findings and conclusions of this review are extensive and complex. For a comprehensive understanding of the review’s results, I recommend accessing the full review through appropriate medical databases or sources.
For more details: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006221/abstract
Huppert FA, Van Niekerk JK, Herbert J. Dehydroepiandrosterone (DHEA) supplementation for cognition and well-being. The Cochrane database of systematic reviews. 2000.
Dehydroepiandrosterone (DHEA) supplementation for cognition and well-being
The Cochrane database of systematic reviews published a review in 2000 on dehydroepiandrosterone (DHEA) supplementation for cognition and well-being. This review aimed to evaluate the effects of DHEA supplementation on cognitive function and overall well-being. The review concluded that there was limited evidence to support the use of DHEA for cognitive improvement or enhancing well-being in healthy individuals. Further research was recommended to establish its effectiveness. For a more detailed understanding of the review’s findings, it is advisable to access the full review through relevant medical databases or sources.
For more details, visit at https://cir.nii.ac.jp/crid/1570854175235093248
De Menezes KJ, Peixoto C, Nardi AE, Carta MG, Machado S, Veras AB. Dehydroepiandrosterone, Its Sulfate and Cognitive Functions. Clinical Practice and Epidemiology in Mental Health : CP & EMH. 2016;12:24-37. doi:10.2174/1745017901612010024.
Dehydroepiandrosterone, Its Sulfate and Cognitive Functions
The study titled “Dehydroepiandrosterone, Its Sulfate and Cognitive Functions” explored the relationship between dehydroepiandrosterone (DHEA), its sulfate form (DHEAS), and cognitive functions. The research discussed the potential cognitive-enhancing effects of DHEA and DHEAS. It emphasized the role of these hormones in cognitive performance and mood regulation. However, the study also highlighted the need for further research to fully understand the mechanisms and benefits of DHEA and DHEAS on cognitive functions.
For more in-depth information, please refer: https://doi.org/10.2174/1745017901612010024
Maggio M, De Vita F, Fisichella A, et al. DHEA and cognitive function in the elderly. The Journal of steroid biochemistry and molecular biology. 2015; 145:281-92.
DHEA and cognitive function in the elderly
The study investigated the relationship between dehydroepiandrosterone (DHEA) and cognitive function in the elderly. It discussed the potential cognitive benefits of DHEA supplementation, including improved memory and mood. However, the study also noted the need for further research to establish clear guidelines for DHEA use in cognitive enhancement in older adults.
For more information: https://www.sciencedirect.com/science/article/pii/S0960076014002229
Pluchino N, Drakopoulos P, Bianchi-Demicheli F, Wenger JM, Petignat P, Genazzani AR. Neurobiology of DHEA and effects on sexuality, mood and cognition. The Journal of steroid biochemistry and molecular biology. 2015; 145:273-80.
Neurobiology of DHEA and effects on sexuality, mood and cognition
This study explores the neurobiology of dehydroepiandrosterone (DHEA) and its impact on sexuality, mood, and cognition. It delves into the potential roles of DHEA in enhancing sexual function, mood regulation, and cognitive abilities. The research highlights the complex interplay between DHEA and these aspects of human physiology, shedding light on its potential therapeutic applications.
For more in-depth information, please refer to the full study: https://www.sciencedirect.com/science/article/pii/S0960076015000203
Kritz-Silverstein D, von Mühlen D, Laughlin GA, Bettencourt R. Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well-Ness (DAWN) Trial. Journal of the American Geriatrics Society. 2008; 56(7):1292-8.
Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life
The DHEA and Well-Ness (DAWN) Trial investigated the effects of dehydroepiandrosterone (DHEA) supplementation on cognitive function and quality of life. The study found that DHEA supplementation did not significantly impact cognitive function or quality of life in older adults. However, it’s important to note that this study had limitations, and further research may be needed to fully understand the potential effects of DHEA on cognitive function and quality of life in this population.
Read the full article at https://onlinelibrary.wiley.com/doi/full/10.1111/j.1532-5415.2008.01768.x
Heald AH, Walther A, Davis JRE, et al. No Difference in Mood and Quality of Life in DHEA-S Deficient Adults with Addison’s Disease vs. Type 2 Diabetes Patients with Normal DHEA-S Levels: Implications for Management of These Conditions. Frontiers in psychology. 2017; 8:764.
No Difference in Mood and Quality of Life in DHEA-S Deficient Adults with Addison’s Disease vs. Type 2 Diabetes Patients with Normal DHEA-S Levels
A study comparing adults with DHEA-S deficiency due to Addison’s disease and individuals with normal DHEA-S levels in type 2 diabetes found no significant difference in mood and quality of life between the two groups. These findings have implications for the management of these conditions, suggesting that DHEA-S supplementation may not necessarily improve mood and quality of life in Addison’s disease patients. Further research may be needed to explore the potential benefits of DHEA-S supplementation in specific clinical contexts.
Read the full article at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441639/
Nordmark G, Bengtsson C, Larsson A, Karlsson FA, Sturfelt G, Rönnblom L. Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus. Autoimmunity. 2005; 38(7):531-40.
Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus
In a study involving glucocorticoid-treated female patients with systemic lupus erythematosus (SLE), supplementation with dehydroepiandrosterone (DHEA) did not significantly improve health-related quality of life. While DHEA has shown potential benefits in other contexts, its impact on SLE patients’ quality of life in this study was limited. Further research may be needed to determine the potential role of DHEA in managing SLE-related symptoms and well-being.
Read the full article at https://www.tandfonline.com/doi/abs/10.1080/08916930500204268
Bovenberg SA, van Uum SH, Hermus AR. Dehydroepiandrosterone administration in humans: evidence based? The Netherlands journal of medicine. 2005; 63(8):300-4.
Dehydroepiandrosterone administration in humans
The administration of dehydroepiandrosterone (DHEA) in humans is a subject of debate regarding its evidence-based use. While DHEA has been investigated for various potential benefits, including mood and cognitive function, the evidence supporting its use in different contexts remains inconclusive. Studies have shown mixed results, and more research is needed to establish clear guidelines for DHEA supplementation in humans. The efficacy and safety of DHEA should be carefully considered, and its use should be based on individual health conditions and medical advice.
Read the full article at https://repository.ubn.ru.nl/bitstream/handle/2066/48414/48414.pdf
Elraiyah T, Sonbol MB, Wang Z, et al. Clinical review: The benefits and harms of systemic dehydroepiandrosterone (DHEA) in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. The Journal of clinical endocrinology and metabolism. 2014; 99(10):3536-42.
Clinical review: The benefits and harms of systemic dehydroepiandrosterone (DHEA) in postmenopausal women with normal adrenal function
A systematic review and meta-analysis examined the benefits and harms of systemic dehydroepiandrosterone (DHEA) supplementation in postmenopausal women with normal adrenal function. The analysis found that DHEA had a limited impact on various health outcomes, including bone density, body composition, and quality of life. However, it was associated with a higher risk of adverse events, including acne and hair growth. Overall, the benefits of DHEA in this population may be limited, and its use should be carefully considered due to potential side effects.
For more details: https://academic.oup.com/jcem/article/99/10/3536/2836206
Eden JA. DHEA replacement for postmenopausal women: placebo or panacea? Climacteric : the journal of the International Menopause Society. 2015; 18(4):439-40.
DHEA replacement for postmenopausal women
In the article “DHEA Replacement for Postmenopausal Women: Placebo or Panacea?” by Eden JA, the author questions the true benefits of DHEA replacement therapy for postmenopausal women. The article suggests that the efficacy of DHEA in improving various aspects of women’s health remains a topic of debate and uncertainty. It emphasizes the need for further research to determine whether DHEA truly offers significant benefits or if its effects are more akin to a placebo.
For more information: https://www.tandfonline.com/doi/full/10.3109/13697137.2015.1041956
Lang K, Burger-Stritt S, Hahner S. Is DHEA replacement beneficial in chronic adrenal failure? Best practice & research. Clinical endocrinology & metabolism. 2015; 29(1):25-32.
Is DHEA Replacement Beneficial in Chronic Adrenal Failure?
The article “Is DHEA Replacement Beneficial in Chronic Adrenal Failure?” by Lang, Burger-Stritt, and Hahner examines the potential benefits of DHEA replacement in individuals with chronic adrenal failure. It discusses the role of DHEA in adrenal insufficiency and whether supplementation can improve clinical outcomes. The article emphasizes the need for further research to establish the effectiveness and safety of DHEA replacement therapy in this context.
For more detailed information: https://www.sciencedirect.com/science/article/pii/S1521690X14001195
Virkki LM, Porola P, Forsblad-d’Elia H, Valtysdottir S, Solovieva SA, Konttinen YT. Dehydroepiandrosterone (DHEA) substitution treatment for severe fatigue in DHEA-deficient patients with primary Sjögren’s syndrome. Arthritis care & research. 2010; 62(1):118-24.
Dehydroepiandrosterone (DHEA) substitution treatment for severe fatigue in DHEA-deficient patients with primary Sjögren’s syndrome
The study investigates the use of Dehydroepiandrosterone (DHEA) substitution therapy for severe fatigue in individuals with primary Sjögren’s syndrome who have DHEA deficiency. The research aims to assess whether DHEA supplementation can alleviate fatigue in these patients. The results suggest that DHEA replacement therapy may provide some relief from severe fatigue in individuals with primary Sjögren’s syndrome who have low DHEA levels. However, further studies are needed to establish its efficacy and safety in this context.
For more detailed information: https://onlinelibrary.wiley.com/doi/full/10.1002/acr.20025
Boudarene M, Legros JJ, Timsit-Berthier M. [Study of the stress response: role of anxiety, cortisol and DHEAs]. L’Encephale. ; 28(2):139-46.
Study of the stress response: role of anxiety, cortisol and DHEAs
The study investigates the stress response and the roles of anxiety, cortisol, and Dehydroepiandrosterone (DHEA). It explores how these factors are interconnected in the context of stress. The findings suggest that anxiety can influence the levels of cortisol and DHEA, which are hormones associated with the stress response. Understanding these interactions can provide insights into the physiological mechanisms involved in stress and anxiety.
For more detailed information: https://pubmed.ncbi.nlm.nih.gov/12016302/
Lennartsson AK, Kushnir MM, Bergquist J, Jonsdottir IH. DHEA and DHEA-S response to acute psychosocial stress in healthy men and women. Biological psychology. 2012; 90(2):143-9.
DHEA and DHEA-S response to acute psychosocial stress in healthy men and women
The study examines the response of Dehydroepiandrosterone (DHEA) and its sulfate form (DHEA-S) to acute psychosocial stress in both men and women. It investigates how stress influences the levels of these hormones, which play a role in the body’s stress response. The findings suggest that DHEA and DHEA-S responses to stress may differ between men and women, providing insights into gender-specific stress reactions.
For more details: https://pubmed.ncbi.nlm.nih.gov/22554747/
Maninger N, Capitanio JP, Mason WA, Ruys JD, Mendoza SP. Acute and chronic stress increase DHEAS concentrations in rhesus monkeys. Psychoneuroendocrinology. 2010;35(7):1055-1062. doi:10.1016/j.psyneuen.2010.01.006.
Acute and chronic stress increase DHEAS concentrations in rhesus monkeys
This study explores the impact of acute and chronic stress on Dehydroepiandrosterone sulfate (DHEAS) levels in rhesus monkeys. The findings indicate that both acute and chronic stress lead to increased DHEAS concentrations in these primates, shedding light on the hormonal response to stress in a non-human primate model.
For more details: https://pubmed.ncbi.nlm.nih.gov/20153110/
Kamin HS, Kertes DA. Cortisol and DHEA in development and psychopathology. Hormones and behavior. 2017; 89:69-85.
Cortisol and DHEA in development and psychopathology. Hormones and behavior
This review article discusses the roles of cortisol and Dehydroepiandrosterone (DHEA) in development and psychopathology. It explores how these hormones influence various aspects of development, stress response, and mental health. The article provides insights into the complex interplay between cortisol and DHEA in the context of psychopathological conditions.
For more detailed information: https://pubmed.ncbi.nlm.nih.gov/27601245/
Lennartsson AK, Theorell T, Rockwood AL, Kushnir MM, Jonsdottir IH. Perceived stress at work is associated with lower levels of DHEA-S. PloS one. 2013; 8(8):e72460.
Perceived stress at work is associated with lower levels of DHEA-S
This study found that perceived stress at work is associated with lower levels of Dehydroepiandrosterone sulfate (DHEA-S), an adrenal hormone. The research suggests a link between workplace stress and alterations in DHEA-S levels, which may have implications for overall well-being and health.
For more information: https://pubmed.ncbi.nlm.nih.gov/23967260/
Qiao S, Li X, Zilioli S, et al. Hair Measurements of Cortisol, DHEA, and DHEA to Cortisol Ratio as Biomarkers of Chronic Stress among People Living with HIV in China: Known-Group Validation. Nater UM, ed. PLoS ONE. 2017;12(1):e0169827. doi:10.1371/journal.pone.0169827.
Hair Measurements of Cortisol, DHEA, and DHEA to Cortisol Ratio as Biomarkers of Chronic Stress among People Living with HIV in China: Known-Group Validation
This study investigated the use of hair measurements of cortisol, DHEA, and the DHEA to cortisol ratio as biomarkers of chronic stress in people living with HIV in China. The research aimed to validate these biomarkers for assessing chronic stress levels in this population. The findings suggest that hair cortisol and the DHEA to cortisol ratio are potential biomarkers for chronic stress in individuals with HIV in China, providing valuable insights into the assessment of stress in this context.
For details: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0169827
Phillips AC, Carroll D, Gale CR, Lord JM, Arlt W, Batty GD. Cortisol, DHEAS, their ratio and the metabolic syndrome: evidence from the Vietnam Experience Study. European journal of endocrinology. 2010; 162(5):919-23.
Cortisol, DHEAS, their ratio and the metabolic syndrome: evidence from the Vietnam Experience Study
The study analyzed data from the Vietnam Experience Study and revealed a significant association between the cortisol to DHEAS ratio and the metabolic syndrome. A higher ratio was linked to an elevated risk of developing the metabolic syndrome, implying that the balance between cortisol and DHEAS may have implications for metabolic health. This finding highlights the potential importance of these hormone levels in understanding and managing metabolic disorders.
For more detailed information: https://eje.bioscientifica.com/view/journals/eje/162/5/919.xml
Phillips AC, Carroll D, Gale CR, Lord JM, Arlt W, Batty GD. Cortisol, DHEAS, their ratio and the metabolic syndrome: evidence from the Vietnam Experience Study. European journal of endocrinology. 2010; 162(5):919-23.
Cortisol, DHEAS, their ratio and the metabolic syndrome
The study titled “Cortisol, DHEAS, their ratio, and the metabolic syndrome: evidence from the Vietnam Experience Study,” published in the European Journal of Endocrinology in 2010, aimed to investigate the relationship between cortisol, DHEAS (dehydroepiandrosterone sulfate), and their ratio with metabolic syndrome (MetS) and its components. The study was cross-sectional and involved 4255 Vietnam-era US army veterans. Data were collected from military service files, telephone interviews, and medical examinations, including information on body mass index, blood glucose, blood pressure, high-density lipoprotein cholesterol, and triglyceride levels. The study found that while cortisol was related to MetS, it was not significant in the fully adjusted analysis. High cortisol levels were linked to an increased risk of MetS, while high DHEAS levels seemed protective. The cortisol:DHEAS ratio had the strongest association with MetS, with a higher ratio indicating a greater risk. This ratio was also significantly related to four of the five MetS components. The study concluded that the cortisol:DHEAS ratio is positively associated with MetS and suggested that this ratio merits further research in this and other health contexts
Click for more information: https://pubmed.ncbi.nlm.nih.gov/20164211/
Goodyer IM, Park RJ, Netherton CM, Herbert J. Possible role of cortisol and dehydroepiandrosterone in human development and psychopathology. The British journal of psychiatry : the journal of mental science. 2001; 179:243-9.
Possible role of cortisol and dehydroepiandrosterone in human development and psychopathology
The study “Possible role of cortisol and dehydroepiandrosterone in human development and psychopathology,” published in the British Journal of Psychiatry in 2001, explored the impact of adrenal hormones, specifically cortisol and dehydroepiandrosterone (DHEA), on human development and psychopathology. The study highlighted that changes in adrenal hormone secretion during infancy are significant and can lead to psychological dysfunction and psychopathology in young people. The research aimed to connect developmental changes in cortisol and DHEA, their role in young people’s psychopathology, and their actions in the brain. The findings indicated that developmentally mediated changes in brain sensitivity following excessive cortisol exposure could impair mental and behavioral functions. Furthermore, DHEA and gonadal steroids might modulate cortisol’s actions. The conclusion drawn was that steroid hormones significantly shape behavioral functions during early development and can act as risk factors for psychopathology.
For more details: https://pubmed.ncbi.nlm.nih.gov/11532802/
Panjari M, Davis SR. DHEA therapy for women: effect on sexual function and wellbeing. Human reproduction update. ; 13(3):239-48.
DHEA therapy for women
The study “DHEA therapy for women: effect on sexual function and wellbeing,” published in Human Reproduction Update, examined the use of dehydroepiandrosterone (DHEA) as a supplement for improving libido and wellbeing in postmenopausal women. DHEA and its sulfate, DHEAS, are crucial sex steroid hormones in women and decline with age. The study reviewed the physiology of DHEA and DHEAS and the existing literature on DHEA therapy’s effectiveness for libido and wellbeing in postmenopausal women. The findings indicated that while DHEA is commercially available for these purposes, there is little evidence supporting its effectiveness, and safety data are lacking. The results from randomized controlled trials were limited due to small sample sizes and short treatment durations, leading to inconsistent outcomes. Although some studies on women with adrenal insufficiency suggested potential improvements in mood and libido, these were also constrained by short treatment phases. The study concluded that the potential value of DHEA therapy for women, especially those with adrenal insufficiency, necessitates further exploration in well-designed, adequately powered randomized placebo-controlled trials.
For more information: https://pubmed.ncbi.nlm.nih.gov/17208951/
Panjari M, Bell RJ, Jane F, et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. The journal of sexual medicine. 2009; 6(9):2579-90.
A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido
The study “A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido,” published in The Journal of Sexual Medicine in 2009, investigated the effectiveness of DHEA (dehydroepiandrosterone) in enhancing sexual function and overall well-being in postmenopausal women. The study involved 93 postmenopausal women who were not using estrogen therapy. They participated in a 52-week randomized, double-blind, placebo-controlled trial, receiving either 50 mg of DHEA or a placebo daily. The primary outcome measures assessed over 26 weeks included changes in satisfying sexual events and scores on the Sabbatsberg Sexual Self-Rating Scale, along with secondary measures like the Psychological General Well-Being Questionnaire and the Menopause-Specific Quality of Life Questionnaire. The results showed no significant difference between the DHEA and placebo groups in improving sexual function or well-being. Additionally, women in the DHEA group experienced more androgenic effects like acne and increased hair growth. The study concluded that DHEA at a dose of 50 mg/day did not significantly improve sexual function in postmenopausal women with low libido compared to placebo therapy.
For more detailed information: https://pubmed.ncbi.nlm.nih.gov/19619146/
Baulieu E-E, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(8):4279-4284.
Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue
The study “Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue,” published in the Proceedings of the National Academy of Sciences of the United States of America in 2000, investigated the effects of DHEA supplementation in aging. The study involved 280 healthy individuals aged 60-79 years, who received either 50 mg of DHEA or a placebo daily for a year. The findings showed no harmful accumulation of DHEAS or active steroids. Notably, DHEA supplementation led to an increase in testosterone and estradiol levels, particularly in women. This change was associated with improvements in bone turnover in women over 70 years, as measured by dual-energy x-ray absorptiometry and a decrease in osteoclastic activity. Additionally, there was a significant increase in libido parameters in older women and improvements in skin hydration, epidermal thickness, sebum production, and pigmentation. The study concluded that DHEA supplementation at 50 mg/day can normalize some aging effects without adverse consequences but does not produce extreme enhancements (“supermen/women”)
For more detailed information: https://pubmed.ncbi.nlm.nih.gov/10760294/
Panjari M, Bell RJ, Jane F, et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. The journal of sexual medicine. 2009; 6(9):2579-90.
A randomized trial of oral DHEA treatment for sexual function
The study “A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido,” published in The Journal of Sexual Medicine in 2009, was conducted by Panjari, Bell, Jane, and others. It examined the effect of DHEA (dehydroepiandrosterone) on sexual function, well-being, and menopausal symptoms in postmenopausal women. The study involved 93 postmenopausal women who were not on estrogen therapy and participated in a 52-week randomized, double-blind, placebo-controlled trial, receiving either 50 mg of DHEA or a placebo daily. The results showed no significant improvements in sexual function or well-being in the DHEA group compared to the placebo group over 26 weeks
For detailed information: https://pubmed.ncbi.nlm.nih.gov/19619146/
Panjari, Susan R. Davis; DHEA therapy for women: effect on sexual function and wellbeing, Human Reproduction Update, Volume 13, Issue 3, 1 May 2007, Pages 239–248.
DHEA therapy for women: effect on sexual function and wellbeing
The study “DHEA therapy for women: effect on sexual function and wellbeing,” by Panjari and Davis, published in Human Reproduction Update in 2007, reviewed the role of dehydroepiandrosterone (DHEA) in improving libido and wellbeing in postmenopausal women. DHEA and its sulfate DHEAS are key sex steroid hormones in women, and their levels decline with age. The study examined the potential of restoring DHEA levels to those found in younger individuals for anti-aging effects and enhancing wellbeing and sexual function. However, the review found limited support for DHEA’s effectiveness in these aspects from the published literature. The interpretation of data from randomized controlled trials was constrained by small sample sizes and short treatment durations, leading to inconsistent results. Moreover, while some studies suggested potential improvements in mood and libido in women with adrenal insufficiency, these were also limited by short treatment phases. The study concluded that the value of DHEA therapy for women, especially those with adrenal insufficiency, requires further exploration in well-designed, randomized, placebo-controlled trials
For more details: https://pubmed.ncbi.nlm.nih.gov/17208951/
Hackbert L, Heiman JR. Acute dehydroepiandrosterone (DHEA) effects on sexual arousal in postmenopausal women. Journal of women’s health & gender-based medicine. 2002; 11(2):155-62.
Acute dehydroepiandrosterone (DHEA) effects on sexual arousal in postmenopausal women
The study “Acute dehydroepiandrosterone (DHEA) effects on sexual arousal in postmenopausal women,” published in the Journal of Women’s Health & Gender-Based Medicine in 2002, investigated the impact of DHEA on sexual arousal in postmenopausal women. The study involved 16 sexually functional postmenopausal women who participated in a randomized, double-blind, crossover protocol. They were administered oral DHEA (300 mg) or a placebo 60 minutes before viewing an erotic video. The study measured changes in blood DHEA sulfate (DHEAS), subjective and physiological sexual responses, and affective responses. The results showed a 2-5 fold increase in DHEAS concentration after DHEA administration. Subjective ratings indicated significantly greater mental and physical sexual arousal with DHEA compared to placebo. While vaginal pulse amplitude and blood volume increased in response to the erotic video in both the DHEA and placebo conditions, these measures did not differ between the two conditions. The study concluded that acute doses of DHEA significantly increased mental and physical sexual arousal ratings in postmenopausal women.
For more details: https://pubmed.ncbi.nlm.nih.gov/11975863/
Hackbert L, Heiman JR. Acute dehydroepiandrosterone (DHEA) effects on sexual arousal in postmenopausal women. Journal of women’s health & gender-based medicine. 2002; 11(2):155-62.
Acute dehydroepiandrosterone (DHEA) effects on sexual arousal in postmenopausal women
The study “Acute dehydroepiandrosterone (DHEA) effects on sexual arousal in postmenopausal women,” conducted by Hackbert and Heiman, was published in the Journal of Women’s Health & Gender-Based Medicine in 2002. It explored the effects of DHEA on sexual arousal in postmenopausal women. The study involved 16 postmenopausal women and used a randomized, double-blind, crossover protocol with oral DHEA or a placebo administered before viewing an erotic video. The findings indicated a significant increase in mental and physical sexual arousal ratings with DHEA compared to the placebo.
For more details: https://pubmed.ncbi.nlm.nih.gov/11975863/
Weiss EP, Villareal DT, Fontana L, Han D-H, Holloszy JO. Dehydroepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans. Aging (Albany NY). 2011;3(5):533-542.
Dehydroepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans
The study “Dehydroepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans,” conducted by Weiss, Villareal, Fontana, Han, and Holloszy, was published in Aging (Albany NY) in 2011. The research found that DHEA treatment led to significant decreases in abdominal fat and improved insulin sensitivity, as evidenced by a reduction in the insulin area under the oral glucose tolerance curve without altering glucose levels. Additionally, DHEA replacement improved glucose tolerance in participants who initially had abnormal glucose tolerance (GT), reduced plasma triglycerides, and lowered the levels of inflammatory cytokines IL6 and TNFα.
Dhatariya K, Bigelow ML, Nair KS. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes. 2005; 54(3):765-9.
Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women.
The study “Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women,” published in Diabetes in 2005, investigated the effects of DHEA (dehydroepiandrosterone) replacement on insulin sensitivity and lipid profiles in hypoadrenal women. In this randomized, double-blind, placebo-controlled, crossover study, 28 hypoadrenal women received a daily 50-mg dose of DHEA or placebo for 12 weeks. The study found that DHEA replacement significantly increased DHEA-S (sulfated ester of DHEA), bioavailable testosterone, and androstenedione, and decreased sex hormone-binding globulin levels. It also lowered fasting plasma insulin and glucagon levels, and reduced total cholesterol, triglycerides, LDL cholesterol, and HDL cholesterol. The results suggested that DHEA replacement therapy could enhance insulin sensitivity in hypoadrenal women, potentially impacting the prevention of type 2 diabetes.
For more details: https://pubmed.ncbi.nlm.nih.gov/15734854/
Brennan K, Huang A, Azziz R. Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome. Fertility and sterility. 2009;91(5):1848-1852. doi:10.1016/j.fertnstert.2008.02.101.
Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome
The study “Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome” by Brennan, Huang, and Azziz, published in Fertility and Sterility in 2009, aimed to assess whether increasing levels of DHEAS (dehydroepiandrosterone sulfate) are linked to improved insulin resistance in patients with polycystic ovary syndrome (PCOS). Conducted as a cross-sectional cohort analysis at an academic medical center, the study involved 352 women with PCOS. The main outcome measures included circulating DHEAS, total testosterone, free testosterone, sex hormone-binding globulin (SHBG), 17-hydroxyprogesterone levels, and the calculated homeostasis model assessment of insulin resistance (HOMA-IR). The results showed a negative correlation between DHEAS levels and insulin resistance, with increases in DHEAS, SHBG, 17-OHP, and age associated with decreasing insulin resistance. In contrast, increases in free testosterone, body mass index (BMI), and waist-to-hip ratio (WHR) were linked to increasing insulin resistance. The study concluded that DHEAS is negatively correlated to insulin resistance in PCOS patients, ranking just behind other well-established predictors such as BMI, WHR, and age. However, it remains to be determined whether this correlation is due to a direct beneficial effect of adrenal androgens like DHEA on insulin action or whether DHEAS levels simply reflect circulating hyperinsulinemia levels.
For more detailed information: https://pubmed.ncbi.nlm.nih.gov/18439591/
Villareal DT, Holloszy JO, Kohrt WM. Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. Clinical endocrinology. 2000; 53(5):561-8.
The study “Effects of DHEA replacement on bone mineral density and body composition in elderly women and men,” conducted by Villareal, Holloszy, and Kohrt and published in Clinical Endocrinology in 2000, investigated the impact of DHEA (dehydroepiandrosterone) replacement on bone mineral density (BMD) and body composition in elderly individuals with low serum DHEAS levels. In this 6-month trial, 18 elderly participants (10 women and 8 men) received oral DHEA supplementation at 50 mg/day. The results showed an increase in BMD of the total body and lumbar spine, a decrease in fat mass, and an increase in fat-free mass following DHEA replacement. Additionally, DHEA replacement led to increases in serum IGF-I and total serum testosterone concentrations. The study provided preliminary evidence that DHEA replacement can partially reverse age-related changes in body composition and BMD in elderly individuals with very low serum DHEAS levels.
For more detailed information: https://pubmed.ncbi.nlm.nih.gov/11106916/
Ohnaka K. [Dehydroepiandrosterone(DHEA)and bone metabolism]. Clinical calcium. 2016; 26(7):987-93.
Dehydroepiandrosterone(DHEA)and bone metabolism
The study “[Dehydroepiandrosterone (DHEA) and bone metabolism]” by Ohnaka K., published in Clinical Calcium in 2016, focused on the role of DHEA, an adrenal androgen, in bone metabolism. Recognized as an anti-aging hormone and a marker for senescence, DHEA has been reported to have various beneficial effects, including anti-diabetes, anti-obesity, and anti-atherosclerosis properties. Specifically, DHEA has been shown to have anti-osteoporosis effects, potentially increasing bone mineral density as observed in randomized controlled trials. The hormone’s action against osteoporosis may be due to its metabolites, as osteoblasts express aromatase which converts androgen to estrogen. However, the study notes that there is no report on fracture risk associated with DHEA administration, indicating a need for further research to understand the effects of DHEA on human bone metabolism fully.
For more details: https://pubmed.ncbi.nlm.nih.gov/27346309/
Von Mühlen D, Laughlin GA, Kritz-Silverstein D, Bergstrom J, Bettencourt R. Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2008;19(5):699-707. doi:10.1007/s00198-007-0520-z.
Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial
The study “Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial,” published in Osteoporosis International in 2008, investigated the effects of DHEA supplementation on bone mineral density (BMD), bone metabolism, and body composition in older adults. The randomized, placebo-controlled trial involved 225 healthy adults aged 55 to 85 years, who received 50 mg of oral DHEA daily for one year. The results indicated that DHEA treatment increased serum DHEA and DHEA sulfate levels to concentrations seen in young adults. In women, but not men, DHEA led to increases in testosterone, estradiol, and insulin-like growth factor levels. The treatment showed a positive effect on lumbar spine BMD in women, but no significant impact on hip, femoral neck, or total body BMD, and no significant changes in men. Body composition was not affected by DHEA treatment in either sex. The study concluded that DHEA supplementation has a modest and selective beneficial effect on BMD and bone resorption in women, but no significant bone benefits for men.
For more information: https://pubmed.ncbi.nlm.nih.gov/18084691/
Cormier C, Souberbielle JC, Kahan A. DHEA in bone and joint diseases. Joint, bone, spine : revue du rhumatisme. 2001; 68(6):588-94.
DHEA in bone and joint diseases
The study “DHEA in bone and joint diseases” by Cormier, Souberbielle, and Kahan, published in Joint, Bone, Spine in 2001, explored the role of dehydroepiandrosterone (DHEA) in bone and joint diseases. It noted that serum concentrations of DHEA and its sulfate ester (sDHEA) decrease significantly with age, coinciding with the emergence of age-related health issues. This observation led to the hypothesis that DHEA replacement therapy might benefit older patients. Short-term administration (6 months to 1 year) of daily oral doses that restore sDHEA levels to those seen in young adults was found to be well-tolerated. It showed a modest positive impact on bone in elderly women, especially those with low sDHEA levels before treatment. This effect is attributed to both decreased bone resorption and increased bone formation, likely due to the conversion of DHEA into active sex steroids like estradiol and testosterone. The absence of an effect on bone in men is explained by continued testosterone production by the testes throughout life. The study also suggested other mechanisms, such as an increase in insulin growth factor-1, might be involved. However, DHEA is not recommended as a treatment for osteoporosis at present due to the lack of studies evaluating its efficacy in reducing the fracture rate and understanding its long-term side effects.
For more details: https://pubmed.ncbi.nlm.nih.gov/11809003/
Rutkowski K, Sowa P, Rutkowska-Talipska J, Kuryliszyn-Moskal A, Rutkowski R. Dehydroepiandrosterone (DHEA): hypes and hopes. Drugs. 2014; 74(11):1195-207.
Dehydroepiandrosterone (DHEA): hypes and hopes
The study “Dehydroepiandrosterone (DHEA): hypes and hopes,” published in Drugs in 2014, discussed the role of DHEA and its sulfated form, DHEAS, the most abundant circulating steroid hormones in humans. This study highlighted the various potential benefits of DHEA, such as immunomodulatory actions in the elderly, improving physical and psychological well-being, muscle strength, bone density, and reducing body fat and age-related skin atrophy. In adrenal insufficiency, DHEA restoration leads to improvements in well-being, sexual satisfaction, insulin sensitivity, and prevention of bone mineral density loss. Additionally, DHEA demonstrates protective effects in asthma and allergy and has been shown to have cardiovascular benefits. However, the study also noted inconsistencies in research results, attributing them to factors like over-reliance on animal models, varying dosing protocols, rapid metabolism of DHEA, and comorbidities. It concluded that while DHEA is not merely an overrated dietary supplement, large-scale randomized controlled trials are needed to establish its role in clinical practice
To read the full article visit at: https://pubmed.ncbi.nlm.nih.gov/25022952/
Weiss EP, Shah K, Fontana L, Lambert CP, Holloszy JO, Villareal DT. Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone. The American Journal of Clinical Nutrition. 2009;89(5):1459-1467. doi:10.3945/ajcn.2008.27265.
Dehydroepiandrosterone replacement therapy in older adults
The study “Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone,” published in The American Journal of Clinical Nutrition in 2009, aimed to determine the impact of DHEA supplementation on bone mineral density (BMD) in older adults when combined with vitamin D and calcium. The study included a randomized trial where men and women aged 65-75 years took 50 mg/day of oral DHEA supplements or placebo for the first year, and all participants received open-label DHEA in the second year, along with vitamin D and calcium supplements. The results indicated that DHEA supplementation in older women, but not men, improved spine BMD. In women, spine BMD increased significantly during both years of DHEA supplementation, whereas hip BMD remained unchanged. Increases in testosterone, estradiol, and insulin-like growth factor 1 were noted in the DHEA group, but there were no significant differences in bone turnover markers between groups
For more information: https://pubmed.ncbi.nlm.nih.gov/19321570/
Luo S, Labrie C, Bélanger A, Labrie F. Effect of dehydroepiandrosterone on bone mass, serum lipids, and dimethylbenz(a)anthracene-induced mammary carcinoma in the rat. Endocrinology. 1997; 138(8):3387-94.
Effect of dehydroepiandrosterone on bone mass, serum lipids, and dimethylbenz(a)anthracene-induced mammary carcinoma in the rat
The study “Effect of dehydroepiandrosterone on bone mass, serum lipids, and dimethylbenz(a)anthracene-induced mammary carcinoma in the rat,” conducted by Luo et al. and published in Endocrinology in 1997, examined the impact of DHEA on bone mass, serum lipids, and mammary carcinoma in rats. The rats received DHEA daily for nine months, following a dose of DMBA. The study found that DHEA increased bone mineral content and density in the total skeleton, lumbar spine, and femur. It also led to a reduction in serum triglyceride levels and a decrease in the incidence of mammary carcinoma. Additionally, DHEA increased serum total alkaline phosphatase activity and reduced urinary calcium excretion. These results suggest that DHEA could have beneficial effects on bone and lipid metabolism, as well as a potential preventive effect on mammary carcinoma.
For more detailed information: https://pubmed.ncbi.nlm.nih.gov/9231792/
Gordon CM, Grace E, Emans SJ, et al. Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. The Journal of clinical endocrinology and metabolism. 2002; 87(11):4935-41.
Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa
The study “Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial,” published in The Journal of Clinical Endocrinology and Metabolism in 2002, investigated the effects of DHEA versus conventional hormonal replacement therapy (HRT) on bone mineral density (BMD) in young women with anorexia nervosa. The study involved 61 young women who received either oral DHEA or HRT. While both treatments showed similar increases in total hip BMD, no significant change in lumbar BMD was observed in either group. Bone formation markers, including bone-specific alkaline phosphatase and osteocalcin, transiently increased in the DHEA group. Both therapies significantly reduced levels of bone resorption markers. Additionally, DHEA showed anabolic effects, evidenced by a positive correlation between hip BMD increases and IGF-I levels, and significantly increased bone formation markers. The study also noted improvements in specific psychological parameters in patients receiving DHEA.
For more details: https://pubmed.ncbi.nlm.nih.gov/12414853/
Baulieu E-E, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(8):4279-4284.
Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue
The DHEAge Study, led by Baulieu et al., published in the Proceedings of the National Academy of Sciences in 2000, focused on the effects of DHEA supplementation on aging. Involving 280 healthy individuals aged 60-79, the study administered 50 mg of DHEA daily for a year, along with a placebo. Results indicated no harmful accumulation of DHEAS or active steroids. Improvements were seen in bone turnover in women over 70, libido parameters in older women, and skin status, particularly in hydration, epidermal thickness, sebum production, and pigmentation. The study suggested that DHEA supplementation normalized some aging effects without adverse consequences.
For more details: https://pubmed.ncbi.nlm.nih.gov/10760294/
Ghebre MA, Hart DJ, Hakim AJ, et al. Association between DHEAS and bone loss in postmenopausal women: a 15-year longitudinal population-based study. Calcified tissue international. 2011; 89(4):295-302.
Association between DHEAS and bone loss in postmenopausal women
The study “Association between DHEAS and bone loss in postmenopausal women: a 15-year longitudinal population-based study,” published in Calcified Tissue International in 2011, aimed to examine the relationship between serum dehydroepiandrosterone sulfate (DHEAS) and bone mineral density (BMD) changes in postmenopausal women over a 15-year period. The study included 1,003 postmenopausal women aged 45-68 years at baseline. It found that higher serum DHEAS levels at baseline were associated with less bone loss at the femoral neck and lumbar spine. This association, however, weakened over time. The study suggests that maintaining a high level of DHEAS might be beneficial in managing bone density loss in postmenopausal women.
For more details: https://pubmed.ncbi.nlm.nih.gov/21789637/
Porsová-Dutoit I, Sulcová J, Stárka L. Do DHEA/DHEAS play a protective role in coronary heart disease? Physiological research. 2000; 49 Suppl 1:S43-56.
Do DHEA/DHEAS play a protective role in coronary heart disease? Physiological research
The research conducted by Porsová-Dutoit, Sulcová, and Stárka, titled “Do DHEA/DHEAS play a protective role in coronary heart disease?” offers a comprehensive analysis of the role of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulfate (DHEAS) in coronary heart disease. Their critical review of existing studies led to two main conclusions. Firstly, they found no evidence to support a protective role of DHEA and DHEAS in women. Secondly, their analysis suggested that men with low levels of plasma DHEA and DHEAS might be at increased risk of experiencing fatal cardiovascular events. While this specific study highlights a lack of protective effects in women and potential risks in men with low levels of these androgens, it is important to note the broader context where other research has suggested some cardiovascular benefits of DHEA/DHEAS. These benefits include lowering low-density cholesterol levels in humans and reducing atherosclerotic plaques in rabbits. This dichotomy in findings highlights the complexity of understanding the role of these androgens in coronary heart disease.
For detailed information: https://pubmed.ncbi.nlm.nih.gov/10984146/
Savineau JP, Marthan R, Dumas de la Roque E. Role of DHEA in cardiovascular diseases. Biochemical pharmacology. 2013; 85(6):718-26.
Role of DHEA in cardiovascular diseases
The study “Role of DHEA in Cardiovascular Diseases” by Savineau JP, Marthan R, and Dumas de la Roque E, published in Biochemical Pharmacology in 2013, discusses the significance of dehydroepiandrosterone (DHEA) in cardiovascular diseases (CVD). DHEA, a steroid hormone synthesized from cholesterol by the adrenal glands, and its ester DHEA-S are the most abundant circulating steroid hormones. The study notes an age-related decline in serum DHEA and DHEA-S, suggesting a potential link to the development of age-associated diseases, including CVD. The paper highlights DHEA’s beneficial effects in treating diseases such as hypertension, coronary artery disease, and atherosclerosis, especially noting its advantageous role in pulmonary hypertension. It also explores the cellular mechanisms of DHEA, including its interaction with various receptors and signaling pathways. Acknowledging DHEA as an anti-remodeling and vasorelaxant drug, the study emphasizes its potential as a valuable yet inexpensive treatment in CVD, warranting further research at molecular levels and in clinical trials.
For detailed information: https://pubmed.ncbi.nlm.nih.gov/23270992/
Tivesten Å, Vandenput L, Carlzon D, et al. Dehydroepiandrosterone and its sulfate predict the 5-year risk of coronary heart disease events in elderly men. Journal of the American College of Cardiology. 2014; 64(17):1801-10.
Dehydroepiandrosterone and its sulfate predict the 5-year risk of coronary heart disease events in elderly men
The study “Dehydroepiandrosterone and its sulfate predict the 5-year risk of coronary heart disease events in elderly men” by Tivesten, Vandenput, Carlzon, et al., published in the Journal of the American College of Cardiology in 2014, investigates the role of dehydroepiandrosterone (DHEA) and its sulfate (DHEA-S) in predicting coronary heart disease (CHD) in elderly men. DHEA, an adrenal sex hormone and the most abundant steroid hormone in human blood, declines with age. The study aimed to determine if serum levels of DHEA and DHEA-S are predictors of major CHD and cerebrovascular disease (CBD) events in a large cohort of elderly men.
Using chromatography-mass spectrometry, the study analyzed baseline levels of DHEA and DHEA-S in 2,416 men aged 69 to 81 years. Over a 5-year follow-up, 302 participants experienced a CHD event, and 225 had a CBD event. The results indicated that both DHEA and DHEA-S levels were inversely associated with the age-adjusted risk of a CHD event. However, there was no significant association between DHEA/-S levels and the risk of CBD events. The inverse association between DHEA levels and CHD risk remained significant even after adjusting for various cardiovascular risk factors.
In conclusion, low serum levels of DHEA and its sulfate are predictors of an increased risk of CHD, but not CBD, in elderly men.
For detailed information: https://pubmed.ncbi.nlm.nih.gov/25443702/
Porsová-Dutoit I, Sulcová J, Stárka L. Do DHEA/DHEAS play a protective role in coronary heart disease? Physiological research. 2000; 49 Suppl 1:S43-56.
Do DHEA/DHEAS play a protective role in coronary heart disease?
The study by Porsová-Dutoit, Sulcová, and Stárka, titled “Do DHEA/DHEAS play a protective role in coronary heart disease?”, published in Physiological Research in 2000, evaluates the role of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulfate (DHEAS) in coronary heart disease (CHD). The study, based on a critical review of existing literature, concludes that there is no evidence supporting a protective role of DHEA and DHEAS in women. In contrast, low plasma levels of DHEA and DHEAS in men are considered a risk factor for developing fatal cardiovascular events. The study also explores how these androgens might interact with the atherogenic process, affecting various enzymes and influencing factors like platelet aggregation and fibrinolysis. However, the study notes that there is insufficient data to recommend DHEA supplementation in elderly men, suggesting the need for further research in this area.
For more details: https://pubmed.ncbi.nlm.nih.gov/10984071/
Shufelt C, Bretsky P, Almeida CM, et al. DHEA-S Levels and Cardiovascular Disease Mortality in Postmenopausal Women: Results from the National Institutes of Health—National Heart, Lung, and Blood Institute (NHLBI)-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). The Journal of Clinical Endocrinology and Metabolism. 2010;95(11):4985-4992. doi:10.1210/jc.2010-0143.
DHEA-S Levels and Cardiovascular Disease Mortality in Postmenopausal Women: Results from the National Institutes of Health—National Heart, Lung, and Blood Institute (NHLBI)-Sponsored Women’s Ischemia Syndrome Evaluation (WISE)
The study by Porsová-Dutoit, Sulcová, and Stárka, titled “Do DHEA/DHEAS play a protective role in coronary heart disease?”, published in Physiological Research in 2000, evaluates the role of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulfate (DHEAS) in coronary heart disease (CHD). The study, based on a critical review of existing literature, concludes that there is no evidence supporting a protective role of DHEA and DHEAS in women. In contrast, low plasma levels of DHEA and DHEAS in men are considered a risk factor for developing fatal cardiovascular events. The study also explores how these androgens might interact with the atherogenic process, affecting various enzymes and influencing factors like platelet aggregation and fibrinolysis. However, the study notes that there is insufficient data to recommend DHEA supplementation in elderly men, suggesting the need for further research in this area.
For more details: https://pubmed.ncbi.nlm.nih.gov/10984071/
Wu TT, Chen Y, Zhou Y, et al. Prognostic Value of Dehydroepiandrosterone Sulfate for Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis. Journal of the American Heart Association. 2017; 6(5).
Prognostic Value of Dehydroepiandrosterone Sulfate for Patients With Cardiovascular Disease
The study “Prognostic Value of Dehydroepiandrosterone Sulfate for Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis,” conducted by Wu TT, Chen Y, Zhou Y, et al., aimed to assess the impact of dehydroepiandrosterone sulfate (DHEAS) on the prognosis of cardiovascular disease patients. The systematic review and meta-analysis included 25 studies, with 18 studies being part of the meta-analysis. The results showed that lower levels of DHEAS were associated with a significantly increased risk for all-cause mortality, fatal cardiovascular events, and nonfatal cardiovascular events in patients with cardiovascular disease. The study concluded that patients with cardiovascular disease having lower DHEAS levels might have a poorer prognosis compared to those with higher levels.
For more details: https://pubmed.ncbi.nlm.nih.gov/28476876/
Alzoubi A, Toba M, Abe K, et al. Dehydroepiandrosterone restores right ventricular structure and function in rats with severe pulmonary arterial hypertension. American journal of physiology. Heart and circulatory physiology. 2013; 304(12):H1708-18.
Dehydroepiandrosterone restores right ventricular structure and function in rats with severe pulmonary arterial hypertension
The study “Dehydroepiandrosterone restores right ventricular structure and function in rats with severe pulmonary arterial hypertension” by Alzoubi A, Toba M, Abe K, et al., published in the American Journal of Physiology, explores the effects of Dehydroepiandrosterone (DHEA) on pulmonary arterial hypertension (PAH) and right ventricular (RV) function. The study found that chronic DHEA treatment over five weeks significantly reduced elevated RV systolic pressure and restored impaired cardiac index to normal levels, as assessed by echocardiography. Additionally, DHEA treatment inhibited RV capillary rarefaction, apoptosis, fibrosis, and oxidative stress, and decreased NADPH levels in the RV. These effects were attributed to DHEA’s ability to reduce the expression and activity of Rho kinases in the RV, associated with the inhibition of cardiac remodeling-related transcription factors STAT3 and NFATc3. These findings demonstrate DHEA’s potential in slowing the progression of severe PAH and protecting the RV against damage, primarily through its antioxidant activity
For more details: https://pubmed.ncbi.nlm.nih.gov/23585128/
Kang J, Ge C, Yu L, Li L, Ma H. Long-Term Administration of Dehydroepiandrosterone Accelerates Glucose Catabolism via Activation of PI3K/Akt-PFK-2 Signaling Pathway in Rats Fed a High-Fat Diet. Peterson JM, ed. PLoS ONE. 2016;11(7):e0159077. doi:10.1371/journal.pone.0159077.
Long-Term Administration of Dehydroepiandrosterone Accelerates Glucose Catabolism via Activation of PI3K/Akt-PFK-2 Signaling Pathway in Rats Fed a High-Fat Diet
The study “Long-Term Administration of Dehydroepiandrosterone Accelerates Glucose Catabolism via Activation of PI3K/Akt-PFK-2 Signaling Pathway in Rats Fed a High-Fat Diet” by Kang J, Ge C, Yu L, Li L, Ma H, published in PLoS ONE in 2016, investigates the effects of Dehydroepiandrosterone (DHEA) on glucose metabolism. The study administered varying doses of DHEA to rats on a high-fat diet for 8 weeks. The findings showed that long-term DHEA administration inhibited body weight gain and enhanced glycogen storage, accelerating glucose catabolism. This effect is attributed to the activation of the PI3K/Akt-PFK-2 signaling pathway. The study concluded that DHEA treatment could be a potential strategy for regulating glucose metabolism in the context of a high-fat diet.
For more details: https://pubmed.ncbi.nlm.nih.gov/27410429/
Ostojic SM, Calleja J, Jourkesh M. Effects of short-term dehydroepiandrosterone supplementation on body composition in young athletes. The Chinese journal of physiology. 2010; 53(1):19-25.
Effects of short-term dehydroepiandrosterone supplementation on body composition in young athletes
The study “Effects of short-term dehydroepiandrosterone supplementation on body composition in young athletes” by Ostojic SM, Calleja J, Jourkesh M., published in The Chinese Journal of Physiology in 2010, examined the effects of DHEA on body composition and serum steroid hormones in young athletes. Twenty male soccer players aged 19 to 22 years were divided into two groups, with one receiving 100 mg of DHEA daily and the other a placebo for 28 days. The study found no significant changes in body mass, BMI, waist-to-hip ratio, body fat, total muscle mass, arm fat index, or corrected mid-upper-arm muscle area. However, DHEA supplementation did result in a significant increase in total testosterone, estradiol, and DHEA-S levels compared to the placebo group. The study concluded that DHEA supplementation does not have beneficial effects on body composition in young competitive athletes
For more information: https://pubmed.ncbi.nlm.nih.gov/21789881/
de Heredia FP, Cerezo D, Zamora S, Garaulet M. Effect of dehydroepiandrosterone on protein and fat digestibility, body protein and muscular composition in high-fat-diet-fed old rats. The British journal of nutrition. 2007; 97(3):464-70.
Effect of dehydroepiandrosterone on protein and fat digestibility
The study “Effects of short-term dehydroepiandrosterone supplementation on body composition in young athletes” by Ostojic SM, Calleja J, Jourkesh M., published in The Chinese Journal of Physiology in 2010, examined the effects of DHEA on body composition and serum steroid hormones in young athletes. Twenty male soccer players aged 19 to 22 years were divided into two groups, with one receiving 100 mg of DHEA daily and the other a placebo for 28 days. The study found no significant changes in body mass, BMI, waist-to-hip ratio, body fat, total muscle mass, arm fat index, or corrected mid-upper-arm muscle area. However, DHEA supplementation did result in a significant increase in total testosterone, estradiol, and DHEA-S levels compared to the placebo group. The study concluded that DHEA supplementation does not have beneficial effects on body composition in young competitive athletes.
For more details: https://pubmed.ncbi.nlm.nih.gov/21789881/
Bromberger JT, Schott LL, Kravitz HM, et al. Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: results from the Study of Women’s Health Across the Nation (SWAN). Archives of general psychiatry. 2010; 67(6):598-607.
Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition
The study “Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: results from the Study of Women’s Health Across the Nation (SWAN)” by Bromberger JT, Schott LL, Kravitz HM, et al., published in Archives of General Psychiatry in 2010, focuses on the relationship between hormone levels and depressive symptoms during menopause. The study analyzed data from 3302 multiethnic women, aged 42 to 52, assessing hormone levels and depressive symptoms using the Center for Epidemiological Studies Depression Scale (CES-D). It found that increased testosterone levels were significantly associated with higher odds of depressive symptoms (CES-D score of 16 or higher). This association was independent of menopausal status, which itself was a predictor of higher depressive symptoms. The study highlights the complex relationship between hormonal changes during menopause and mood alterations.
For more details: https://pubmed.ncbi.nlm.nih.gov/20530009/
Available at http://drannacabeca.com/Vaginal_Atrophy.pdf.
Available at https://onlinelibrary.wiley.com/doi/full/10.1111/jmwh.12628.
Available at http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD011066.pub2/abstract
Barrett-Connor E, von Mühlen D, Laughlin GA, Kripke A. Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: the Rancho Bernardo Study. Journal of the American Geriatrics Society. 1999; 47(6):685-91.
Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: the Rancho Bernardo Study
The study “Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: the Rancho Bernardo Study” by Barrett-Connor E, von Mühlen D, Laughlin GA, Kripke A, published in the Journal of the American Geriatrics Society in 1999, explores the relationship between DHEA sulfate levels and mood in older women. Unfortunately, the specific details and conclusions of this study aren’t immediately available from the source.
For more details: https://pubmed.ncbi.nlm.nih.gov/10366167/
Available at https://www.cadth.ca/media/pdf/htis/feb2015/RB0795%20DHEA%20for%20Menopause%20Final.pdf.
Parsons TD, Kratz KM, Thompson E, Stanczyk FZ, Buckwalter JG. Dhea supplementation and cognition in postmenopausal women. The International journal of neuroscience. 2006; 116(2):141-55.
Dhea supplementation and cognition in postmenopausal women.
The study “DHEA supplementation and cognition in postmenopausal women” by Parsons TD, Kratz KM, Thompson E, Stanczyk FZ, Buckwalter JG, published in The International Journal of Neuroscience in 2006, investigated the effects of DHEA on cognition in postmenopausal women. The study found that DHEA supplementation may have adverse cognitive effects. This conclusion was based on analyzing 24-hour measurements of DHEA, DHEAS, and cortisol. The results showed that DHEA administration increased cortisol levels at various times during the day, and there was a positive association between cortisol and cognition in the treatment group. However, the study found a negative association between DHEA(S) levels and cognition, suggesting a direct adverse effect of exogenous DHEA on cognition, independent of cortisol levels.
For more details: https://pubmed.ncbi.nlm.nih.gov/16393880/
Stangl B, Hirshman E, Verbalis J. Administration of Dehydroepiandrosterone (DHEA) Enhances Visual-Spatial Performance in Post-Menopausal Women. Behavioral neuroscience. 2011;125(5):742-752. doi:10.1037/a0025151.
Administration of Dehydroepiandrosterone (DHEA) Enhances Visual-Spatial Performance in Post-Menopausal Women
The study “Administration of Dehydroepiandrosterone (DHEA) Enhances Visual-Spatial Performance in Post-Menopausal Women” by Stangl B, Hirshman E, Verbalis J, published in Behavioral Neuroscience in 2011, investigated the effects of DHEA on visual-spatial performance in postmenopausal women. The study involved administering 50 mg of oral DHEA daily in a double-blind, placebo-controlled crossover design to 24 women aged 55-80. It found that DHEA administration significantly enhanced performance in various visual-spatial tasks, such as Mental Rotation and Subject-Ordered Pointing. Additionally, DHEA administration increased serum levels of DHEA, DHEAS, testosterone, and estrone, with regression analyses showing these levels positively related to cognitive performance in the visual-spatial tasks under DHEA condition
For more details: https://pubmed.ncbi.nlm.nih.gov/21942436/
Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.). 2016; 23(3):243-56.
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause
The study “Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause” by Labrie F, Archer DF, Koltun W, et al., published in Menopause in 2016, evaluated the effects of intravaginal DHEA on symptoms of vulvovaginal atrophy and genitourinary syndrome of menopause. In this randomized, double-blind, placebo-controlled trial, 482 women received either 0.50% DHEA (6.5 mg) or placebo daily for 12 weeks. The study observed significant improvements with DHEA in reducing parabasal cells, increasing superficial cells, lowering vaginal pH, and decreasing pain during sexual activity. Improvements were also noted in vaginal dryness, secretions, epithelial integrity, and surface thickness. The treatment was well-tolerated, with vaginal discharge being the only notable side effect. The study concluded that intravaginal DHEA has clinically significant effects on various symptoms associated with menopausal changes in the vagina, suggesting a high benefit-to-risk ratio.
For more details: https://pubmed.ncbi.nlm.nih.gov/26731686/
Morrison MF, Freeman EW, Lin H, Sammel MD. Higher DHEA-S (Dehydroepiandrosterone Sulfate) Levels are Associated with Depressive Symptoms during the Menopausal Transition: Results from the PENN Ovarian Aging Study. Archives of women’s mental health. 2011;14(5):375-382. doi:10.1007/s00737-011-0231-5.
Higher DHEA-S (Dehydroepiandrosterone Sulfate) Levels are Associated with Depressive Symptoms during the Menopausal Transition: Results from the PENN Ovarian Aging Study
The study “Higher DHEA-S (Dehydroepiandrosterone Sulfate) Levels are Associated with Depressive Symptoms during the Menopausal Transition: Results from the PENN Ovarian Aging Study” by Morrison MF, Freeman EW, Lin H, Sammel MD, published in Archives of Women’s Mental Health in 2011, explores the relationship between DHEA-S levels and depressive symptoms during the menopausal transition. The study is part of the PENN Ovarian Aging Study, which focuses on understanding the biopsychosocial factors related to depression during this transition period.
For more detailed information: https://bmcwomenshealth.biomedcentral.com/articles/10.1186/s12905-019-0782-4#B38
https://www.ncbi.nlm.nih.gov/pubmed/23889217https://www.ncbi.nlm.nih.gov/pubmed/23889217Fusi FM, Ferrario M, Bosisio C, Arnoldi M, Zanga L. DHEA supplementation positively affects spontaneous pregnancies in women with diminished ovarian function. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2013; 29(10):940-3.
DHEA supplementation positively affects spontaneous pregnancies in women with diminished ovarian function
The study “DHEA supplementation positively affects spontaneous pregnancies in women with diminished ovarian function,” by Fusi FM, Ferrario M, Bosisio C, Arnoldi M, Zanga L, published in Gynecological Endocrinology in 2013, investigates the impact of dehydroepiandrosterone (DHEA) supplementation on spontaneous pregnancies in women with long-term infertility. The study involved two groups of women: those under 40 years and those over 40, both with poor responses to fertility treatments. The women received DHEA supplementation prior to in vitro fertilization (IVF). The study found a significant increase in spontaneous pregnancy rates in both groups, suggesting that DHEA supplementation can improve ovarian function and increase the success of fertility treatments in women with poor prognosis for pregnancy.
For more details: https://pubmed.ncbi.nlm.nih.gov/23889217/
Gleicher N, Barad DH. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reproductive Biology and Endocrinology : RB&E. 2011;9:67. doi:10.1186/1477-7827-9-67.
Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR)
The study “Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR)” by Gleicher N, Barad DH, published in Reproductive Biology and Endocrinology in 2011, reviews the impact of DHEA on women with diminished ovarian reserve. The study highlights that DHEA supplementation is increasingly being used worldwide by about one-third of all IVF centers. The evidence reviewed suggests that DHEA can improve ovarian function, increase pregnancy chances, and reduce miscarriage rates by decreasing aneuploidy. It also seems to enhance ovarian reserve over time. This suggests a potential new concept of ovarian aging, where the ovarian environment ages rather than the oocytes themselves, positioning DHEA as a promising agent in addressing aging ovarian environments.
For more detailed information: https://rbej.biomedcentral.com/articles/10.1186/1477-7827-9-67
Naredi N, Sandeep K, Jamwal VDS, Nagraj N, Rai S. Dehydroepiandrosterone: A panacea for the ageing ovary? Medical Journal, Armed Forces India. 2015;71(3):274-277. doi:10.1016/j.mjafi.2014.12.022.
Dehydroepiandrosterone: A panacea for the ageing ovary?
The study “Dehydroepiandrosterone: A panacea for the ageing ovary?” by Naredi N, Sandeep K, Jamwal VDS, Nagraj N, and Rai S, published in the Medical Journal, Armed Forces India in 2015, explores the potential benefits of Dehydroepiandrosterone (DHEA) in addressing age-related issues in the ovary. While the study is titled as a “panacea,” it reviews the existing literature on DHEA’s effects on ovarian aging and discusses its potential role in improving ovarian function. However, it’s important to note that DHEA’s efficacy and safety in this context may vary, and further research is needed to establish its definitive role.
For more information: https://www.sciencedirect.com/science/article/pii/S0377123715000102
Fouany MR, Sharara FI. Is there a role for DHEA supplementation in women with diminished ovarian reserve? Journal of Assisted Reproduction and Genetics. 2013;30(9):1239-1244. doi:10.1007/s10815-013-0018-x.
Is there a role for DHEA supplementation in women with diminished ovarian reserve?
The study titled “Is there a role for DHEA supplementation in women with diminished ovarian reserve?” by Fouany MR and Sharara FI, published in the Journal of Assisted Reproduction and Genetics in 2013, explores the potential benefits of DHEA (Dehydroepiandrosterone) supplementation in women with diminished ovarian reserve.
In this study, the authors investigate whether DHEA supplementation can have a positive impact on women who have diminished ovarian reserve, which is a condition associated with reduced fertility potential. They likely conducted experiments or reviewed relevant literature to analyze the effects of DHEA supplementation on ovarian reserve and reproductive outcomes in this specific group of women.
Poli E, Manfé S, Capuzzo D, et al. DHEA pre-treated patients, poor responders to a first IVF (ICSI) cycle: clinical results. Clinical and experimental obstetrics & gynecology. 2014; 41(1):5-9.
DHEA pre-treated patients, poor responders to a first IVF (ICSI) cycle
The study titled “DHEA pre-treated patients, poor responders to a first IVF (ICSI) cycle: clinical results” by Poli E et al., published in the journal Clinical and Experimental Obstetrics & Gynecology in 2014, investigates the clinical outcomes of women who had poor responses to their initial IVF (In Vitro Fertilization) or ICSI (Intracytoplasmic Sperm Injection) cycle and were pre-treated with DHEA (Dehydroepiandrosterone). The study likely involves a clinical trial or research study to assess the effectiveness of DHEA supplementation in improving outcomes for these specific patients. It may include data on pregnancy rates, live birth rates, and any potential side effects or adverse events associated with DHEA supplementation in this particular group of patients.
For more information: https://article.imrpress.com/journal/CEOG/41/1/10.12891/ceog16742014/1630293994810-2011851739.pdf
Gat I, Blanco Mejia S, Balakier H, Librach CL, Claessens A, Ryan EA. The use of coenzyme Q10 and DHEA during IUI and IVF cycles in patients with decreased ovarian reserve. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2016; 32(7):534-7.
The use of coenzyme Q10 and DHEA during IUI and IVF cycles in patients with decreased ovarian reserve.
This study, published in Gynecological Endocrinology in 2016, investigates the utilization of coenzyme Q10 (CoQ10) and DHEA (Dehydroepiandrosterone) in patients with diminished ovarian reserve during IUI (Intrauterine Insemination) and IVF (In Vitro Fertilization) cycles. The authors likely conducted research or a clinical trial to examine the effects of CoQ10 and DHEA supplementation on the outcomes of assisted reproductive techniques such as IUI and IVF in women with decreased ovarian reserve. For the complete article, you can search on academic databases or the journal’s website using the reference details provided.
For more information: https://www.tandfonline.com/doi/abs/10.3109/09513590.2015.1137095
Gleicher N, Ryan E, Weghofer A, Blanco-Mejia S, Barad DH. Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve: a case control study. Reproductive Biology and Endocrinology : RB&E. 2009;7:108. doi:10.1186/1477-7827-7-108.
Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve
The study titled “Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve: a case-control study” by Gleicher N, Ryan E, Weghofer A, Blanco-Mejia S, and Barad DH, was published in the journal Reproductive Biology and Endocrinology in 2009. This case-control study aimed to investigate the impact of DHEA (Dehydroepiandrosterone) supplementation on miscarriage rates in women with diminished ovarian reserve. The authors likely conducted this study to assess whether DHEA supplementation had any effect on reducing the miscarriage rates in this specific group of women. To access the full article and obtain detailed findings, you can search for it on academic databases or access it through the provided DOI (Digital Object Identifier): 10.1186/1477-7827-7-108.
For more detailed information: https://link.springer.com/article/10.1186/1477-7827-7-108
Keane KN, Hinchliffe PM, Rowlands PK, et al. DHEA Supplementation Confers No Additional Benefit to that of Growth Hormone on Pregnancy and Live Birth Rates in IVF Patients Categorized as Poor Prognosis. Frontiers in endocrinology. 2018; 9:14.
DHEA Supplementation Confers No Additional Benefit to that of Growth Hormone on Pregnancy and Live Birth Rates in IVF Patients Categorized as Poor Prognosis
The study titled “DHEA Supplementation Confers No Additional Benefit to that of Growth Hormone on Pregnancy and Live Birth Rates in IVF Patients Categorized as Poor Prognosis” by Keane KN, Hinchliffe PM, Rowlands PK, et al., was published in Frontiers in Endocrinology in 2018. This study examined the effect of DHEA (Dehydroepiandrosterone) supplementation on pregnancy and live birth rates in IVF (In Vitro Fertilization) patients who were categorized as having a poor prognosis for successful fertility outcomes. The research aimed to determine whether the addition of DHEA provided any additional benefits beyond those of growth hormone in improving IVF success rates for this group of patients.
For more detailed information: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5812302/
Qin JC, Fan L, Qin AP. The effect of dehydroepiandrosterone (DHEA) supplementation on women with diminished ovarian reserve (DOR) in IVF cycle: Evidence from a meta-analysis. Journal of gynecology obstetrics and human reproduction. 2017; 46(1):1-7.
The effect of dehydroepiandrosterone (DHEA) supplementation on women with diminished ovarian reserve (DOR) in IVF cycle
In the study titled “The effect of dehydroepiandrosterone (DHEA) supplementation on women with diminished ovarian reserve (DOR) in IVF cycle: Evidence from a meta-analysis” by Qin JC, Fan L, and Qin AP, published in the Journal of Gynecology, Obstetrics, and Human Reproduction in 2017, a comprehensive meta-analysis was conducted to assess the impact of DHEA (Dehydroepiandrosterone) supplementation on women with diminished ovarian reserve (DOR) undergoing IVF (In Vitro Fertilization) cycles. By pooling data from various studies, the authors aimed to provide a conclusive evaluation of the overall effect of DHEA supplementation on IVF outcomes in this specific patient group.
For more detailed information: https://www.sciencedirect.com/science/article/pii/S036823151600003X
Tartagni M, Cicinelli MV, Baldini D, et al. Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old. Reproductive Biology and Endocrinology : RB&E. 2015;13:18. doi:10.1186/s12958-015-0014-3.
Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old
The study titled “Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old” by Tartagni M, Cicinelli MV, Baldini D, et al., was published in Reproductive Biology and Endocrinology in 2015. This study aimed to investigate the impact of Dehydroepiandrosterone (DHEA) supplementation on the in vitro fertilization (IVF) outcomes in women under the age of 40. The research focused on whether DHEA could mitigate the age-related decline in IVF success rates for this specific age group.
For more detailed information, visit at: https://rbej.biomedcentral.com/articles/10.1186/s12958-015-0014-3
Scheffers CS, Armstrong S, Cantineau AE, Farquhar C, Jordan V. Dehydroepiandrosterone for women in the peri- or postmenopausal phase. The Cochrane database of systematic reviews. 2015; 1:CD011066.
Dehydroepiandrosterone for women in the peri- or postmenopausal phase
The study titled “Dehydroepiandrosterone for women in the peri- or postmenopausal phase” by Scheffers CS, Armstrong S, Cantineau AE, Farquhar C, and Jordan V, was published in The Cochrane Database of Systematic Reviews in 2015. This systematic review aimed to assess the use of Dehydroepiandrosterone (DHEA) in women during the peri- or postmenopausal phase. The Cochrane Database of Systematic Reviews is known for its comprehensive and evidence-based analysis of various medical interventions.
For more information: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011066.pub2/abstract
Davis SR, Panjari M, Stanczyk FZ. Clinical review: DHEA replacement for postmenopausal women. The Journal of clinical endocrinology and metabolism. 2011; 96(6):1642-53.
DHEA replacement for postmenopausal women
The clinical review titled “DHEA replacement for postmenopausal women” authored by Davis SR, Panjari M, and Stanczyk FZ was published in The Journal of Clinical Endocrinology and Metabolism in 2011. This review article explores the use of Dehydroepiandrosterone (DHEA) replacement therapy for postmenopausal women. It likely provides an overview of the existing literature, studies, and clinical evidence related to the use of DHEA as a hormonal replacement therapy in postmenopausal women.
For more detailed information: https://pubmed.ncbi.nlm.nih.gov/21411558/
Labrie F, Labrie C. DHEA and intracrinology at menopause, a positive choice for evolution of the human species. Climacteric : the journal of the International Menopause Society. 2013; 16(2):205-13.
DHEA and intracrinology at menopause
The article titled “DHEA and intracrinology at menopause, a positive choice for evolution of the human species” by Labrie F and Labrie C was published in Climacteric: The Journal of the International Menopause Society in 2013. In this article, the authors likely discuss the role of Dehydroepiandrosterone (DHEA) and intracrinology in the context of menopause. It may provide insights into how DHEA and the concept of intracrinology (local production of sex hormones) influence various aspects of menopause and the evolution of the human species. For a more in-depth understanding and detailed information
For more information: https://www.tandfonline.com/doi/abs/10.3109/13697137.2012.733983
Panjari M, Bell RJ, Jane F, et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. The journal of sexual medicine. 2009; 6(9):2579-90.
A randomized trial of oral DHEA treatment for sexual function
In the study titled “A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido” by Panjari M, Bell RJ, Jane F, et al., published in The Journal of Sexual Medicine in 2009, researchers conducted a randomized trial to investigate the effects of oral DHEA (Dehydroepiandrosterone) treatment on sexual function, overall well-being, and menopausal symptoms in postmenopausal women who reported low libido. The study likely involved participants receiving either DHEA or a placebo, and various outcomes, including sexual function, overall well-being, and menopausal symptom relief, were assessed.
For more details: https://pubmed.ncbi.nlm.nih.gov/19619146/
Lasley BL, Santoro N, Randolf JF, et al. The relationship of circulating dehydroepiandrosterone, testosterone, and estradiol to stages of the menopausal transition and ethnicity. The Journal of clinical endocrinology and metabolism. 2002; 87(8):3760-7.
The relationship of circulating dehydroepiandrosterone, testosterone, and estradiol to stages of the menopausal transition and ethnicity
The study titled “The relationship of circulating dehydroepiandrosterone, testosterone, and estradiol to stages of the menopausal transition and ethnicity” by Lasley BL, Santoro N, Randolf JF, et al., published in The Journal of Clinical Endocrinology and Metabolism in 2002, investigated how circulating hormone levels, including dehydroepiandrosterone (DHEA), testosterone, and estradiol, correlate with different stages of the menopausal transition and whether ethnicity plays a role in these hormonal variations. The study likely involved assessing hormone levels in women at various menopausal stages, considering their ethnic backgrounds.
For more detailed information: https://academic.oup.com/jcem/article-abstract/87/8/3760/2846984
Panjari M, Davis SR. DHEA therapy for women: effect on sexual function and wellbeing. Human reproduction update. ; 13(3):239-48.
DHEA therapy for women
The study titled “DHEA therapy for women: effect on sexual function and wellbeing” by Panjari M and Davis SR, published in Human Reproduction Update, examined the impact of DHEA (Dehydroepiandrosterone) therapy on sexual function and overall well-being in women. This study likely involved a comprehensive review and analysis of existing research to evaluate how DHEA treatment affects sexual function and the overall sense of well-being in women
For more detailed information: https://academic.oup.com/humupd/article-abstract/13/3/239/2457836
Panjari M, Bell RJ, Jane F, et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. The journal of sexual medicine. 2009; 6(9):2579-90.
A randomized trial of oral DHEA treatment for sexual function
A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido” by Panjari M, Bell RJ, Jane F, et al., published in The Journal of Sexual Medicine in 2009, conducted a randomized trial to investigate the effects of oral DHEA (Dehydroepiandrosterone) treatment on sexual function, overall well-being, and menopausal symptoms in postmenopausal women who reported low libido. The study likely involved participants receiving either DHEA or a placebo, and various outcomes, including sexual function, overall well-being, and menopausal symptom relief, were assessed.
For more information: https://academic.oup.com/jsm/article-abstract/6/9/2579/6834489
Baulieu E-E, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(8):4279-4284.
Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging
The study titled “Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue” by Baulieu E-E, Thomas G, Legrain S, et al., published in the Proceedings of the National Academy of Sciences of the United States of America in 2000, presents the findings of the DHEAge Study, which aimed to address the sociobiomedical issue of the role of Dehydroepiandrosterone (DHEA) and DHEA sulfate in the aging process. This study likely involved a comprehensive investigation into the relationship between DHEA, DHEA sulfate, and the aging process, shedding light on their potential contributions to various aspects of aging.
For more detailed information: https://www.pnas.org/doi/abs/10.1073/pnas.97.8.4279
Panjari M, Bell RJ, Jane F, et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. The journal of sexual medicine. 2009; 6(9):2579-90.
A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido
The study titled “A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido” by Panjari M, Bell RJ, Jane F, et al., published in The Journal of Sexual Medicine in 2009, conducted a randomized trial to investigate the effects of oral DHEA (Dehydroepiandrosterone) treatment on sexual function, overall well-being, and menopausal symptoms in postmenopausal women who reported low libido. The study involved participants receiving either DHEA or a placebo, and various outcomes, including sexual function, overall well-being, and menopausal symptom relief, were assessed.
For more information: https://academic.oup.com/jsm/article-abstract/6/9/2579/6834489
Panjari, Susan R. Davis; DHEA therapy for women: effect on sexual function and wellbeing, Human Reproduction Update, Volume 13, Issue 3, 1 May 2007, Pages 239–248.
DHEA therapy for women: effect on sexual function and wellbeing, Human Reproduction Update
The article titled “DHEA therapy for women: effect on sexual function and wellbeing” authored by Panjari and Susan R. Davis was published in Human Reproduction Update in May 2007 (Volume 13, Issue 3, Pages 239–248). This article likely provides a comprehensive review and analysis of the impact of DHEA (Dehydroepiandrosterone) therapy on sexual function and overall well-being in women. It may summarize existing research and clinical evidence related to DHEA treatment and its effects on sexual health and the general sense of well-being in women.
For more detailed information: https://academic.oup.com/humupd/article-abstract/13/3/239/2457836
Hackbert L, Heiman JR. Acute dehydroepiandrosterone (DHEA) effects on sexual arousal in postmenopausal women. Journal of women’s health & gender-based medicine. 2002; 11(2):155-62.
Acute dehydroepiandrosterone (DHEA) effects on sexual arousal in postmenopausal women
The study titled “Acute dehydroepiandrosterone (DHEA) effects on sexual arousal in postmenopausal women” by Hackbert L and Heiman JR, published in the Journal of Women’s Health & Gender-Based Medicine in 2002, investigates the immediate effects of Dehydroepiandrosterone (DHEA) on sexual arousal in postmenopausal women. This study likely involved examining the impact of DHEA administration on sexual arousal in a controlled experiment.
For more in-deepth knowledge read the full article on https://www.liebertpub.com/doi/abs/10.1089/152460902753645290
Baulieu E-E, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(8):4279-4284.
Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue
The study titled “Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue” by Baulieu E-E, Thomas G, Legrain S, et al., was published in the Proceedings of the National Academy of Sciences of the United States of America in 2000. The DHEAge Study aimed to address a sociobiomedical issue by investigating the roles of Dehydroepiandrosterone (DHEA) and DHEA sulfate in the aging process. This study likely conducted extensive research to examine how DHEA and DHEA sulfate are associated with various aspects of aging.
For more information: https://www.pnas.org/doi/abs/10.1073/pnas.97.8.4279
Nouveau S, Bastien P, Baldo F, de Lacharriere O. Effects of topical DHEA on aging skin: a pilot study. Maturitas. 2008; 59(2):174-81.
Effects of topical DHEA on aging skin: a pilot study. Maturitas.
The study titled “Effects of topical DHEA on aging skin: a pilot study” by Nouveau S, Bastien P, Baldo F, and de Lacharriere O, was published in Maturitas in 2008. This pilot study likely investigated the impact of topically applied Dehydroepiandrosterone (DHEA) on aging skin. The study may have involved assessing various skin-related parameters to understand how DHEA application affects the aging process and the condition of the skin.
To know more about this study visit at https://www.sciencedirect.com/science/article/pii/S0378512207003611
Hennebert O, Chalbot S, Alran S, Morfin R. Dehydroepiandrosterone 7alpha-hydroxylation in human tissues: possible interference with type 1 11beta-hydroxysteroid dehydrogenase-mediated processes. The Journal of steroid biochemistry and molecular biology. 2007; 104(3-5):326-33.
Dehydroepiandrosterone 7alpha-hydroxylation in human tissues
The study titled “Dehydroepiandrosterone 7alpha-hydroxylation in human tissues: possible interference with type 1 11beta-hydroxysteroid dehydrogenase-mediated processes” by Hennebert O, Chalbot S, Alran S, and Morfin R, was published in The Journal of Steroid Biochemistry and Molecular Biology in 2007. This study likely explored the enzymatic process of dehydroepiandrosterone (DHEA) 7alpha-hydroxylation in human tissues and its potential impact on interfering with type 1 11beta-hydroxysteroid dehydrogenase-mediated processes. The research may have examined how DHEA metabolism could influence other hormonal processes, especially those related to glucocorticoids.
To know more about this study visit at https://www.sciencedirect.com/science/article/pii/S0960076007000799
Villareal DT, Holloszy JO. DHEA enhances effects of weight training on muscle mass and strength in elderly women and men. American journal of physiology. Endocrinology and metabolism. 2006; 291(5):E1003-8.
DHEA enhances effects of weight training on muscle mass and strength in elderly women and men
The study titled “DHEA enhances effects of weight training on muscle mass and strength in elderly women and men” by Villareal DT and Holloszy JO was published in the American Journal of Physiology – Endocrinology and Metabolism in 2006. This study likely investigated the effects of Dehydroepiandrosterone (DHEA) supplementation in combination with weight training on muscle mass and strength in elderly women and men. It may have involved a controlled experiment to assess the potential benefits of DHEA supplementation for enhancing the outcomes of resistance training in the elderly population.
For more information: https://journals.physiology.org/doi/abs/10.1152/ajpendo.00100.2006
Chen W-C, Chen Y-M, Huang C-C, Tzeng Y-D. Dehydroepiandrosterone Supplementation Combined with Whole-Body Vibration Training Affects Testosterone Level and Body Composition in Mice. International Journal of Medical Sciences. 2016;13(10):730-740. doi:10.7150/ijms.16132.
Dehydroepiandrosterone Supplementation Combined with Whole-Body Vibration Training Affects Testosterone Level and Body Composition in Mice
The study titled “Dehydroepiandrosterone Supplementation Combined with Whole-Body Vibration Training Affects Testosterone Level and Body Composition in Mice” by Chen W-C, Chen Y-M, Huang C-C, and Tzeng Y-D, was published in the International Journal of Medical Sciences in 2016. This research likely examined the combined effects of Dehydroepiandrosterone (DHEA) supplementation and whole-body vibration training on testosterone levels and body composition in mice. The study may have involved assessing hormonal changes and body composition alterations in mice exposed to both DHEA supplementation and whole-body vibration training. For a more comprehensive understanding and detailed findings.
You can access the full article through https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066508/
Hwang AC, Liu LK, Lee WJ, et al. Association of androgen with skeletal muscle mass and muscle function among men and women aged 50 years and older in Taiwan: results from the I-Lan longitudinal aging study. Rejuvenation research. 2013; 16(6):453-9.
Association of androgen with skeletal muscle mass and muscle function among men and women aged 50 years and older in Taiwan
The study titled “Association of androgen with skeletal muscle mass and muscle function among men and women aged 50 years and older in Taiwan: results from the I-Lan longitudinal aging study” by Hwang AC, Liu LK, Lee WJ, et al., was published in Rejuvenation Research in 2013. This study likely investigated the relationship between androgen levels and skeletal muscle mass as well as muscle function in individuals aged 50 years and older in Taiwan. The research may have explored how androgen levels influence muscle-related parameters in both men and women within this age group.
For a deeper understanding and detailed findings visit at https://www.liebertpub.com/doi/abs/10.1089/rej.2013.1442
Dayal M, Sammel MD, Zhao J, Hummel AC, Vandenbourne K, Barnhart KT. Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids. Journal of women’s health (2002). 2005; 14(5):391-400.
Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids
The study titled “Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids” by Dayal M, Sammel MD, Zhao J, Hummel AC, Vandenbourne K, and Barnhart KT, was published in the Journal of Women’s Health (2002) in 2005. This study likely examined the impact of Dehydroepiandrosterone (DHEA) supplementation on parameters such as muscle size, strength, quality of life, and lipid levels. The research may have involved assessing these outcomes in individuals who received DHEA supplementation to understand its effects.
For more detailed findings and insights, you can access the full article through https://www.liebertpub.com/doi/abs/10.1089/jwh.2005.14.391
Villareal DT, Holloszy JO. DHEA enhances effects of weight training on muscle mass and strength in elderly women and men. American journal of physiology. Endocrinology and metabolism. 2006; 291(5):E1003-8.
DHEA enhances effects of weight training on muscle mass and strength in elderly women and men
The study titled “DHEA enhances effects of weight training on muscle mass and strength in elderly women and men” by Villareal DT and Holloszy JO was published in the American Journal of Physiology – Endocrinology and Metabolism in 2006. This study likely investigated the effects of Dehydroepiandrosterone (DHEA) supplementation in combination with weight training on muscle mass and strength in elderly women and men. It may have involved a controlled experiment to assess the potential benefits of DHEA supplementation for enhancing the outcomes of resistance training in the elderly population.
For more information: https://journals.physiology.org/doi/abs/10.1152/ajpendo.00100.2006
Clore JN. Dehydroepiandrosterone and body fat. Obesity research. 1995; 3 Suppl 4:613S-616S.
Dehydroepiandrosterone and body fat
The research article by Clore JN, titled “Dehydroepiandrosterone and body fat,” published in Obesity Research in 1995, concludes that Dehydroepiandrosterone (DHEA) does not play a significant role in the pharmacological treatment of human obesity. Studies have failed to show a beneficial effect of DHEA on body composition or energy expenditure at either pharmacologic or physiologic replacement doses for durations of 1 to 3 months.
For more detailed information: https://www.semanticscholar.org/paper/Dehydroepiandrosterone-and-body-fat.-Clore/8b14e31aa8188844e08934ad40673c201138b78e
Libè R, Barbetta L, Dall’Asta C, et al. Effects of dehydroepiandrosterone (DHEA) supplementation on hormonal, metabolic and behavioral status in patients with hypoadrenalism. Journal of endocrinological investigation. 2004; 27(8):736-41.
Effects of dehydroepiandrosterone (DHEA) supplementation on hormonal, metabolic and behavioral status in patients with hypoadrenalism
The 2004 study by Libè et al. in the Journal of Endocrinological Investigation investigated the effects of DHEA supplementation in hypoadrenalism patients. Involving 20 participants, the study found significant hormonal changes, particularly in women, with increases in DHEAS, testosterone, and androstenedione levels. Metabolically, DHEA reduced cholesterol and low-density lipoproteins in Addison’s disease patients but did not affect glucose metabolism or insulin sensitivity. There was also a decrease in serum osteocalcin and body fat mass percentage. However, DHEA supplementation did not significantly alter subjective health scales and sexuality in either sex, suggesting its primary benefit in hypoadrenalism might be in restoring androgen levels.
For more detailed information: https://pubmed.ncbi.nlm.nih.gov/15636426/
Reiter WJ, Pycha A, Schatzl G, et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology. 1999; 53(3):590-4; discussion 594-5.
Dehydroepiandrosterone in the treatment of erectile dysfunction.
The 1999 study by Reiter et al., published in Urology, investigated the efficacy of dehydroepiandrosterone (DHEA) in treating erectile dysfunction (ED) through a double-blind, randomized, placebo-controlled trial. Forty patients with ED were divided into two groups: one received 50 mg DHEA and the other a placebo daily for six months. The International Index of Erectile Function (IIEF) was used to assess therapy success. Results indicated that DHEA treatment led to higher mean scores across all five IIEF domains, with no significant impact on serum levels of PSA, prolactin, testosterone, prostate volume, or postvoid residual urine volume. The study concluded that DHEA might benefit ED treatment, suggesting a need for more extensive studies despite the small patient base.
Visit this link for more studies: https://pubmed.ncbi.nlm.nih.gov/10096389/
Reiter WJ, Schatzl G, Märk I, Zeiner A, Pycha A, Marberger M. Dehydroepiandrosterone in the treatment of erectile dysfunction in patients with different organic etiologies. Urological research. 2001; 29(4):278-81.
The study by Reiter et al., titled “Dehydroepiandrosterone in the treatment of erectile dysfunction in patients with different organic etiologies,” published in Urological Research in 2001, examined the use of DHEA in treating erectile dysfunction (ED) in patients with various organic causes. The study administered 50 mg of oral DHEA daily for six months. The results suggested that DHEA might be beneficial for ED patients with hypertension or those without an organic etiology. However, the study found that DHEA treatment had no significant impact on erectile dysfunction in patients with diabetes.
For more in-depth studies visit at: https://www.researchgate.net/publication/11764899_Dehydroepiandrosterone_in_the_Treatment_of_Erectile_Dysfunction_in_Patients_With_Different_Organic_Etiologies
Peixoto C, Carrilho CG, Barros JA, et al. The effects of dehydroepiandrosterone on sexual function: a systematic review. Climacteric : the journal of the International Menopause Society. 2017; 20(2):129-137.
The effects of dehydroepiandrosterone on sexual function
The 2017 systematic review by Peixoto et al., published in Climacteric: The Journal of the International Menopause Society, focused on evaluating the effects of dehydroepiandrosterone (DHEA) on sexual function. This review was motivated by the increasing interest in DHEA’s actions and benefits, particularly in light of the negative impact of sexual dysfunctions on quality of life. The review analyzed various clinical studies, encompassing a total of 183 references, out of which 38 were considered eligible. The findings indicated that DHEA supplementation improved aspects like sexual interest, lubrication, pain, arousal, orgasm, and sexual frequency. The effects of DHEA were particularly pronounced in populations with sexual dysfunction, most notably in perimenopausal and postmenopausal women. The conclusion drawn from the available studies was that DHEA is effective in enhancing several facets of sexual function, although the benefits were not universally applicable across all populations studied.
To know about full article visit at: https://pubmed.ncbi.nlm.nih.gov/28118059/
Vakina TN, Shutov AM, Shalina SV, Zinov’eva EG, Kiselev IP. [Dehydroepiandrosterone and sexual function in men with chronic prostatitis]. Urologiia (Moscow, Russia : 1999).
Dehydroepiandrosterone and sexual function in men with chronic prostatitis
To locate the study by Vakina TN, Shutov AM, Shalina SV, Zinov’eva EG, and Kiselev IP on the topic of dehydroepiandrosterone (DHEA) and sexual function in men with chronic prostatitis, I will conduct a search for you. Please hold on for a moment.
I couldn’t find the specific study by Vakina TN, Shutov AM, Shalina SV, Zinov’eva EG, and Kiselev IP on “Dehydroepiandrosterone and sexual function in men with chronic prostatitis” published in Urologiia. It’s possible that the study might be less accessible online due to various reasons such as publication in a less digitized journal, language barriers, or limited online distribution. For access to this specific study, I recommend consulting academic databases, university libraries, or contacting the authors directly if possible.
For more details: https://innoscience.ru/1728-2985/article/view/274377
Persu C, Cauni V, Gutue S, Albu E, Jinga V, Geavlete P. Diagnosis and treatment of erectile dysfunction– a practical update. Journal of Medicine and Life. 2009;2(4):394-400.
Diagnosis and treatment of erectile dysfunction– a practical update
The article “Diagnosis and treatment of erectile dysfunction– a practical update” by Persu et al., published in the Journal of Medicine and Life in 2009, discusses the evolving understanding and treatment of erectile dysfunction (ED). Previously, ED was often attributed solely to aging or psychogenic factors when no other causes were apparent. However, advancements in understanding the physiology of penile tumescence and detumescence have led to more nuanced approaches to diagnosing and treating various diseases associated with ED. The development of modern phosphodiesterase-5 (PDE-5) inhibitors, along with other therapies, has significantly changed the medical management of ED, acknowledging the unique circumstances of each patient.
For full article visit at https://pubmed.ncbi.nlm.nih.gov/20108753/
Maingat FG, Polyak MJ, Paul AM, et al. Neurosteroid-mediated regulation of brain innate immunity in HIV/AIDS: DHEA-S suppresses neurovirulence. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2013; 27(2):725-37.
Neurosteroid-mediated regulation of brain innate immunity in HIV/AIDS: DHEA-S suppresses neurovirulence. FASEB journal : official publication of the Federation of American Societies for Experimental Biology
The study by Maingat et al., titled “Neurosteroid-mediated regulation of brain innate immunity in HIV/AIDS: DHEA-S suppresses neurovirulence,” published in the FASEB Journal in 2013, explored the role of neurosteroids in the brain’s immune response in the context of HIV/AIDS. The study found that lentivirus infections lead to reduced neurosteroid synthesis in the brain, but treatment with DHEA-S (dehydroepiandrosterone sulfate) limited neuroinflammation and prevented neurobehavioral deficits. This suggests that DHEA-S could be effective in treating virus- or inflammation-mediated neurodegeneration, highlighting the trophic and protective actions of neurosteroids, which are cholesterol-derived molecules synthesized within the brain.
To read the full article: Visit https://www.semanticscholar.org/paper/Neurosteroid%E2%80%90mediated-regulation-of-brain-innate-in-Maingat-Polyak/13396110d63c10d5ed22876cbd26aa80ffb4b66d
Maingat FG, Polyak MJ, Paul AM, et al. Neurosteroid-mediated regulation of brain innate immunity in HIV/AIDS: DHEA-S suppresses neurovirulence. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2013; 27(2):725-37.
Neurosteroid-mediated regulation of brain innate immunity in HIV/AIDS: DHEA-S suppresses neurovirulence
The study “Neurosteroid-mediated regulation of brain innate immunity in HIV/AIDS: DHEA-S suppresses neurovirulence,” authored by Maingat FG, Polyak MJ, Paul AM, and others, published in the FASEB Journal in 2013, focused on the impact of neurosteroids, particularly dehydroepiandrosterone sulfate (DHEA-S), on brain innate immunity in the context of HIV/AIDS. This research found that in lentivirus infections, there was a reduction in neuronal neurosteroid synthesis. However, treatment with DHEA-S limited neuroinflammation and prevented neurobehavioral deficits. This suggests that DHEA-S could be effective in treating virus- or inflammation-mediated neurodegeneration. Neurosteroids, which are cholesterol-derived molecules synthesized within the brain, are known for their trophic and protective actions.
For more details visit https://commons.erau.edu/
Straub RH, Schölmerich J, Zietz B. Replacement therapy with DHEA plus corticosteroids in patients with chronic inflammatory diseases–substitutes of adrenal and sex hormones. Zeitschrift fur Rheumatologie. 2000; 59 Suppl 2:II/108-18.
Replacement therapy with DHEA plus corticosteroids in patients with chronic inflammatory diseases–substitutes of adrenal and sex hormones
The study “Replacement therapy with DHEA plus corticosteroids in patients with chronic inflammatory diseases” by Straub RH, Schölmerich J, Zietz B, published in Zeitschrift fur Rheumatologie in 2000, focused on the dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis in chronic inflammatory diseases. This dysfunction, particularly in diseases like rheumatoid arthritis, results in low cortisol secretion relative to adrenocorticotropic hormone (ACTH) secretion. The study noted that serum levels of dehydroepiandrosterone (DHEA) were significantly lower in these patients compared to healthy controls. DHEA, an inhibitor of cytokines, plays a critical role in regulating inflammation. The study highlighted that low levels of DHEA, due to its role in inhibiting cytokines like IL-6 and TNF, could be detrimental in chronic inflammatory diseases. This led to the suggestion of a combined therapy with corticosteroids and DHEA in such conditions.
For more details: https://pubmed.ncbi.nlm.nih.gov/11155790/
Rutkowski K, Sowa P, Rutkowska-Talipska J, Kuryliszyn-Moskal A, Rutkowski R. Dehydroepiandrosterone (DHEA): hypes and hopes. Drugs. 2014; 74(11):1195-207.
Dehydroepiandrosterone (DHEA): hypes and hopes. Drugs
The 2014 study “Dehydroepiandrosterone (DHEA): hypes and hopes” by Rutkowski et al., published in the journal Drugs, explores the varied implications of DHEA and DHEAS, the most abundant human steroid hormones. Highlighting their potential anti-aging effects, the study notes DHEA’s immunomodulatory actions in the elderly, enhancing well-being, muscle strength, bone density, and reducing body fat and skin atrophy. It’s beneficial in adrenal insufficiency and systemic lupus erythematosus, and shows promising effects in cardiovascular and allergic diseases. DHEA also improves sexual satisfaction and fertility in women. However, research variability and challenges underscore the need for large-scale trials to confirm these benefits and establish clinical applications of DHEA.
For more details visit at https://pubmed.ncbi.nlm.nih.gov/25022952/
Alves VB, Basso PJ, Nardini V, Silva A, Chica JE, Cardoso CR. Dehydroepiandrosterone (DHEA) restrains intestinal inflammation by rendering leukocytes hyporesponsive and balancing colitogenic inflammatory responses. Immunobiology. 2016; 221(9):934-43.
The study “Dehydroepiandrosterone (DHEA) restrains intestinal inflammation by rendering leukocytes hyporesponsive and balancing colitogenic inflammatory responses” by Alves VB, Basso PJ, Nardini V, and others, published in Immunobiology in 2016, explored the role of DHEA in modulating inflammatory responses, particularly in the context of inflammatory bowel diseases (IBD). The research demonstrated that low doses of DHEA inhibited the proliferation of spleen cells and the production of IFN-γ. In a mouse model, DHEA treatment during colitis induction led to reduced weight loss and clinical signs of the disease. This treatment also resulted in decreased peripheral blood monocytes, increased circulating neutrophils during tissue repair, reduced lamina propria cellularity, and restoration of normal colon length. Additionally, DHEA reduced IL-6 and TGF-β mRNA expression, while increasing IL-13 in the colon, which likely contributed to inflammation attenuation. The study concluded that DHEA modifies leukocyte activity and balances immune responses in IBD, reducing both local and systemic damages.
For more in-depth knowledge visit at https://pubmed.ncbi.nlm.nih.gov/27263829/
Andus T, Klebl F, Rogler G, Bregenzer N, Schölmerich J, Straub RH. Patients with refractory Crohn’s disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. Alimentary pharmacology & therapeutics. 2003; 17(3):409-14.
Patients with refractory Crohn’s disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study
The pilot study “Patients with refractory Crohn’s disease or ulcerative colitis respond to dehydroepiandrosterone” by Andus T, Klebl F, Rogler G, et al., published in Alimentary Pharmacology & Therapeutics in 2003, examined the effectiveness of dehydroepiandrosterone (DHEA) in treating inflammatory bowel disease. This phase II trial involved 20 patients with chronic active inflammatory bowel disease (seven with Crohn’s disease and 13 with ulcerative colitis) who took 200 mg of DHEA daily for 56 days. The study found that six out of seven Crohn’s disease patients and eight out of thirteen ulcerative colitis patients responded to the treatment, showing a significant decrease in disease activity indices. Additionally, a number of these patients went into remission, and no side effects led to withdrawal from the study.
To know more about this study visit at https://pubmed.ncbi.nlm.nih.gov/12562454/
Petri MA, Lahita RG, Van Vollenhoven RF, et al. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2002;46(7):1820-1829.
Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial
The 2002 study “Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus” by Petri et al., published in Arthritis Rheum, investigated the efficacy of prasterone (DHEA) in reducing corticosteroid requirements in women with systemic lupus erythematosus (SLE). In this double-blind, randomized trial involving 191 female SLE patients, participants were treated daily with either placebo, 100 mg, or 200 mg of oral prasterone for 7-9 months. The study found that a significantly greater proportion of patients treated with 200 mg prasterone daily achieved a sustained reduction in prednisone dosage to ≤7.5 mg/day for at least two months, compared to the placebo group. This reduction in corticosteroid dosage was achieved while maintaining stable or improved disease activity. The study concluded that prasterone could be beneficial in reducing corticosteroid requirements in women with active lupus disease.
To read the full article click on https://pubmed.ncbi.nlm.nih.gov/12124866/
Alves VB, Basso PJ, Nardini V, Silva A, Chica JE, Cardoso CR. Dehydroepiandrosterone (DHEA) restrains intestinal inflammation by rendering leukocytes hyporesponsive and balancing colitogenic inflammatory responses. Immunobiology. 2016; 221(9):934-43.
Dehydroepiandrosterone (DHEA) restrains intestinal inflammation by rendering leukocytes hyporesponsive and balancing colitogenic inflammatory responses. Immunobiology
The 2016 study by Alves VB, Basso PJ, Nardini V, et al., titled “Dehydroepiandrosterone (DHEA) restrains intestinal inflammation by rendering leukocytes hyporesponsive and balancing colitogenic inflammatory responses,” published in Immunobiology, examined the impact of DHEA on intestinal inflammation. The study found that low doses of DHEA inhibited spleen cell proliferation and IFN-γ production. In a mouse model of colitis, DHEA treatment reduced weight loss and clinical signs of the disease, decreased peripheral blood monocytes, increased circulating neutrophils during tissue repair, reduced lamina propria cellularity, and restored normal colon length. DHEA also led to decreased IL-6 and TGF-β mRNA expression, while increasing IL-13 in the colon, contributing to reduced inflammation. The study concluded that DHEA modifies leukocyte activity and balances immune responses in inflammatory bowel disease, reducing local and systemic damages.
For more details: https://pubmed.ncbi.nlm.nih.gov/27263829/
Lichte P, Pfeifer R, Werner BE, et al. Dehydroepiandrosterone modulates the inflammatory response in a bilateral femoral shaft fracture model. European Journal of Medical Research. 2014;19(1):27. doi:10.1186/2047-783X-19-27.
Dehydroepiandrosterone modulates the inflammatory response in a bilateral femoral shaft fracture model
The 2014 study “Dehydroepiandrosterone modulates the inflammatory response in a bilateral femoral shaft fracture model,” conducted by Lichte P, Pfeifer R, Werner BE, et al., investigated the role of dehydroepiandrosterone (DHEA) in managing inflammation following musculoskeletal injuries. The study, which used a bilateral femoral shaft fracture model in male C57/BL6 mice, examined the effects of administering DHEA after such fractures. The findings demonstrated that DHEA reduced the systemic inflammatory response, particularly the levels of systemic IL-6, IL-1β, and MCP-1. However, it did not significantly affect pulmonary inflammation. This suggests that DHEA might be a viable option for treating systemic inflammation in the context of musculoskeletal injuries.
For more details: https://pubmed.ncbi.nlm.nih.gov/24886543/
Available at https://link.springer.com/article/10.1134/S199074781704002X.
Alexaki VI, Fodelianaki G, Neuwirth A, et al. DHEA inhibits acute microglia-mediated inflammation through activation of the TrkA-Akt1/2-CREB-Jmjd3 pathway. Molecular psychiatry. 2017.
DHEA inhibits acute microglia-mediated inflammation through activation of the TrkA-Akt1/2-CREB-Jmjd3 pathway. Molecular psychiatry
The 2017 study by Alexaki et al., titled “DHEA inhibits acute microglia-mediated inflammation through activation of the TrkA-Akt1/2-CREB-Jmjd3 pathway,” explored the role of dehydroepiandrosterone (DHEA) in neuroinflammation. This research demonstrated that DHEA, the most abundant circulating steroid hormone in humans, can reduce microglia-mediated inflammation. The mechanism involves DHEA binding to the nerve growth factor receptor, TrkA, leading to phosphorylation of TrkA and activation of a pathway involving Akt1/Akt2 and cAMP response element-binding protein (CREB). This activation induces the expression of the histone 3 lysine 27 demethylase Jumonji d3 (Jmjd3), which controls the expression of inflammation-related genes and microglial polarization. These findings suggest that DHEA-activated TrkA signaling is a significant regulator of microglia-mediated inflammation in a Jmjd3-dependent manner, providing insights for potential therapeutic interventions in neuro-inflammatory diseases.
For in-depth details: https://pubmed.ncbi.nlm.nih.gov/28894299/
Du C, Khalil MW, Sriram S. Administration of dehydroepiandrosterone suppresses experimental allergic encephalomyelitis in SJL/J mice. Journal of immunology (Baltimore, Md. : 1950). 2001; 167(12):7094-101.
Administration of dehydroepiandrosterone suppresses experimental allergic encephalomyelitis in SJL/J mice
The 2001 study by Du, Khalil, and Sriram titled “Administration of dehydroepiandrosterone suppresses experimental allergic encephalomyelitis in SJL/J mice,” published in the Journal of Immunology, investigated the effect of dehydroepiandrosterone (DHEA) on experimental allergic encephalomyelitis (EAE), a Th1-mediated inflammatory demyelinating disease of the CNS and an animal model of multiple sclerosis. The study found that the addition of DHEA to cultures of myelin basic protein-primed splenocytes significantly reduced T cell proliferation and the secretion of proinflammatory cytokines (IFN-γ, IL-12 p40, and TNF-α) and nitric oxide (NO) in response to myelin basic protein. This effect was associated with a decrease in the activation and translocation of NF-kappaB. Moreover, the in vivo administration of DHEA significantly reduced the severity and incidence of acute EAE, as well as decreased demyelination/inflammation and the expression of proinflammatory cytokines in the CNS. These findings suggest that DHEA possesses potent anti-inflammatory properties, which are partly mediated by its ability to inhibit NF-kappaB activation.
For more details: https://pubmed.ncbi.nlm.nih.gov/11739531/
Straub RH, Konecna L, Hrach S, et al. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin‐6 (IL‐6), and DHEA inhibits IL‐6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. J Clin Endocrinol Metab 1998; 83(6): 2012–7.
Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin‐6 (IL‐6), and DHEA inhibits IL‐6 secretion from mononuclear cells in man in vitro
The 1998 study by Straub RH et al., titled “Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence,” published in the Journal of Clinical Endocrinology and Metabolism, explored the relationship between DHEA and IL-6. The study found that serum levels of DHEA, DHEA sulfate (DHEAS), and androstenedione (ASD) significantly decreased with age, while IL-6 levels increased. An inverse correlation was observed between DHEA/DHEAS and IL-6. Additionally, DHEA and ASD were found to concentration-dependently inhibit IL-6 production from peripheral blood mononuclear cells. The study suggests a functional link between DHEA/ASD and IL-6, indicating that the increase in IL-6 production during aging might be due to diminished DHEA and ASD secretion, potentially contributing to immunosenescence related to endocrinosenescence.
For more details: https://pubmed.ncbi.nlm.nih.gov/9626133/
Poynter ME, Daynes RA. Peroxisome proliferator‐activated receptor alpha activation modulates cellular redox status, represses nuclear factor‐kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998; 273(49): 32 833–41.
Peroxisome proliferator‐activated receptor alpha activation modulates cellular redox status, represses nuclear factor‐kappaB signaling, and reduces inflammatory cytokine production in aging
The 1998 study by Poynter ME and Daynes RA, published in the Journal of Biological Chemistry, focused on the role of peroxisome proliferator-activated receptor alpha (PPARα) activation in aging. The study found that activation of PPARα modulated cellular redox status, repressed nuclear factor-kappaB (NF-κB) signaling, and reduced inflammatory cytokine production in aged mice. This was evidenced by a decrease in tissue lipid peroxidation, the elimination of constitutively active NF-κB, and a reduction in spontaneous inflammatory cytokine production. These findings suggest that PPARα plays a critical role in controlling oxidative stress and inflammation associated with aging, indicating its potential therapeutic significance in age-related diseases.
For in-depth study, visit at https://pubmed.ncbi.nlm.nih.gov/9830030/
Cheng GF, Tseng J. Regulation of murine interleukin‐10 production by dehydroepiandrosterone. J Interferon Cytokine Res 2000; 20(5): 471–8.
Regulation of murine interleukin‐10 production by dehydroepiandrosterone
The 2000 study by Cheng GF and Tseng J, titled “Regulation of murine interleukin-10 production by dehydroepiandrosterone,” published in the Journal of Interferon & Cytokine Research, investigated the immunological effects of dehydroepiandrosterone (DHEA). The study found that administering DHEA or DHEA-sulfate (DHEAS) to mice significantly increased serum levels of interleukin-10 (IL-10) and IL-10 secretion and mRNA expression in spleen cells. This effect was observed after activating the cells with concanavalin A (ConA). The research suggested that DHEA might influence the function of B lymphocytes by stimulating IL-10 production, which is crucial for B cell differentiation and immunoglobulin production.
For more details: https://pubmed.ncbi.nlm.nih.gov/10841075/
Villareal DT, Holloszy JO, Kohrt WM. Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. Clinical endocrinology. 2000; 53(5):561-8.
Effects of DHEA replacement on bone mineral density and body composition in elderly women and men
The 2000 study by Villareal DT, Holloszy JO, Kohrt WM, titled “Effects of DHEA replacement on bone mineral density and body composition in elderly women and men,” published in Clinical Endocrinology, investigated the impact of DHEA replacement on bone mineral density (BMD) and body composition in elderly individuals with low serum DHEA sulfate (DHEAS) levels. The study, a 6-month trial involving 18 elderly subjects, found that DHEA replacement led to increased BMD in the total body and lumbar spine, decreased fat mass, and increased fat-free mass. Additionally, there were increases in serum IGF-I and total serum testosterone concentrations. These results suggest that DHEA replacement can partially reverse age-related changes in body composition and BMD, potentially mediated by increases in IGF-I and/or testosterone.
For more details: https://pubmed.ncbi.nlm.nih.gov/11106916/
Labrie F. Adrenal androgens and intracrinology. Semin Reprod Med. 2004;22:299–309.
Adrenal androgens and intracrinology
The study “Adrenal androgens and intracrinology” by Labrie F, published in Seminars in Reproductive Medicine in 2004, delves into the field of intracrinology, focusing on the local formation of sex steroids from dehydroepiandrosterone (DHEA). It highlights that in postmenopausal women, all estrogens and nearly all androgens are locally produced from DHEA, while in adult men, approximately 50% of androgens are made locally. This local production allows cell-specific control over steroid formation and action. The study also emphasizes the therapeutic potential of DHEA, noting its benefits in increasing bone mineral density, muscle mass, well-being, and libido in postmenopausal women, along with positive effects against skin atrophy, type 2 diabetes, and obesity.
For more details: https://pubmed.ncbi.nlm.nih.gov/15635498/
Leng SX, Cappola AR, Andersen RE, Blackman MR, Koenig K, Blair M, Walston JD. Serum levels of insulin-like growth factor-I (IGF-I) and dehydroepiandrosterone sulfate (DHEA-S), and their relationships with serum interleukin-6 in the geriatric syndrome of frailty. Aging Clin Exp Res. 2004;16:153–157.
Serum levels of insulin-like growth factor-I (IGF-I) and dehydroepiandrosterone sulfate (DHEA-S), and their relationships with serum interleukin-6 in the geriatric syndrome of frailty
In the study titled “Serum levels of insulin-like growth factor-I (IGF-I) and dehydroepiandrosterone sulfate (DHEA-S), and their relationships with serum interleukin-6 in the geriatric syndrome of frailty” by Leng SX et al. published in Aging Clin Exp Res in 2004, the authors investigated the relationship between serum levels of insulin-like growth factor-I (IGF-I), dehydroepiandrosterone sulfate (DHEA-S), and interleukin-6 (IL-6) in elderly individuals with frailty.
The study aimed to understand if there was a connection between these biomarkers and the geriatric syndrome of frailty. Frailty is a condition characterized by increased vulnerability to adverse health outcomes.
To know more about this study https://link.springer.com/article/10.1007/BF03324492
Kahn AJ, Halloran B, Wolkowitz O, Brizendine L. Dehydroepiandrosterone supplementation and bone turnover in middle-aged to elderly men. J Clin Endocrinol Metab. 2002;87:1544–1549.
Dehydroepiandrosterone supplementation and bone turnover in middle-aged to elderly men
In the study titled “Dehydroepiandrosterone supplementation and bone turnover in middle-aged to elderly men” by Kahn AJ et al., published in the Journal of Clinical Endocrinology & Metabolism in 2002, the authors investigated the impact of dehydroepiandrosterone (DHEA) supplementation on bone turnover in middle-aged to elderly men.
The study aimed to assess whether DHEA supplementation had any effects on bone health markers and turnover in this population. Bone turnover refers to the process of bone formation and resorption, which can be indicative of bone health.
For more details: https://academic.oup.com/jcem/article/87/4/1544/2846710
Von Mühlen D, Laughlin GA, Kritz-Silverstein D, Bergstrom J, Bettencourt R. Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2008;19(5):699-707. doi:10.1007/s00198-007-0520-z.
Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults
In the study titled “Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial” by Von Mühlen D et al., published in Osteoporosis International in 2008, the authors conducted the DAWN trial to investigate the impact of dehydroepiandrosterone (DHEA) supplementation on various aspects of bone health and body composition in older adults.
The study aimed to assess how DHEA supplementation affected bone mineral density, bone markers (indicators of bone turnover), and body composition in older adults.
To read more about this study: https://doi.org/10.1007/s00198-007-0520-z
Villareal DT. Effects of dehydroepiandrosterone on bone mineral density: what implications for therapy? Treat Endocrinol. 2002;1:349–357.
Effects of dehydroepiandrosterone on bone mineral density
In the paper titled “Effects of dehydroepiandrosterone on bone mineral density: what implications for therapy?” by Villareal DT, published in Treat Endocrinol in 2002, the author explores the potential effects of dehydroepiandrosterone (DHEA) on bone mineral density (BMD) and considers the therapeutic implications of these effects.
The study likely discusses whether DHEA supplementation has any impact on BMD, which is an important measure of bone health. Understanding the relationship between DHEA and BMD can have implications for potential therapeutic interventions for conditions related to bone density.
For in-depth knowledge visit at https://link.springer.com/article/10.2165/00024677-200201060-00001
Kahn AJ, Halloran B, Wolkowitz O, Brizendine L. Dehydroepiandrosterone supplementation and bone turnover in middle-aged to elderly men. J Clin Endocrinol Metab. 2002;87:1544–1549.
Dehydroepiandrosterone supplementation and bone turnover in middle-aged to elderly men
In the study titled “Dehydroepiandrosterone supplementation and bone turnover in middle-aged to elderly men” by Kahn AJ et al., published in the Journal of Clinical Endocrinology & Metabolism in 2002, the authors investigated the impact of dehydroepiandrosterone (DHEA) supplementation on bone turnover in middle-aged to elderly men.
The study aimed to assess whether DHEA supplementation had any effects on bone health markers and turnover in this population. Bone turnover refers to the process of bone formation and resorption, which can be indicative of bone health.
For more details: https://academic.oup.com/jcem/article/87/4/1544/2846710
Callies F, Fassnacht M, van Vlijmen JC, Koehler I, Huebler D, Seibel MJ, Arlt W, Allolio B. Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity. J Clin Endocrinol Metab. 2001;86:1968–1972
Dehydroepiandrosterone replacement in women with adrenal insufficiency
In the study titled “Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity” by Callies F et al., published in the Journal of Clinical Endocrinology & Metabolism in 2001, the authors investigated the impact of dehydroepiandrosterone (DHEA) replacement therapy in women with adrenal insufficiency. The study examined several physiological aspects, including changes in body composition, such as muscle mass and fat mass, as well as overall body weight. Additionally, the research explored the influence of DHEA replacement on serum leptin levels, a hormone crucial for appetite and metabolism regulation. It also assessed how DHEA replacement affected bone turnover markers, crucial for bone health in individuals with adrenal insufficiency. Finally, the study looked into whether DHEA replacement had any effects on the exercise capacity of women with adrenal insufficiency. The findings of this study can provide valuable insights into the potential benefits of DHEA replacement therapy for women with adrenal insufficiency regarding these critical health parameters. For a more in-depth understanding of the study’s methodology and results, you can access the original research paper through the provided link.
For more details: https://academic.oup.com/jcem/article/86/4/1968/2848816
Gordon CM, Grace E, Emans SJ, Feldman HA, Goodman E, Becker KA, Rosen CJ, Gundberg CM, LeBoff MS. Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. J Clin Endocrinol Metab. 2002;87:4935–4941.
Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa
In the study titled “Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial” by Gordon CM et al., published in the Journal of Clinical Endocrinology & Metabolism in 2002, the authors conducted a randomized trial to investigate the impact of oral dehydroepiandrosterone (DHEA) on bone density in young women diagnosed with anorexia nervosa.
The study aimed to assess whether DHEA supplementation had any positive effects on bone density in this population, as individuals with anorexia nervosa often experience significant bone loss and increased risk of osteoporosis due to malnutrition and hormonal imbalances.
For a more comprehensive understanding: https://academic.oup.com/jcem/article/87/10/4935/2847411
Arlt W, Callies F, Koehler I, van Vlijmen JC, Fassnacht M, Strasburger CJ, Seibel MJ, Huebler D, Ernst M, Oettel M, Reincke M, Schulte HM, Allolio B. Dehydroepiandroster-one supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. J Clin Endocrinol Metab. 2001;86:4686–4692.
Dehydroepiandroster-one supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion
In the study titled “Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion” by Arlt W et al., published in the Journal of Clinical Endocrinology & Metabolism in 2001, the authors conducted a study to investigate the effects of dehydroepiandrosterone (DHEA) supplementation in healthy men who were experiencing an age-related decline in DHEA secretion.
The study aimed to assess whether DHEA supplementation had any beneficial effects on various aspects of health and physiology in these men, particularly in relation to the decline in DHEA levels associated with aging.
For a more detailed understanding: https://academic.oup.com/jcem/article/86/10/4686/2849081
Labrie F, Diamond P, Cusan L, Gomez JL, Belanger A, Candas B. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab. 1997;82:3498–3505.
Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women
In the study titled “Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women” by Labrie F et al., published in the Journal of Clinical Endocrinology & Metabolism in 1997, the authors conducted a 12-month-long investigation to assess the impact of dehydroepiandrosterone (DHEA) replacement therapy on various aspects of health in postmenopausal women.
The study aimed to examine the effects of DHEA supplementation on bone density, vaginal health, and the endometrium (the lining of the uterus) in postmenopausal women. This research is significant because postmenopausal women often experience changes in these areas, and DHEA is a hormone that may influence these changes.
For a more detailed understanding: https://academic.oup.com/jcem/article/82/10/3498/2823400
Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf) 1998;49:421–432.
The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women
In the study titled “The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition, and muscle strength in age-advanced men and women” by Morales AJ et al., published in Clinical Endocrinology in 1998, the authors conducted a six-month-long investigation to assess the impact of daily supplementation with a 100 mg dose of dehydroepiandrosterone (DHEA) on various aspects of health in both men and women who were experiencing age-related changes.
The study aimed to examine the effects of DHEA supplementation on circulating sex steroids, changes in body composition, and muscle strength in individuals who were experiencing age-related declines in these areas. This research is significant because it sought to determine if DHEA could potentially reverse or mitigate some of the effects of aging on these parameters.
For a more detailed understanding: https://onlinelibrary.wiley.com/doi/full/10.1046/j.1365-2265.1998.00531.x
Jankowski CM, Gozansky WS, Schwartz RS, Dahl DJ, Kittelson JM, Scott SM, Van Pelt RE, Kohrt WM. Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial. J Clin Endocrinol Metab. 2006;91:2986–2993.
Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial
In the study titled “Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial” by Jankowski CM et al., published in the Journal of Clinical Endocrinology & Metabolism in 2006, the authors conducted a randomized, controlled trial to investigate the impact of dehydroepiandrosterone (DHEA) replacement therapy on bone mineral density (BMD) in older adults.
The study aimed to assess whether DHEA supplementation had any beneficial effects on BMD, a crucial measure of bone health, in older individuals. Maintaining bone density is particularly important in aging populations, as decreased BMD can lead to an increased risk of osteoporosis and fractures.
For a more detailed understanding: https://academic.oup.com/jcem/article/91/8/2986/2656340
Baulieu EE, Thomas G, Legrain S, Lahlou N, Roger M, Debuire B, Faucounau V, Girard L, Hervy MP, Latour F, Leaud MC, Mokrane A, Pitti-Ferrandi H, Trivalle C, de Lacharriere O, Nouveau S, Rakoto-Arison B, Souberbielle JC, Raison J, Le Bouc Y, Raynaud A, Girerd X, Forette F. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA. 2000;97:4279–4284.
Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging
In the study titled “Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue” by Baulieu EE et al., published in the Proceedings of the National Academy of Sciences of the United States of America (PNAS) in 2000, the authors conducted the DHEAge Study to explore the relationship between dehydroepiandrosterone (DHEA) and its sulfate form (DHEA-S) and the aging process. This study addressed a significant sociobiomedical issue by investigating the potential role of these hormones in the aging process.
The research aimed to provide insights into the contribution of DHEA and DHEA-S to the aging process and to determine whether these hormones played a role in age-related changes and health outcomes. The study likely involved examining their levels in individuals of different age groups and exploring their potential effects on various aspects of aging, such as physical and cognitive health.
For more details: https://www.pnas.org/content/97/8/4279
Ohnaka K. [Dehydroepiandrosterone(DHEA)and bone metabolism]. Clinical calcium. 2016; 26(7):987-93.
Dehydroepiandrosterone(DHEA)and bone metabolism
The article titled “[Dehydroepiandrosterone (DHEA) and bone metabolism]” by Ohnaka K, published in Clinical Calcium in 2016, likely discusses the relationship between dehydroepiandrosterone (DHEA) and bone metabolism. The study may delve into how DHEA, a steroid hormone produced by the adrenal glands, impacts bone health and bone metabolism. Understanding this relationship is essential because DHEA has been studied for its potential role in bone density and bone-related conditions like osteoporosis.
For more details: https://europepmc.org/article/med/27346309
Weiss EP, Shah K, Fontana L, Lambert CP, Holloszy JO, Villareal DT. Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone. The American Journal of Clinical Nutrition. 2009;89(5):1459-1467. doi:10.3945/ajcn.2008.27265.
Dehydroepiandrosterone replacement therapy in older adults
In the study titled “Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone” by Weiss EP et al., published in The American Journal of Clinical Nutrition in 2009, the authors conducted a study to investigate the effects of dehydroepiandrosterone (DHEA) replacement therapy on bone health in older adults over a period of 1 and 2 years.
The study aimed to assess the impact of DHEA supplementation on bone density and bone-related parameters in older individuals. Maintaining bone health is especially important in aging populations, as reduced bone density can lead to an increased risk of osteoporosis and fractures.
For a more detailed understanding: https://doi.org/10.3945/ajcn.2008.27265
Jankowski CM, Gozansky WS, Schwartz RS, et al. Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial. J Clin Endocrinol Metab 2006;91:2986–93.
Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults
In the study titled “Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial” by Jankowski CM et al., published in the Journal of Clinical Endocrinology & Metabolism in 2006, the authors conducted a randomized, controlled trial to investigate the impact of dehydroepiandrosterone (DHEA) replacement therapy on bone mineral density (BMD) in older adults.
The study aimed to assess whether DHEA supplementation had any beneficial effects on BMD, which is an important measure of bone health, in older individuals. This research is significant because maintaining bone density is crucial for preventing osteoporosis and fractures, which are more common in aging populations.
For more details: https://academic.oup.com/jcem/article-abstract/91/8/2986/2656474
von Mühlen D, Laughlin GA, Kritz-Silverstein D, Bergstrom J, Bettencourt R. Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial. Osteoporos Int 2008;19:699–707.
Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults
In the study titled “Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial” by von Mühlen D et al., published in Osteoporosis International in 2008, the authors conducted the DAWN trial to investigate the impact of dehydroepiandrosterone (DHEA) supplementation on various aspects of health in older adults.
The study aimed to assess how DHEA supplementation affected bone mineral density (BMD), bone markers (indicators of bone turnover), and body composition in older individuals. These are critical factors to consider as aging is often associated with changes in bone health and body composition.
For a detailed understanding visit at https://link.springer.com/article/10.1007/s00198-007-0520-z
Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA 2000;97:4279–84.
Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging
In the study titled “Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue” by Baulieu EE et al., published in the Proceedings of the National Academy of Sciences of the United States of America (PNAS) in 2000, the authors conducted the DHEAge Study to explore the relationship between dehydroepiandrosterone (DHEA) and its sulfate form (DHEA-S) and the aging process. This study addressed a significant sociobiomedical issue by investigating the potential role of these hormones in the aging process.
The research aimed to provide insights into the contribution of DHEA and DHEA-S to the aging process and to determine whether these hormones played a role in age-related changes and health outcomes. The study likely involved examining their levels in individuals of different age groups and exploring their potential effects on various aspects of aging, such as physical and cognitive health.
For a more detailed understanding visit at https://www.pnas.org/doi/abs/10.1073/pnas.97.8.4279
Nair KS, Rizza RA, O’Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006;355:1647–59.
DHEA in elderly women and DHEA or testosterone in elderly men
In the study titled “DHEA in elderly women and DHEA or testosterone in elderly men” by Nair KS et al., published in the New England Journal of Medicine in 2006, the authors conducted a study to investigate the effects of dehydroepiandrosterone (DHEA) supplementation in elderly women and DHEA or testosterone supplementation in elderly men.
The study aimed to assess the impact of DHEA supplementation in elderly women and either DHEA or testosterone supplementation in elderly men on various aspects of health, including hormone levels, body composition, and overall well-being. The research is significant because it explores the potential benefits of hormone replacement therapies in the context of aging.
For a more detailed understanding visit at https://www.nejm.org/doi/full/10.1056/NEJMoa054629
Cormier C, Souberbielle JC, Kahan A. DHEA in bone and joint diseases. Joint, bone, spine : revue du rhumatisme. 2001; 68(6):588-94.
DHEA in bone and joint diseases. Joint, bone, spine
In the article titled “DHEA in bone and joint diseases” by Cormier C, Souberbielle JC, and Kahan A, published in the journal Joint, Bone, Spine: Revue du Rhumatisme in 2001, the authors likely discuss the role of dehydroepiandrosterone (DHEA) in the context of bone and joint diseases. This article may explore how DHEA, a hormone produced by the adrenal glands, is implicated in bone health and joint conditions.
The study could cover topics such as the effects of DHEA on bone mineral density, bone turnover markers, and its potential role in addressing or managing bone and joint diseases. Understanding the relationship between DHEA and these health issues is essential for providing insights into potential therapeutic approaches or interventions.
For a comprehensive understanding: https://www.sciencedirect.com/science/article/pii/S1297319X0100327X
Gordon CM, Grace E, Emans SJ, et al. Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. The Journal of clinical endocrinology and metabolism. 2002; 87(11):4935-41.
Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa
In the study titled “Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial” by Gordon CM et al., published in The Journal of Clinical Endocrinology and Metabolism in 2002, the authors conducted a randomized trial to investigate the impact of oral dehydroepiandrosterone (DHEA) supplementation on bone density in young women diagnosed with anorexia nervosa.
The study aimed to assess whether DHEA supplementation had any positive effects on bone density in this population, as individuals with anorexia nervosa often experience significant bone loss due to malnutrition and hormonal imbalances.
For a more detailed understanding: https://academic.oup.com/jcem/article-abstract/87/11/4935/2823114
Ghebre MA, Hart DJ, Hakim AJ, et al. Association between DHEAS and bone loss in postmenopausal women: a 15-year longitudinal population-based study. Calcified tissue international. 2011; 89(4):295-302.
Association between DHEAS and bone loss in postmenopausal women
In the study titled “Association between DHEAS and bone loss in postmenopausal women: a 15-year longitudinal population-based study” by Ghebre MA et al., published in Calcified Tissue International in 2011, the authors conducted a 15-year longitudinal study to explore the relationship between dehydroepiandrosterone sulfate (DHEAS) levels and bone loss in postmenopausal women.
The study aimed to assess whether there was an association between DHEAS levels and changes in bone density over time in postmenopausal women. Understanding this association is essential because postmenopausal women often experience a decline in bone density, which can increase the risk of osteoporosis and fractures.
For a more detailed understanding: https://link.springer.com/article/10.1007/s00223-011-9518-9
Labrie F, Diamond P, Cusan L, Gomez JL, Bélanger A, Candas B. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. The Journal of clinical endocrinology and metabolism. 1997; 82(10):3498-505.
Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women
In the study titled “Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women” by Labrie F et al., published in The Journal of Clinical Endocrinology and Metabolism in 1997, the authors conducted a 12-month study to investigate the impact of dehydroepiandrosterone (DHEA) replacement therapy on various aspects of health in postmenopausal women.
The study aimed to assess how DHEA supplementation affected bone health, vaginal health, and the endometrium (the lining of the uterus) in postmenopausal women. These areas are of particular interest as they can be affected by hormonal changes associated with menopause.
For more details: https://academic.oup.com/jcem/article-abstract/82/10/3498/2823508
Shufelt C, Bretsky P, Almeida CM, et al. DHEA-S Levels and Cardiovascular Disease Mortality in Postmenopausal Women: Results from the National Institutes of Health—National Heart, Lung, and Blood Institute (NHLBI)-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). The Journal of Clinical Endocrinology and Metabolism. 2010;95(11):4985-4992. doi:10.1210/jc.2010-0143.
DHEA-S Levels and Cardiovascular Disease Mortality in Postmenopausal Women
In the study titled “DHEA-S Levels and Cardiovascular Disease Mortality in Postmenopausal Women: Results from the National Institutes of Health—National Heart, Lung, and Blood Institute (NHLBI)-Sponsored Women’s Ischemia Syndrome Evaluation (WISE)” by Shufelt C et al., published in The Journal of Clinical Endocrinology and Metabolism in 2010, the authors conducted research to investigate the association between dehydroepiandrosterone sulfate (DHEA-S) levels and cardiovascular disease (CVD) mortality in postmenopausal women.
The study aimed to assess whether there was a relationship between DHEA-S levels and the risk of cardiovascular disease-related mortality in postmenopausal women. Understanding this association is crucial, as cardiovascular disease is a significant health concern for women during and after menopause.
For more understanding visit at https://academic.oup.com/jcem/article-abstract/95/11/4985/2835247
Barrett-Connor E, Khaw KT, Yen SS. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. The New England journal of medicine. 1986; 315(24):1519-24.
A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease
In the study titled “A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease” by Barrett-Connor E, Khaw KT, and Yen SS, published in The New England Journal of Medicine in 1986, the authors conducted a prospective study to investigate the relationship between dehydroepiandrosterone sulfate (DHEA-S) levels, mortality, and cardiovascular disease.
The study aimed to assess whether there was an association between DHEA-S levels and the risk of mortality and cardiovascular disease in the study population. Understanding this relationship is important, as it can provide insights into the potential role of DHEA-S in these health outcomes.
For a more detailed understanding: https://www.nejm.org/doi/full/10.1056/NEJM198612113152405
LaCroix AZ, Yano K, Reed DM. Dehydroepiandrosterone sulfate, incidence of myocardial infarction, and extent of atherosclerosis in men. Circulation. 1992; 86(5):1529-35.
Dehydroepiandrosterone sulfate, incidence of myocardial infarction, and extent of atherosclerosis in men
In the study titled “Dehydroepiandrosterone sulfate, incidence of myocardial infarction, and extent of atherosclerosis in men” by LaCroix AZ, Yano K, and Reed DM, published in Circulation in 1992, the authors conducted research to examine the relationship between dehydroepiandrosterone sulfate (DHEA-S) levels and the incidence of myocardial infarction (heart attack) as well as the extent of atherosclerosis in men.
The study aimed to determine whether there was an association between DHEA-S levels and the risk of myocardial infarction and the severity of atherosclerosis in the male study population. Understanding this relationship could provide insights into the potential role of DHEA-S in cardiovascular health and disease.
For more details: https://www.ahajournals.org/doi/abs/10.1161/01.CIR.86.5.1529
Trivedi DP, Khaw KT. Dehydroepiandrosterone sulfate and mortality in elderly men and women. The Journal of clinical endocrinology and metabolism. 2001; 86(9):4171-7.
Dehydroepiandrosterone sulfate and mortality in elderly men and women
In the study titled “Dehydroepiandrosterone sulfate and mortality in elderly men and women” by Trivedi DP and Khaw KT, published in The Journal of Clinical Endocrinology and Metabolism in 2001, the authors conducted research to investigate the relationship between dehydroepiandrosterone sulfate (DHEA-S) levels and mortality in elderly men and women.
The study aimed to assess whether there was an association between DHEA-S levels and the risk of mortality in the elderly population, both in men and women. Understanding this relationship is important for gaining insights into the potential role of DHEA-S in aging and mortality.
For more depth understanding visit at https://academic.oup.com/jcem/article-abstract/86/9/4171/2848651
Golden SH, Maguire A, Ding J, et al. Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort. American journal of epidemiology. 2002; 155(5):437-45.
Endogenous postmenopausal hormones and carotid atherosclerosis
In the study titled “Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort” by Golden SH, Maguire A, Ding J, et al., published in the American Journal of Epidemiology in 2002, the authors conducted a case-control study to investigate the relationship between endogenous postmenopausal hormones and carotid atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) cohort.
The study aimed to assess whether there was an association between postmenopausal hormone levels and the presence of carotid atherosclerosis in women. Understanding this relationship is essential because atherosclerosis is a key factor in the development of cardiovascular disease, and hormonal changes in postmenopausal women can influence cardiovascular risk.
For a more detailed understanding: https://academic.oup.com/aje/article-abstract/155/5/437/171506
Johannes CB, Stellato RK, Feldman HA, Longcope C, McKinlay JB. Relation of dehydroepiandrosterone and dehydroepiandrosterone sulfate with cardiovascular disease risk factors in women: longitudinal results from the Massachusetts Women’s Health Study. Journal of clinical epidemiology. 1999; 52(2):95-103.
Relation of dehydroepiandrosterone and dehydroepiandrosterone sulfate with cardiovascular disease risk factors in women
In the study titled “Relation of dehydroepiandrosterone and dehydroepiandrosterone sulfate with cardiovascular disease risk factors in women: longitudinal results from the Massachusetts Women’s Health Study” by Johannes CB, Stellato RK, Feldman HA, Longcope C, and McKinlay JB, published in the Journal of Clinical Epidemiology in 1999, the authors conducted a longitudinal study to investigate the relationship between dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEA-S) levels and cardiovascular disease risk factors in women.
The study aimed to assess whether there was an association between DHEA and DHEA-S levels and various cardiovascular disease risk factors in women over time. Understanding this relationship is important because cardiovascular disease is a significant health concern for women, and hormonal factors may play a role in influencing risk factors.
For more details: https://www.sciencedirect.com/science/article/pii/S0895435698001449
Thijs L, Fagard R, Forette F, Nawrot T, Staessen JA. Are low dehydroepiandrosterone sulphate levels predictive for cardiovascular diseases? A review of prospective and retrospective studies. Acta cardiologica. 2003; 58(5):403-10.
Are low dehydroepiandrosterone sulphate levels predictive for cardiovascular diseases?
In the review article titled “Are low dehydroepiandrosterone sulphate levels predictive for cardiovascular diseases? A review of prospective and retrospective studies” by Thijs L, Fagard R, Forette F, Nawrot T, and Staessen JA, published in Acta Cardiologica in 2003, the authors conducted a comprehensive review of both prospective and retrospective studies to investigate the predictive value of low dehydroepiandrosterone sulfate (DHEA-S) levels for cardiovascular diseases.
The review aimed to examine the collective evidence from various studies to assess whether there is a consistent association between low DHEA-S levels and the risk of cardiovascular diseases. Understanding this association is crucial because it can provide insights into the potential role of DHEA-S as a predictive marker for cardiovascular disease risk.
For more details: https://www.tandfonline.com/doi/abs/10.2143/AC.58.5.2005304
Bernini GP, Moretti A, Sgró M, et al. Influence of endogenous androgens on carotid wall in postmenopausal women. Menopause (New York, N.Y.). ; 8(1):43-50.
Influence of endogenous androgens on carotid wall in postmenopausal women
In the study titled “Influence of endogenous androgens on carotid wall in postmenopausal women” by Bernini GP, Moretti A, Sgró M, et al., published in Menopause (New York, N.Y.) in an issue that appears to be Volume 8, Issue 1, the authors conducted research to investigate the influence of endogenous androgens on the carotid artery wall in postmenopausal women.
The study aimed to assess whether there was a relationship between endogenous androgens (natural hormones like testosterone) and the condition of the carotid artery wall in postmenopausal women. Understanding this relationship is important because changes in the carotid artery wall can be indicative of cardiovascular health.
For more details: https://journals.lww.com/menopausejournal/Fulltext/2001/01000/Influence_of_endogenous_androgens_on_carotid_wall.8.aspx
Herrington DM. Dehydroepiandrosterone and coronary atherosclerosis. Annals of the New York Academy of Sciences. 1995; 774:271-80.
Dehydroepiandrosterone and coronary atherosclerosis
In the article titled “Dehydroepiandrosterone and coronary atherosclerosis” by Herrington DM, published in the Annals of the New York Academy of Sciences in 1995, the author explores the potential relationship between dehydroepiandrosterone (DHEA) and coronary atherosclerosis.
The article likely discusses research and evidence related to DHEA and its potential impact on coronary artery disease, atherosclerosis, and cardiovascular health. Understanding this relationship is essential because it can shed light on the role of DHEA in heart health and the development of atherosclerotic plaques in coronary arteries.
For more details: https://europepmc.org/article/med/8597465
Herrington DM, Gordon GB, Achuff SC, et al. Plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography. Journal of the American College of Cardiology. 1990; 16(6):862-70.
Plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography
In the study titled “Plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography” by Herrington DM, Gordon GB, Achuff SC, et al., published in the Journal of the American College of Cardiology in 1990, the authors conducted research to investigate the levels of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEA-S) in patients undergoing diagnostic coronary angiography.
The study aimed to examine the relationship between plasma levels of DHEA and DHEA-S and the presence of coronary artery disease in patients undergoing coronary angiography. Understanding this relationship is important for exploring the potential association between DHEA hormones and coronary artery health.
For more details: https://www.sciencedirect.com/science/article/pii/S0735109710803341
Bernini GP, Sgro’ M, Moretti A, et al. Endogenous androgens and carotid intimal-medial thickness in women. The Journal of clinical endocrinology and metabolism. 1999; 84(6):2008-12.
Endogenous androgens and carotid intimal-medial thickness in women
In the study titled “Endogenous androgens and carotid intimal-medial thickness in women” by Bernini GP, Sgro’ M, Moretti A, et al., published in The Journal of Clinical Endocrinology and Metabolism in 1999, the authors conducted research to investigate the relationship between endogenous androgens (natural hormones like testosterone) and carotid intimal-medial thickness in women.
The study aimed to assess whether there was an association between levels of endogenous androgens and the thickness of the carotid artery wall in women. Understanding this relationship is important because changes in carotid intimal-medial thickness can be indicative of cardiovascular health.
For more details: https://academic.oup.com/jcem/article-abstract/84/6/2008/2864598
Wu T, Chen Y, Zhou Y, et al. Prognostic Value of Dehydroepiandrosterone Sulfate for Patients With Cardiovascular Disease: A Systematic Review and Meta‐Analysis. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease. 2017;6(5):e004896. doi:10.1161/JAHA.116.004896.
Prognostic Value of Dehydroepiandrosterone Sulfate for Patients With Cardiovascular Disease
The study titled “Prognostic Value of Dehydroepiandrosterone Sulfate for Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis” aimed to estimate the impact of dehydroepiandrosterone sulfate (DHEAS) on the prognosis of patients with cardiovascular disease. This systematic review and meta-analysis involved searching databases like Embase, PubMed, Web of Science, CNKI, and WanFang until September 5, 2016, to find relevant studies. The meta-analysis included 18 studies and showed that lower levels of DHEAS were significantly associated with increased risks for all-cause mortality, fatal cardiovascular events, and nonfatal cardiovascular events in patients with cardiovascular disease. The risk ratios for these associations were 1.47 for all-cause mortality, 1.58 for fatal cardiovascular events, and 1.42 for nonfatal cardiovascular events. The conclusion drawn from the study was that patients with cardiovascular disease who have lower DHEAS levels may have a poorer prognosis than those with higher DHEAS levels
For more details: https://pubmed.ncbi.nlm.nih.gov/28476876/
Rutkowski K, Sowa P, Rutkowska-Talipska J, Kuryliszyn-Moskal A, Rutkowski R. Dehydroepiandrosterone (DHEA): hypes and hopes. Drugs. 2014; 74(11):1195-207.
Dehydroepiandrosterone (DHEA): hypes and hopes. Drugs
The article “Dehydroepiandrosterone (DHEA): hypes and hopes” published in 2014 in the journal Drugs explores the various roles and potential benefits of DHEA and its sulfated form, DHEAS, which are the most abundant circulating steroid hormones in humans. The study highlights that DHEA has been marketed as a ‘superhormone’ and an ‘anti-aging’ panacea, with some claims supported by recent human studies. DHEA has shown to have several positive effects, such as immunomodulatory action in the elderly, improvement in physical and psychological well-being, muscle strength, bone density, and reduction in body fat and age-related skin atrophy. It has also shown benefits in conditions like adrenal insufficiency, systemic lupus erythematosus, and inflammatory bowel disease. Furthermore, DHEA is noted to modulate cardiovascular signaling pathways and have anti-inflammatory effects. However, the article also points out the inconsistencies and negative results in some studies, attributing them to factors like overreliance on animal models, varying dosing protocols, and rapid metabolism of DHEA. The conclusion emphasizes the need for large-scale randomized controlled trials to establish the efficacy of DHEA in clinical practice.
For more details: https://pubmed.ncbi.nlm.nih.gov/25022952/
Jiménez MC, Sun Q, Schürks M, et al. Low dehydroepiandrosterone sulphate is associated with increased risk of ischemic stroke among women: DHEAS and Risk of Ischemic Stroke in Women. Stroke; a journal of cerebral circulation. 2013;44(7):10.1161/STROKEAHA.111.000485. doi:10.1161/STROKEAHA.111.000485.
Low dehydroepiandrosterone sulphate is associated with increased risk of ischemic stroke among women
The study “Low dehydroepiandrosterone sulphate is associated with increased risk of ischemic stroke among women: DHEAS and Risk of Ischemic Stroke in Women” published in Stroke journal in 2013 found that low levels of dehydroepiandrosterone (DHEA) are associated with an increased risk of ischemic stroke in women. Specifically, women in the lowest quartile of DHEA levels had a relative risk of 1.41 for ischemic stroke compared to those with higher levels.
For more details: https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.117.018415
Savineau JP, Marthan R, Dumas de la Roque E. Role of DHEA in cardiovascular diseases. Biochemical pharmacology. 2013; 85(6):718-26.
Role of DHEA in cardiovascular diseases
The article “Role of DHEA in cardiovascular diseases,” published in Biochemical Pharmacology in 2013, delves into the potential impact and therapeutic benefits of dehydroepiandrosterone (DHEA) in cardiovascular diseases (CVD). DHEA and its sulfated form (DHEA-S) are abundant circulating steroid hormones derived from cholesterol. The study highlights the age-related decline in serum DHEA and DHEA-S levels, suggesting a possible link to the development of CVD and other age-associated diseases. It emphasizes the potential benefits of DHEA in treating diseases like hypertension, coronary artery disease, and atherosclerosis, particularly in pulmonary hypertension. The article discusses DHEA’s cellular mechanisms of action, including its effects on various receptors and signaling pathways, and its role as an anti-remodeling and vasorelaxant drug. Despite its potential benefits, the study calls for further research at the molecular level and large clinical trials to establish DHEA’s efficacy in CVD treatment.
For more details: https://pubmed.ncbi.nlm.nih.gov/23270992/
Porsová-Dutoit I, Sulcová J, Stárka L. Do DHEA/DHEAS play a protective role in coronary heart disease? Physiological research. 2000; 49 Suppl 1:S43-56.
Do DHEA/DHEAS play a protective role in coronary heart disease?
The study “Do DHEA/DHEAS play a protective role in coronary heart disease?” published in Physiological Research in 2000, explores the role of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulfate (DHEAS) in coronary heart disease (CHD). The study suggests that DHEA and DHEAS, major androgens secreted by human adrenal glands, might play a role in the pathogenesis of atherosclerosis and CHD. However, the review concluded that there is no evidence of a protective role of these androgens in women. In contrast, men with low plasma levels of DHEA and DHEAS may be at increased risk of developing fatal cardiovascular events. These androgens could interfere with the atherogenic process through several mechanisms, such as influencing enzymes that modify the lipid spectrum, inhibiting human platelet aggregation, enhancing fibrinolysis, reducing cell proliferation, and lowering plasma levels of plasminogen activator inhibitor type 1 and tissue plasminogen activator antigen. The study suggests that these actions of DHEA(S) are dependent on sex hormone metabolic pathways and indicates that while there is insufficient data to recommend DHEA supplementation in elderly men, this approach merits further investigation.
For more details: https://pubmed.ncbi.nlm.nih.gov/10984071/
Savineau JP, Marthan R, Dumas de la Roque E. Role of DHEA in cardiovascular diseases. Biochemical pharmacology. 2013; 85(6):718-26.
Role of DHEA in cardiovascular diseases
The article “Role of DHEA in cardiovascular diseases,” published in Biochemical Pharmacology in 2013, focuses on the impact and therapeutic potential of dehydroepiandrosterone (DHEA) in cardiovascular diseases (CVD). DHEA and its sulfated form (DHEA-S) are abundant circulating steroid hormones derived from cholesterol. The study discusses the age-related decline in serum DHEA and DHEA-S levels and its possible link to the development of CVD and other age-associated diseases. It emphasizes the benefits of DHEA in treating diseases like hypertension, coronary artery disease, and atherosclerosis, particularly in pulmonary hypertension. The article explores DHEA’s cellular mechanisms of action, including its effects on various receptors and signaling pathways, and its role as an anti-remodeling and vasorelaxant drug. However, the study calls for further research at the molecular level and large clinical trials to establish DHEA’s efficacy in CVD treatment.
For more details: https://pubmed.ncbi.nlm.nih.gov/23270992/
Rabijewski M, Zgliczyński W. [Dehydroepiandrosterone therapy in men with angiographically verified coronary heart disease: the effects on plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA) and fibrinogen plasma concentrations]. Endokrynologia Polska. ; 58(3):213-9.
Dehydroepiandrosterone therapy in men with angiographically verified coronary heart disease
The study “[Dehydroepiandrosterone therapy in men with angiographically verified coronary heart disease: the effects on plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA) and fibrinogen plasma concentrations]” published in Endokrynologia Polska, explored the effects of DHEA therapy on certain cardiovascular risk factors. The therapy, consisting of a 150 mg daily dose of DHEA for 40 days in men with DHEAS levels below 2000 mg/l and verified coronary heart disease, resulted in a significant decrease in fibrinogen concentration and an increase in estradiol levels. However, it did not significantly affect plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (tPA) plasma concentrations.
For more details: https://pubmed.ncbi.nlm.nih.gov/17940987/
Wu TT, Chen Y, Zhou Y, et al. Prognostic Value of Dehydroepiandrosterone Sulfate for Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis. Journal of the American Heart Association. 2017; 6(5).
Prognostic Value of Dehydroepiandrosterone Sulfate for Patients With Cardiovascular Disease
The study “Prognostic Value of Dehydroepiandrosterone Sulfate for Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis,” published in the Journal of the American Heart Association in 2017, aimed to assess the impact of dehydroepiandrosterone sulfate (DHEAS) on the prognosis of cardiovascular disease patients. This extensive review included searching databases like Embase, PubMed, and others, and assessed the quality of each study using the Newcastle-Ottawa Scale. The meta-analysis showed that lower levels of DHEAS were significantly associated with increased risks of all-cause mortality, fatal cardiovascular events, and nonfatal cardiovascular events in these patients. The study concluded that lower DHEAS levels in patients with cardiovascular disease may indicate a poorer prognosis compared to those with higher levels.
For more details: https://pubmed.ncbi.nlm.nih.gov/28476876/
Lasco A, Frisina N, Morabito N, et al. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. European journal of endocrinology. 2001; 145(4):457-61.
Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women
The study “Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women,” published in the European Journal of Endocrinology in 2001, focused on the effects of DHEA on insulin sensitivity and the plasma lipid profile in postmenopausal women. The study involved twenty healthy postmenopausal women with low serum DHEA-S concentrations, who were divided into two groups. One group received micronized DHEA (25 mg/day) for 12 months, while the other received a placebo. The results showed that the group treated with DHEA experienced significant improvements in insulin sensitivity and lipid profile, with increases in high-density lipoprotein cholesterol and decreases in low-density lipoprotein cholesterol and triglycerides. However, there was no change in glucose tolerance. These findings suggest that long-term DHEA treatment can improve some metabolic parameters associated with increased cardiovascular risk, making it a potentially valuable tool in managing postmenopausal syndrome.
For more details: https://pubmed.ncbi.nlm.nih.gov/11581005/
Available at http://www.eje-online.org/content/145/4/457.long.
Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women
The study titled “Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women,” available at the provided link, examines the impact of dehydroepiandrosterone (DHEA) on insulin sensitivity and plasma lipid profile in postmenopausal women. It involved a 12-month treatment period, where one group of women received DHEA and another a placebo. The results indicated a significant improvement in insulin sensitivity and lipid profile, including increased high-density lipoprotein cholesterol and decreased low-density lipoprotein cholesterol and triglycerides, in the DHEA-treated group. However, glucose tolerance remained unchanged. This suggests that long-term DHEA treatment could be beneficial in managing postmenopausal syndrome due to its positive effects on metabolic parameters related to cardiovascular risk.
For more details: http://www.eje-online.org/content/145/4/457.long
do Vale S, Selinger L, Martins JM, et al. The relationship between dehydroepiandrosterone (DHEA), working memory and distraction–a behavioral and electrophysiological approach. PloS one. 2014; 9(8):e104869.
The relationship between dehydroepiandrosterone (DHEA), working memory and distraction–a behavioral and electrophysiological approach
The study “The relationship between dehydroepiandrosterone (DHEA), working memory and distraction—a behavioral and electrophysiological approach,” published in PloS One in 2014, investigated the effects of DHEA and its sulfate form (DHEAS) on working memory and distraction in humans. The study involved 23 young women performing tasks with varying working memory loads while their electroencephalogram (EEG) was recorded. The results showed that under working memory load, a higher baseline cortisol/DHEA ratio was associated with increased distraction, as indicated by enhanced novelty P3 responses. Conversely, DHEA seemed to reduce distraction and enhance working memory processing at the electrophysiological level, as evidenced by an enhanced visual P300. This suggests that DHEA may counteract cortisol’s effects, reducing distraction and enhancing working memory in women.
For more information: https://pubmed.ncbi.nlm.nih.gov/25105970/
Sripada RK, Marx CE, King AP, et al. DHEA enhances emotion regulation neurocircuits and modulates memory for emotional stimuli. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2013; 38(9):1798-807.
DHEA enhances emotion regulation neurocircuits and modulates memory for emotional stimuli
The study “DHEA enhances emotion regulation neurocircuits and modulates memory for emotional stimuli,” published in Neuropsychopharmacology in 2013, investigated the effects of dehydroepiandrosterone (DHEA) on emotion regulation and memory. DHEA, known for its anxiolytic, antidepressant, and antiglucocorticoid properties, was administered to study its impact on brain activity related to emotion modulation. Participants received 400 mg of DHEA or a placebo and underwent functional MRI while performing an emotional processing and regulation task. The findings revealed that DHEA reduced activity in the amygdala and hippocampus, areas associated with negative emotion generation, and increased activity in regions linked to regulatory processes, such as the rACC. Additionally, DHEA enhanced connectivity between the amygdala and hippocampus. These changes were associated with a reduction in negative affect. Notably, DHEA decreased memory accuracy for emotional stimuli and reduced activity in regions involved in conjunctive memory encoding. These results suggest that DHEA may be beneficial as a pharmacological intervention for mood and anxiety disorders, highlighting its role in emotion regulation neurocircuits and memory modulation for emotional stimuli.
For more details: https://pubmed.ncbi.nlm.nih.gov/23552182/
Załuska M, Janota B. [Dehydroepiandrosteron (DHEA) in the mechanisms of stress and depression]. Psychiatria polska. ; 43(3):263-74.
Dehydroepiandrosteron (DHEA) in the mechanisms of stress and depression
The study “[Dehydroepiandrosteron (DHEA) in the mechanisms of stress and depression],” published in Psychiatria Polska, delves into the role of DHEA in depression and its potential cardiovascular implications. It discusses how impairment in the regulatory functions of monoaminergic, glucocorticoid, and GABAergic receptors in the brain’s limbic area, due to genetic factors or stress, could lead to an overproduction of cortisol and, consequently, depression. The excess cortisol also increases cardiovascular risk due to its atherogenic properties. DHEA, with its antiglucocorticoid activity, is considered a protective factor against depression and cardiovascular risk. Clinical trials have shown positive effects of DHEA administration in depression, but results regarding DHEA and SDHEA levels in depressed patients have been inconsistent. In animals, high doses of DHEA decreased experimental atherogenesis. Human studies have shown a correlation between increased DHEA levels and decreased cardiovascular disorder risk in men, but not in women. This highlights the need for further research on the relationship between depression, DHEA, and cardiovascular risk, particularly considering gender differences.
For more details: https://pubmed.ncbi.nlm.nih.gov/19725420/
Nguyen TV, Gower P, Albaugh MD, et al. The developmental relationship between DHEA and visual attention is mediated by structural plasticity of cortico-amygdalar networks. Psychoneuroendocrinology. 2016; 70:122-33.
The developmental relationship between DHEA and visual attention is mediated by structural plasticity of cortico-amygdalar networks
The study “The developmental relationship between DHEA and visual attention is mediated by structural plasticity of cortico-amygdalar networks,” published in Psychoneuroendocrinology in 2016, explored the role of DHEA in the development of visual attention and its association with brain structure in children and adolescents aged 6-22. The research found that DHEA predicts the covariance between the volume of the amygdala and various cortical areas, including the left occipital pole, right somatosensory parietal cortex, and right anterior cingulate cortex. These associations were linked to different aspects of visual attention: amygdala-occipital covariance with visual awareness, amygdala-parietal covariance with visuo-motor dexterity and processing speed, and amygdala-prefrontal covariance with global attentional impairment. The study concluded that DHEA may play a significant role in shaping amygdala-dependent cortical plasticity and regulating visual attention processes from childhood to young adulthood, independent of factors like age, sex, pubertal stage, estradiol, and testosterone.
For more details: https://pubmed.ncbi.nlm.nih.gov/27236606/
De Menezes KJ, Peixoto C, Nardi AE, Carta MG, Machado S, Veras AB. Dehydroepiandrosterone, Its Sulfate and Cognitive Functions. Clinical Practice and Epidemiology in Mental Health : CP & EMH. 2016;12:24-37. doi:10.2174/1745017901612010024.
Dehydroepiandrosterone, Its Sulfate and Cognitive Functions
The study “Dehydroepiandrosterone, Its Sulfate and Cognitive Functions,” published in Clinical Practice and Epidemiology in Mental Health in 2016, is a review of cross-sectional and longitudinal studies examining the relationship between DHEA, DHEA-S, and various cognitive functions. The review encompassed a range of cognitive domains including global cognitive function, memory, attention, executive function, intelligence, perception, and visuospatial ability. The results indicated a positive correlation between DHEA-S blood levels and global cognition in both women and men. Furthermore, correlations were found between DHEA-S and specific cognitive functions such as working memory, attention, and verbal fluency, but these were observed only in women. The study noted that the effects of DHEA on cognition were limited and primarily derived from a single study conducted on young men with high doses of DHEA.
For more details: https://pubmed.ncbi.nlm.nih.gov/27346998/
Castanho T.C., Moreira P.S., Portugal-Nunes C., Novais A., Costa P.S., Palha J.A., Sousa N., Santos N.C. The role of sex and sex-related hormones in cognition, mood and well-being in older men and women. Biol. Psychol. 2014;103:158–166. doi: 10.1016/j.biopsycho.2014.08.015.
The role of sex and sex-related hormones in cognition, mood and well-being in older men and women
The study “The role of sex and sex-related hormones in cognition, mood and well-being in older men and women,” published in Biological Psychology in 2014, examined how hormone levels during aging affect cognition and mood. The research involved 120 participants aged 51 and older, both male and female. The study found that in males, higher levels of prolactin (PRL) were associated with worse cognitive performance, lower well-being, and higher scores on depression scales. Lower levels of estradiol (E2) were linked to poorer cognition and higher depressive mood. Dehydroepiandrosterone sulfate (DHEAS) showed a positive association with executive functioning and memory. These findings suggest that in addition to the well-studied hormones estradiol and testosterone, other sex-related hormones like PRL, follicle-stimulating hormone (FSH), luteinizing hormone (LH), and DHEAS play significant roles in the mental health aging profile, especially in men.
For more details: https://pubmed.ncbi.nlm.nih.gov/25196100/
Alhaj H.A., Massey A.E., McAllister-Williams R.H. Effects of DHEA administration on episodic memory, cortisol and mood in healthy young men: a double-blind, placebo-controlled study. Psychopharmacology (Berl.) 2006;188(4):541–551. doi: 10.1007/s00213-005-0136-y.
Effects of DHEA administration on episodic memory, cortisol and mood in healthy young men
The study “Effects of DHEA administration on episodic memory, cortisol and mood in healthy young men: a double-blind, placebo-controlled study,” published in Psychopharmacology in 2006, investigated the effects of DHEA on episodic memory, cortisol levels, and mood. The results showed that DHEA administration led to a reduction in evening cortisol concentrations and improved mood and memory as measured by visual analogue scales. Additionally, recollection accuracy in episodic memory tests significantly improved following DHEA administration. The study also noted significant hippocampal activation associated with successful episodic memory retrieval following placebo.
For more details: https://link.springer.com/article/10.1007/s00213-005-0136-y
Yamada S, Akishita M, Fukai S, et al. Effects of dehydroepiandrosterone supplementation on cognitive function and activities of daily living in older women with mild to moderate cognitive impairment. Geriatrics & gerontology international. 2010; 10(4):280-7.
Effects of dehydroepiandrosterone supplementation on cognitive function and activities of daily living in older women with mild to moderate cognitive impairment. Geriatrics & gerontology international
The study “Effects of dehydroepiandrosterone supplementation on cognitive function and activities of daily living in older women with mild to moderate cognitive impairment,” published in Geriatrics & Gerontology International in 2010, evaluated the effects of DHEA supplementation on cognitive function and daily activities in older women. The study involved 27 women aged 65-90 with mild to moderate cognitive impairment, who received either DHEA (25 mg/day) or no hormone replacement for 6 months. The results showed that DHEA treatment significantly increased plasma levels of testosterone, DHEA, and DHEA-sulfate, but not estradiol. Importantly, DHEA administration improved cognitive scores and maintained basic activities of daily living (ADL), with particular improvement noted in verbal fluency, compared to the control group, where cognitive and ADL scores deteriorated.
For more details: https://pubmed.ncbi.nlm.nih.gov/20497239/
Aly HF, Metwally FM, Ahmed HH. Neuroprotective effects of dehydroepiandrosterone (DHEA) in rat model of Alzheimer’s disease. Acta biochimica Polonica. 2011; 58(4):513-20.
Neuroprotective effects of dehydroepiandrosterone (DHEA) in rat model of Alzheimer’s disease
The study “Neuroprotective effects of dehydroepiandrosterone (DHEA) in rat model of Alzheimer’s disease,” published in Acta Biochimica Polonica in 2011, explored the potential neuroprotective properties of DHEA in a rat model of Alzheimer’s disease. The study likely investigated how DHEA influences various aspects of Alzheimer’s pathology in rats, such as amyloid plaque formation, neurofibrillary tangle development, neuronal loss, and cognitive impairment. While the specific details and results of the study are not provided in this summary, it would typically focus on evaluating the efficacy of DHEA as a therapeutic agent for Alzheimer’s disease in a controlled experimental setting.
For more details: https://bibliotekanauki.pl/articles/1039841.pdf
Fusi FM, Ferrario M, Bosisio C, Arnoldi M, Zanga L. DHEA supplementation positively affects spontaneous pregnancies in women with diminished ovarian function. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2013; 29(10):940-3.
DHEA supplementation positively affects spontaneous pregnancies in women with diminished ovarian function
The study “DHEA supplementation positively affects spontaneous pregnancies in women with diminished ovarian function,” published in Gynecological Endocrinology in 2013, investigated the impact of dehydroepiandrosterone (DHEA) supplementation on women with reduced ovarian function. The study likely focused on evaluating the effects of DHEA on fertility and the rate of spontaneous pregnancies in women experiencing ovarian function decline. While the specific outcomes and methodology of the study are not detailed here, it presumably explored DHEA’s role as a potential therapeutic option to improve reproductive outcomes in this particular group of women.
For more details: https://www.tandfonline.com/doi/abs/10.3109/09513590.2013.819087
Gleicher N, Barad DH. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reproductive Biology and Endocrinology : RB&E. 2011;9:67. doi:10.1186/1477-7827-9-67.
Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR)
The study “Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR),” published in Reproductive Biology and Endocrinology in 2011, likely explored the effects of DHEA supplementation on women with diminished ovarian reserve (DOR). DOR is a condition characterized by a decreased number and quality of oocytes in the ovaries, often leading to reduced fertility. The study probably investigated how DHEA supplementation impacts ovarian function, including the number of oocytes and their quality, as well as overall fertility outcomes in women diagnosed with DOR.
For more details: https://link.springer.com/article/10.1186/1477-7827-9-67
Gleicher N, Weghofer A, Barad D. Increased euploid embryos after supplementation with dehydroepiandrosterone (DHEA) in women with premature ovarian aging. Fertil Steril. 2007;88(Suppl1):S232.
Increased euploid embryos after supplementation with dehydroepiandrosterone (DHEA) in women with premature ovarian aging
The publication “Increased euploid embryos after supplementation with dehydroepiandrosterone (DHEA) in women with premature ovarian aging,” by Gleicher, Weghofer, and Barad in Fertility and Sterility in 2007, likely focused on the effects of DHEA supplementation in women experiencing premature ovarian aging. This condition involves early decline in ovarian function and is often associated with reduced fertility. The study probably examined how DHEA supplementation influences the quality of embryos, particularly the increase in euploid (chromosomally normal) embryos, which is a critical factor in successful pregnancy outcomes in these women.
For more details: https://www.fertstert.org/article/S0015-0282(07)02448-X/abstract
Gleicher N, Weghofer A, Barad DH. Dehydroepiandrosterone (DHEA) reduces embryo aneuploidy: Direct evidence from preimplantation genetic screening (PGS) Reprod Biol Endocrinol. 2010;8:140. doi: 10.1186/1477-7827-8-140.
Dehydroepiandrosterone (DHEA) reduces embryo aneuploidy
The study “Dehydroepiandrosterone (DHEA) reduces embryo aneuploidy: Direct evidence from preimplantation genetic screening (PGS),” authored by Gleicher, Weghofer, and Barad and published in Reproductive Biology and Endocrinology in 2010, likely investigated the impact of DHEA supplementation on embryo aneuploidy, which refers to the abnormal number of chromosomes in embryos. The study presumably used preimplantation genetic screening (PGS) to assess the chromosomal normality of embryos in women undergoing fertility treatments. The focus would have been on determining whether DHEA supplementation could improve the chromosomal integrity of embryos, thereby potentially enhancing the success rates of fertility treatments.
For more details: https://rbej.biomedcentral.com/articles/10.1186/1477-7827-8-140
Gleicher N, Ryan E, Weghofer A, Blanco-Mejia S, Barad DH. Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve: a case control study. Reprod Biol Endocrinol. 2009;7:108. doi: 10.1186/1477-7827-7-108.
Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve
The study “Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve: a case control study,” by Gleicher, Ryan, Weghofer, Blanco-Mejia, and Barad, published in Reproductive Biology and Endocrinology in 2009, likely focused on examining the effects of DHEA supplementation on miscarriage rates in women with diminished ovarian reserve. This condition often leads to decreased fertility and an increased risk of miscarriage. The study probably compared the rates of miscarriage in women receiving DHEA supplementation to those in a control group, to determine if DHEA could potentially reduce the risk of miscarriage in this specific group of women.
For more details: https://link.springer.com/article/10.1186/1477-7827-7-108
Gleicher N, Weghofer A, Barad DH. Anti-Müllerian hormone (AMH) defines, independent of age, low versus good live birth chances in women with severely ovarian reserve. Fertil Steril. 2010;94:2824–2827. doi: 10.1016/j.fertnstert.2010.04.067.
Anti-Müllerian hormone (AMH) defines, independent of age, low versus good live birth chances in women with severely ovarian reserve
The study “Anti-Müllerian hormone (AMH) defines, independent of age, low versus good live birth chances in women with severely diminished ovarian reserve,” authored by Gleicher, Weghofer, and Barad and published in Fertility and Sterility in 2010, explores how anti-Müllerian hormone (AMH) levels relate to live birth chances in women with severely diminished ovarian reserve. This study suggests that AMH can be a significant predictor of live birth probabilities in these women, regardless of their age. This finding underscores the importance of AMH as a biomarker in assessing fertility potential, particularly in cases of compromised ovarian reserve.
For more information: https://www.fertnstert.org/article/S0015-0282(10)00591-7/fulltext
Gleicher N, Ryan E, Weghofer A, Blanco-Mejia S, Barad DH. Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve: a case control study. Reproductive Biology and Endocrinology : RB&E. 2009;7:108. doi:10.1186/1477-7827-7-108.
Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve
The study “Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve: a case control study,” by Gleicher, Ryan, Weghofer, Blanco-Mejia, and Barad, published in Reproductive Biology and Endocrinology in 2009, investigated the effects of DHEA supplementation on miscarriage rates in women with diminished ovarian reserve. This research is significant in understanding how DHEA, a hormone supplement, might influence pregnancy outcomes, particularly in women facing fertility challenges due to reduced ovarian reserve.
For more in-depth knowledge visit at https://rbej.biomedcentral.com/articles/10.1186/1477-7827-7-108
Barad DH, Gleicher N. Increased oocyte production after treatment with dehydroepiandrosterone. Fertil Steril. 2005;84:756.e1-3.
Increased oocyte production after treatment with dehydroepiandrosterone
The study “Increased oocyte production after treatment with dehydroepiandrosterone” by Barad and Gleicher, published in Fertility and Sterility in 2005, focused on the effects of dehydroepiandrosterone (DHEA) supplementation on oocyte (egg) production. This research is significant for its exploration of how DHEA, a hormone, can influence oocyte production, potentially offering insights into new treatments or approaches for women experiencing fertility issues, especially those related to low oocyte production.
For more detailed information: https://www.fertnstert.org/article/S0015-0282(05)02956-8/fulltext
Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum Reprod. 2006;21:2845–2949. doi: 10.1093/humrep/del254.
Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF
The study “Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF,” authored by Barad and Gleicher and published in Human Reproduction in 2006, examined the impact of dehydroepiandrosterone (DHEA) supplementation on various outcomes of in vitro fertilization (IVF). The study specifically focused on DHEA’s effects on the number of oocytes retrieved, the yields and quality of embryos, as well as the cell number in embryos. This research provides valuable insights into how DHEA supplementation could potentially enhance IVF outcomes.
For more details: https://academic.oup.com/humrep/article/21/11/2845/2939185
Barad D, Brill H, Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J Assist Reprod Genet. 2007;24:629–634. doi: 10.1007/s10815-007-9178-x.
Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function
The publication “Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function” by Barad, Brill, and Gleicher, published in the Journal of Assisted Reproduction and Genetics in 2007, likely provided an overview of the developments and findings related to the use of dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian function. This paper would have discussed the latest research, clinical outcomes, and potential implications of DHEA use in enhancing fertility and ovarian function in this specific group of women.
For more detailed information: https://link.springer.com/article/10.1007/s10815-007-9178-x
Mamas L, Mamas E. Premature ovarian failure and dehydroepiandrosterone, Fertil Steril , 2009, vol. 91 (pg. 644-646)https://doi.org/10.1016/j.fertnstert.2007.11.055.
Premature ovarian failure and dehydroepiandrosterone
The publication “Premature ovarian failure and dehydroepiandrosterone” by Mamas and Mamas, featured in Fertility and Sterility in 2009, likely explores the relationship between dehydroepiandrosterone (DHEA) supplementation and premature ovarian failure. This study probably discusses how DHEA, a hormone supplement, may impact ovarian function and fertility in women experiencing early ovarian failure, a condition where the ovaries stop functioning properly at an early age.
For more information: https://www.fertnstert.org/article/S0015-0282(07)04073-0/fulltext
Gleicher N, Barad D. Misplaced obsession with prospectively randomized studies, Reprod Biomed Online , 2010, vol. 21 (pg. 440-443)https://doi.org/10.1016/j.rbmo.2010.06.042.
Misplaced obsession with prospectively randomized studies, Reprod Biomed Online
The article “Misplaced obsession with prospectively randomized studies” by Gleicher and Barad, published in Reproductive Biomedicine Online in 2010, likely presents a critical perspective on the heavy reliance on prospectively randomized studies in medical research. The authors probably discuss the limitations and potential biases associated with this research methodology, arguing for a more balanced approach that includes other types of studies to gain a comprehensive understanding of medical issues.
For more details: https://www.rbmojournal.com/article/S1472-6483(10)00387-5/fulltext
Gleicher N, Weghofer A, Barad DH. Improvement in diminished ovarian reserve after dehydroepiandrosterone (DHEA) supplementation, Reprod Biomed Online , 2010, vol. 21 (pg. 360-365)https://doi.org/10.1016/j.rbmo.2010.04.006.
Improvement in diminished ovarian reserve after dehydroepiandrosterone (DHEA) supplementation, Reprod Biomed Online
The study “Improvement in diminished ovarian reserve after dehydroepiandrosterone (DHEA) supplementation” by Gleicher, Weghofer, and Barad, published in Reproductive Biomedicine Online in 2010, focuses on the effects of DHEA supplementation on women with diminished ovarian reserve. This paper likely discusses how DHEA, a hormone supplement, may enhance ovarian function and improve fertility outcomes in women facing reduced ovarian reserve, a condition that can significantly impact reproductive capabilities.
For more in-depth understanding: https://www.rbmojournal.com/article/S1472-6483(10)00131-0/fulltext
Jakubowicz DJ, Beer NA, Beer RM, Nestler JE. Disparate effects of weight reduction by diet on serum dehydroepiandrosterone-sulfate levels in obese men and women. The Journal of clinical endocrinology and metabolism. 1995; 80(11):3373-6.
Disparate effects of weight reduction by diet on serum dehydroepiandrosterone-sulfate levels in obese men and women
The study “Disparate effects of weight reduction by diet on serum dehydroepiandrosterone-sulfate levels in obese men and women,” by Jakubowicz, Beer NA, Beer RM, and Nestler JE, published in The Journal of Clinical Endocrinology and Metabolism in 1995, likely examined how dietary weight loss affects serum dehydroepiandrosterone-sulfate (DHEA-S) levels differently in obese men and women. This research would be important in understanding the gender-specific endocrine responses to weight loss, particularly focusing on DHEA-S, a hormone involved in various metabolic processes.
For more information: https://academic.oup.com/jcem/article-abstract/80/11/3373/2651753
Zenk JL, Frestedt JL, Kuskowski MA. HUM5007, a novel combination of thermogenic compounds, and 3-acetyl-7-oxo-dehydroepiandrosterone: each increases the resting metabolic rate of overweight adults. The Journal of nutritional biochemistry. 2007; 18(9):629-34.
HUM5007, a novel combination of thermogenic compounds, and 3-acetyl-7-oxo-dehydroepiandrosterone
The study “HUM5007, a novel combination of thermogenic compounds, and 3-acetyl-7-oxo-dehydroepiandrosterone: each increases the resting metabolic rate of overweight adults,” by Zenk, Frestedt, and Kuskowski, published in The Journal of Nutritional Biochemistry in 2007, likely investigated the effects of a unique combination of thermogenic compounds (HUM5007) and a derivative of dehydroepiandrosterone (3-acetyl-7-oxo-DHEA) on the resting metabolic rate in overweight adults. This research would be significant in exploring potential weight management strategies through the enhancement of metabolic rate.
For more detailed information: https://www.sciencedirect.com/science/article/pii/S0955286307000125
Available at https://www.sciencedirect.com/science/article/pii/S0011393X00800260.
HUM5007, a novel combination of thermogenic compounds, and 3-acetyl-7-oxo-dehydroepiandrosterone: each increases the resting metabolic rate of overweight adults
The study titled “HUM5007, a novel combination of thermogenic compounds, and 3-acetyl-7-oxo-dehydroepiandrosterone: each increases the resting metabolic rate of overweight adults,” by Zenk, Frestedt, and Kuskowski, is available for further reading and detailed information at the provided ScienceDirect link: ScienceDirect Article. This study offers insights into the effects of specific thermogenic compounds and a DHEA derivative on metabolic rates, contributing to the understanding of weight management strategies.
The article from https://www.sciencedirect.com/science/article/pii/S0011393X00800260
Ostojic SM, Calleja J, Jourkesh M. Effects of short-term dehydroepiandrosterone supplementation on body composition in young athletes. The Chinese journal of physiology. 2010; 53(1):19-25.
Effects of short-term dehydroepiandrosterone supplementation on body composition in young athletes
The study “Effects of short-term dehydroepiandrosterone supplementation on body composition in young athletes,” by Ostojic, Calleja, and Jourkesh, published in The Chinese Journal of Physiology in 2010, likely examined the impact of short-term DHEA supplementation on body composition among young athletes. This study would be significant in understanding how DHEA, a hormone known for its potential influence on muscle mass and fat distribution, affects athletes, particularly in terms of their physical composition and performance.
Know more about this download this pdf.
Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clinical endocrinology. 1998; 49(4):421-32.
The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women
The study “The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women,” by Morales, Haubrich, Hwang, Asakura, and Yen, published in Clinical Endocrinology in 1998, examined the impact of a six-month DHEA supplementation (100 mg daily) on sex steroid levels, body composition, and muscle strength in older adults. This research is significant in exploring the potential benefits of DHEA supplementation in aging populations, especially regarding physical health parameters such as muscle strength and body composition.
For in depth knowledge visit at https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365-2265.1998.00507.x
Weiss EP, Villareal DT, Fontana L, Han DH, Holloszy JO. Dehydroepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans. Aging. 2011; 3(5):533-42.
The study “Dehydroepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans,” by Weiss, Villareal, Fontana, Han, and Holloszy, published in Aging in 2011, likely investigated the effects of DHEA replacement on insulin resistance and inflammation in older individuals. This research is important as it explores the potential benefits of DHEA in reducing age-related metabolic and inflammatory conditions, contributing to a better understanding of how hormone supplementation could be used to improve health outcomes in the aging population.
For more understanding visit https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3156603/
Dhatariya K, Bigelow ML, Nair KS. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes. 2005; 54(3):765-9.
Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women
The study “Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women,” by Dhatariya, Bigelow, and Nair, published in Diabetes in 2005, likely focused on evaluating the impact of DHEA replacement therapy on insulin sensitivity and lipid profiles in women with hypoadrenalism. This condition, characterized by inadequate adrenal hormone production, can affect various metabolic processes. The study’s findings would be important in understanding how DHEA supplementation might influence metabolic health, particularly regarding insulin function and lipid metabolism, in women with this endocrine disorder.
Read the full article at https://diabetesjournals.org/diabetes/article-abstract/54/3/765/14840
Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA. 2004; 292(18):2243-8.
Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial
The study “Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial,” by Villareal and Holloszy, published in JAMA in 2004, conducted a randomized controlled trial to investigate the impact of DHEA supplementation on abdominal fat and insulin action in elderly individuals. This research is significant for its examination of the potential role of DHEA in addressing age-related changes in body composition and insulin sensitivity in both women and men.
To know more about this studt visit at https://jamanetwork.com/journals/jama/article-abstract/199765
Brahimaj A, Muka T, Kavousi M, Laven JS, Dehghan A, Franco OH. Serum dehydroepiandrosterone levels are associated with lower risk of type 2 diabetes: the Rotterdam Study. Diabetologia. 2017; 60(1):98-106.
Serum dehydroepiandrosterone levels are associated with lower risk of type 2 diabetes
The study “Serum dehydroepiandrosterone levels are associated with lower risk of type 2 diabetes: the Rotterdam Study,” by Brahimaj et al., published in Diabetologia in 2017, found an association between higher serum dehydroepiandrosterone (DHEA) levels and a reduced risk of developing type 2 diabetes. This research suggests that DHEA may play a protective role against the development of diabetes, providing valuable insights into potential preventive strategies for this metabolic disorder.
Read full article at https://link.springer.com/article/10.1007/s00125-016-4136-8
Straub RH, Konecna L, Hrach S, Rothe G, Kreutz M, Schölmerich J, Falk W, Lang B. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. 1998;83:2017.
Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro
The study by Straub et al. in 1998 found a negative correlation between serum dehydroepiandrosterone (DHEA) and interleukin-6 (IL-6), suggesting that higher DHEA levels are associated with lower IL-6 levels. Additionally, in vitro experiments indicated that DHEA can inhibit IL-6 secretion from mononuclear cells. These findings suggest a potential link between endocrinosenescence (age-related hormonal changes) and immunosenescence (age-related immune system changes), highlighting the role of DHEA in modulating immune responses.
For more informational: https://academic.oup.com/jcem/article/83/6/2012/2865409
Iwasaki Y, Asai M, Yoshida M, Nigawara T, Kambayashi M, Nakashima N. Dehydroepiandrosterone-sulfate inhibits nuclear factor-kB-dependent transcription in hepatocytes, possibly through antioxidant effect. J Clin Endocrinol Metab. 2004;89:3449–3454.
Dehydroepiandrosterone-sulfate inhibits nuclear factor-kB-dependent transcription in hepatocytes, possibly through antioxidant effect
The study by Iwasaki et al. in 2004 demonstrated that dehydroepiandrosterone-sulfate (DHEA-S) can inhibit nuclear factor-kB (NF-kB)-dependent transcription in hepatocytes. This inhibition is possibly mediated through DHEA-S’s antioxidant effects. NF-kB is a transcription factor involved in inflammation and immune responses, and the study suggests that DHEA-S may have anti-inflammatory properties by modulating NF-kB activity in liver cells.
For in-depth understanding visit at https://academic.oup.com/jcem/article/89/7/3449/2844495
Altman R, Motton DD, Kota RS, Rutledge JC. Inhibition of vascular inflammation by dehydroepiandrosterone sulfate in human aortic endothelial cells: roles of PPARa and NF-kB. Vascul Pharmacol. 2008;48:76–84.
Inhibition of vascular inflammation by dehydroepiandrosterone sulfate in human aortic endothelial cells
The study by Altman et al. in 2008 investigated the inhibitory effects of dehydroepiandrosterone sulfate (DHEA-S) on vascular inflammation in human aortic endothelial cells. The research found that DHEA-S can inhibit inflammation in these cells, potentially through the activation of peroxisome proliferator-activated receptor alpha (PPARα) and the inhibition of nuclear factor-kB (NF-kB). These findings suggest that DHEA-S may have a protective role in reducing vascular inflammation, which is important for cardiovascular health.
For more information: https://www.sciencedirect.com/science/article/abs/pii/S1537189107001644
Gutiérrez G, Mendoza C, Zapata E, Montiel A, Reyes E, Montaño LF, López-Marure R. Dehydroepiandrosterone inhibits the TNFa-induced inflammatory response in human unbilical vein endothelial cells. Atherosclerosis. 2007;190:90–99.
Dehydroepiandrosterone inhibits the TNFa-induced inflammatory response in human unbilical vein endothelial cells.
In the study by Gutiérrez et al. in 2007, it was found that dehydroepiandrosterone (DHEA) inhibits the inflammatory response induced by TNF-alpha in human umbilical vein endothelial cells. This suggests that DHEA may have anti-inflammatory properties and could potentially play a protective role in reducing inflammation in endothelial cells, which is relevant to conditions like atherosclerosis.
For more details: https://www.sciencedirect.com/science/article/pii/S0021915006000827
Kipper-Galperin M, Galilly R, Danenberg HD, Brenner T. Dehydroepiandrosterone selectively inhibits production of tumor necrosis factor a and interleukin-6 in astrocytes. Int J Dev Neurosci. 1999;17:765–775.
Dehydroepiandrosterone selectively inhibits production of tumor necrosis factor a and interleukin-6 in astrocytes
The study by Kipper-Galperin et al. in 1999 found that dehydroepiandrosterone (DHEA) selectively inhibits the production of tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) in astrocytes. This suggests that DHEA may have anti-inflammatory effects specifically in astrocytes, which are important cells in the central nervous system. This finding has implications for potential therapeutic interventions in neuroinflammatory conditions.
For more details: https://www.sciencedirect.com/science/article/pii/S0736574899000672
Du C, Khalil MW, Sriram S. Administration of dehydroepiandrosterone suppresses experimental allergic encephalomyelitis in SJL/J mice. J Immunol. 2001;167(12):7094–7101.
Administration of dehydroepiandrosterone suppresses experimental allergic encephalomyelitis in SJL/J mice. J Immunol
In the study by Du et al. in 2001, the administration of dehydroepiandrosterone (DHEA) was found to suppress experimental allergic encephalomyelitis (EAE) in SJL/J mice. EAE is a model for multiple sclerosis, an autoimmune disease of the central nervous system. DHEA’s ability to mitigate EAE suggests a potential role in modulating autoimmune responses and highlights its immunomodulatory effects.
For more detailed information: https://journals.aai.org/jimmunol/article/167/12/7094/1315
Peters JM, Zhou Y-C, Ram PA, Lee SST, Gonzalez FJ, Waxman DJ. Peroxisome proliferator-activated receptor a required for gene induction by dehydroepiandrosterone-3b-sulfate. Mol Pharmacol. 1996;50:67–74.
The study by Peters et al. in 1996 found that peroxisome proliferator-activated receptor alpha (PPARα) is required for the induction of specific genes by dehydroepiandrosterone-3-beta-sulfate (DHEA-S). This suggests that DHEA-S may exert its effects on gene expression through PPARα, which is a nuclear receptor involved in regulating various metabolic processes. This interaction between DHEA-S and PPARα provides insights into the molecular mechanisms underlying DHEA-S’s physiological actions.
For more details: https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=c4083006df46058379d03a45ef1a68943a482b46
Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor a activation modulates cellular redox status, represses nuclear factor-kB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem. 1998;273:32833–32841.
Peroxisome proliferator-activated receptor a activation modulates cellular redox status, represses nuclear factor-kB signaling, and reduces inflammatory cytokine production in aging
The study by Poynter and Daynes in 1998 demonstrated that peroxisome proliferator-activated receptor alpha (PPARα) activation can modulate cellular redox status, inhibit nuclear factor-kB (NF-kB) signaling, and reduce the production of inflammatory cytokines in the context of aging. This suggests a potential role for PPARα activation in mitigating age-related inflammation and oxidative stress, which are associated with various age-related diseases.
For more details: https://www.jbc.org/article/S0021-9258(19)58953-0/abstract
LeFebvre P, Chinetti G, Fruchart J-C, Staels B. Sorting out the roles of PPARa in energy metabolism and vascular homeostasis. J Clin Invest. 2006;116:571–580.
Sorting out the roles of PPARa in energy metabolism and vascular homeostasis
The review by LeFebvre et al. in 2006 discusses the roles of peroxisome proliferator-activated receptor alpha (PPARα) in energy metabolism and vascular homeostasis. It highlights the multifaceted functions of PPARα, including its involvement in lipid metabolism, energy balance, and regulation of vascular processes. The review provides insights into the complex interplay between PPARα and various physiological pathways, emphasizing its significance in maintaining metabolic and vascular health.
For more details: https://www.jci.org/articles/view/27989
Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg H, Leor J, Boyko V, Mandelzweig L, Behar S. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 2004;109:2197–2202.
Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease
The study by Tenenbaum et al. in 2004 investigated the use of the peroxisome proliferator-activated receptor (PPAR) ligand bezafibrate in preventing type 2 diabetes mellitus in patients with coronary artery disease. The research aimed to assess whether bezafibrate could reduce the risk of developing diabetes in this population. While the study did not show a significant reduction in diabetes incidence, it contributed to the understanding of PPAR ligands and their potential roles in metabolic and cardiovascular health in patients with coronary artery disease.
For more details: https://www.ahajournals.org/doi/abs/10.1161/01.cir.0000126824.12785.b6
Kobayashi M, Shigeta Y, Hirata Y, Omori Y, Sakamoto N, Nambu S, Baba S. Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study. DC. 1988;11:495–499.
Improvement of glucose tolerance in NIDDM by clofibrate
The reference you provided seems to be a scientific study titled “Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study” authored by Kobayashi M, Shigeta Y, Hirata Y, Omori Y, Sakamoto N, Nambu S, and Baba S, published in 1988. The study appears to investigate the effects of clofibrate on glucose tolerance in individuals with Non-Insulin Dependent Diabetes Mellitus (NIDDM), commonly known as Type 2 Diabetes.
For more details: https://diabetesjournals.org/care/article-abstract/11/6/495/1181
Idzior-Walus B, Sieradzki J, Rostworowski W, Zdzienicka A, Kawalec E, Wójcik J, Zarnecki A, Blane G. Effects of comicronised fenofibrate on lipids and insulin sensitivity in patients with polymetabolic syndrome X. Eur J Clin Invest. 2000;30:871–878.
Effects of comicronised fenofibrate on lipids and insulin sensitivity in patients with polymetabolic syndrome
The citation you’ve provided refers to a scientific study titled “Effects of comicronised fenofibrate on lipids and insulin sensitivity in patients with polymetabolic syndrome X,” authored by Idzior-Walus B, Sieradzki J, Rostworowski W, Zdzienicka A, Kawalec E, Wójcik J, Zarnecki A, Blane G, and published in the European Journal of Clinical Investigation in 2000. This study appears to focus on the effects of micronized fenofibrate on lipid profiles and insulin sensitivity in patients with what was then referred to as “Syndrome X,” now more commonly known as Metabolic Syndrome.
Metabolic Syndrome is a cluster of conditions including increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels, which together increase the risk of heart disease, stroke, and type 2 diabetes.
Fenofibrate is a medication primarily used to reduce cholesterol levels and is particularly effective at increasing levels of HDL (good cholesterol) and decreasing levels of triglycerides (a type of fat found in the blood).
The study you’re referencing likely investigated how fenofibrate, in a micronized form for better absorption, affected these parameters in patients with Metabolic Syndrome, potentially also exploring its effects on insulin sensitivity, a key component of type 2 diabetes risk.
For more details: https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365-2362.2000.00734.x
Mussoni L, Mannucci L, Sirtori C, Pazzucconi F, Bonfardeci G, Cimminiello C, Notarbartolo A, Scafidi V, Bittolo Bon G, Alessandrini P, Nenci G, Parise P, Colombo L, Piliego T, Tremoli E. Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients. Atherosclerosis. 2000;148:397–406.
Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients
The study “Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients,” published in Atherosclerosis in 2000, likely investigated the impact of gemfibrozil, a medication for lowering triglycerides, on insulin sensitivity and blood clotting factors in patients with high triglyceride levels. This research would be relevant for understanding the broader effects of gemfibrozil in treating hypertriglyceridemia, especially regarding diabetes risk and cardiovascular health. For detailed insights, the full study should be consulted through medical databases.
For more details: https://www.sciencedirect.com/science/article/pii/S002191509900283X
Okopien B, Krysiak R, Herman ZS. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab. 2006;91:1770–1778.
Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance
The study you’re referring to is titled “Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance,” authored by Okopien B, Krysiak R, Herman ZS, and published in the Journal of Clinical Endocrinology and Metabolism in 2006. This research likely focused on how short-term treatment with fenofibrate, a medication primarily used to lower lipid levels, particularly triglycerides, impacts markers of inflammation and blood clotting in patients with impaired glucose tolerance (IGT).
Impaired glucose tolerance is a pre-diabetic state of hyperglycemia that is associated with insulin resistance and increased risk of cardiovascular disease. Fenofibrate’s effects on inflammation and hemostasis are particularly relevant, as both inflammation and abnormal clotting are known contributors to cardiovascular risk, especially in people with glucose metabolism disorders.
This study would be significant in understanding whether fenofibrate could potentially benefit individuals with IGT by modifying their risk factors for heart disease, aside from its lipid-lowering effects.
For more details: https://academic.oup.com/jcem/article-abstract/91/5/1770/2874234
Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B. Peroxisome proliferator-activated receptor a activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000;275:16638–16642.
Peroxisome proliferator-activated receptor a activators improve insulin sensitivity and reduce adiposity
The study “Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity,” authored by Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B, and published in the Journal of Biological Chemistry in 2000, likely explores the effects of activators of the peroxisome proliferator-activated receptor α (PPARα) on insulin sensitivity and body fat.
PPARα is a type of nuclear receptor that plays a crucial role in the regulation of fatty acid metabolism. Activating PPARα can lead to various metabolic effects, including improved lipid metabolism and increased insulin sensitivity.
In the context of this study, the researchers likely investigated how specific PPARα activators affect insulin sensitivity, which is critical in the management of diabetes, particularly Type 2 diabetes. They may also have looked at how these activators influence body fat composition, which is a key factor in obesity and metabolic syndrome.
These findings could be significant for developing new therapeutic strategies for treating conditions like diabetes and obesity.
For more details: https://www.jbc.org/article/S0021-9258(19)80254-5/abstract
Furuhashi M, Ura N, Murakami H, Hyakukoku M, Yamaguchi K, Higashiura K, Shimamoto K. Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and beta-oxidation in skeletal muscle. J Endocrinol. 2002;174:321–329.
Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and beta-oxidation in skeletal muscle
The study “Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and beta-oxidation in skeletal muscle,” published in 2002, explored the effects of fenofibrate on insulin sensitivity, muscle fat content, and fat metabolism in muscle.
For further details, you can access the study at https://europepmc.org/article/MED/12176671
Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes. 2001;50:411–417.
Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation
The study “Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation,” by Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW, published in Diabetes in 2001, likely investigated the effects of activating PPAR-alpha and PPAR-gamma on muscle lipid levels and insulin sensitivity in rats fed a high-fat diet. This research would be significant for understanding how different PPAR receptors influence lipid metabolism and insulin sensitivity, which are crucial factors in managing conditions like diabetes and obesity.